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ABSTRACT 
The B cell response to influenza virus infection has 
been characterized largely on the basis of measurements of 
serum antibody and antibody 1n respiratory secretions. 
However, the cellular component of this response has 
received little attention principally because a reliab le 
method for quantitation has been lacking. An ELISA-plaque 
assay has been developed to enumerate influenza-specific 
antibody-secreting cells ( ASC s) of different antibody 
isotypes. This assay can accurately and reproducibly detect 
cells secreting antibodies of IgM, IgG and IgA isotypes to 
influenza virus type specific antigens. Antibodies of 
different subtype specificity could be distinguished by 
modifying the assay so that only the surface glycoproteins 
are recognized. This assay has been used to study the B 
cell response in the murine lung, spleen and circulation to 
influenza infection and immunization. 
During . primary influenza infection, ASCs of each 
isotype were detected 1n the lungs, demon strating that 
antibody 1n respiratory secretions of each type, not onlv 
IgA, was locally produced. Furthermore, the pulmonary 
response was of greater magnitude than the splenic response 
for each isotype, and markedly so for the IgA component. In 
vitro stimulation of lungs from unprimed mice could also 
generate ASCs, suggesting that resident B cell precursors in 
ll 
the lungs could contribute to the local response during 
primary infection. 
Influenza A virus haemagglutinin-specific antibodies, 
capable of preventing re-infection, may persist for decades 
in humans after the original influenza A virus subtype is no 
longer circulating in the population. To study the possible 
mechanisms involved, the local and systemic components of 
the cellular events underlying the duration of the antibody 
response in murine influenza were analyzed. ASCs, 
predominantly IgG-secreting, were found in the lung and 
spleen up to 18 months after . primary murine influenza 
infection. B cell memory was determined by enumerating ASCs 
generated in stimulated lung and spleen cell cultures 
obtained from primed mice. There was a 50-200 fold increase 
in ASCs generated in vitro after influenza infection. 
Whereas there was no change in the level of B cell memory in 
the spleen up to 18 months after infection, the number of B 
memory cells 1n the lung progressively declined 6 months 
after infection. By 18 months the number of ASCs generated 
1n lung cell cultures was comparable to that 1n unprimed 
mice, although the predominant isotype, being IgG, 
differed. The effect of subsequent viral challenge on ASCs 
and B cell memory was also studied. Homotypic challenge 
increased ASCs 1n the lung only, whereas B cell memory 
increased in both the lung and spleen. Although ASCs, and 
to a lesser extent B cell memory, increased in both the lung 
i j_ i 
and spleen after heterotypic challenge, ASCs and B cell 
memory specific for the original subtype were not increased. 
The development of regional B cell responses was also 
studied in mice immunized intranasally with a cold-adapted 
(ca) variant of influenza A virus. The ca-variant virus was 
100 fold less efficient than the parental virus in the 
induction of influenza-specific ASCs in the lung and failed 
to induce ASCs in the spleen. The ca-variant virus was less 
efficient in priming for secondary IgG and IgA responses 
generated in vitro in both lung and spleen cell cultures . 
Protection against homotypic challenge in mice immunized by 
different . . priming strate.gies was correlated with the 
development of pulmonary B cell responses rather than 
splenic responses. In particular, protection was correlat ed 
with the presence of ASCs and IgG and IgA memory in the lung 
at the time of challenge. 
Local cellular immune responses were studied 
. in mice 
immunized · intranasally with the surface glycoproteins of 
influenza A virus presented 1n either micelles or 
immuno-stimulatory complexes (iscoms). Iscoms were more 
immunogenic that micelles in unprimed mice. Iscoms (given 
in two doses) elicited a primary ASC response in the lung 
but failed to elicit a primary cytotoxic (Tc) cell 
response. However, both local B and Tc cell memory was 
established after immunization with iscoms. In mice primed 
by infectious virus, both iscoms and micelles elicited 
lV 
secondary ASC and Tc cell responses in vivo. The ability of 
iscoms to prime for secondary Tc .cell responses and to 
elicit secondary Tc cell responses in vivo contrasts with 
the failure of previous preparations of inactivated 
influenza vaccines to elicit Tc cell responses. 
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1.1 Preface 
Acute respiratory infections (ARI) are the single 
largest cause of use of heal th serv ices in both developed 
and developing countries (Douglas & Kerby-Eaton, 1985). In 
both settings, children experience approximately seven 
episodes of ARI each year for the first five years of life; 
viruses being the maJor primary cause of these episodes. 
However children in developing countries are much more 
likely, principally as a result of malnutrition, to develop 
secondary bacterial infections leading to a higher mortality 
rate for ARI in developing countries ( Pio et al., 1985). 
ARI, diarrhoeal diseases and malnutrition are the three 
maJor causes of approximately 15 million deaths in children 
under the age of five each year in developing countries 
(Grant, 1985). 
Although absolute mortality from ARI has fallen 
drastically in developed countries, mortality from ARI in 
Australia is still nearly four times higher than all other 
infectious diseases combined (Douglas, 1985). In addition, 
the morbidity from ARI 1n this country is estimated to 
account for a minimum of 50 million dollars in medical and 
drug costs per year 1n young children alone (Douglas, 
1985) . Furthermore, the impact of ARI 1n developed 
countries also includes the increased risk of chronic lung 
diseases following ARI (Woolcock & Peat, 1985). 
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The nature of the association between viral respiratory 
pathogens and ARI is remarkably similar in developed and 
developing countries. The maJor viral pathogens are 
influenza virus types A and B, respiratory syncytial virus 
(RSV), the parainfluenza viruses, rhinoviruses, adenoviruses 
and coronaviruses. The viruses associated with 
exanthematous illnesses may also cause ARI, particularly in 
developing countries. 
Except for influenza . virus vaccine, no vaccines are 
available for the control of other maJor viral respiratory 
pathogens. 
effective 
diversity 
Problems encountered in the development of 
. 
vaccines have included 
of some viruses e.g. 
the wide 
rhinovirus, 
antigenic 
antigenic 
variation e.g. influenza and the development of pathological 
immune responses to some inactivated vaccines e.g. RSV. In 
view of the short incubation period between infection and 
the development of disease in viral ARI, usually less than 
4-5 days, a vaccine, to be successful, must elicit a durable 
immune response capable of preventing infection at the 
respiratory epithelial surface. It is generally accepted 
that neutralizing antibody in respiratory secretions is the 
principal mediator of prevention against viral ARI. The 
development of local immune responses to viral ARI will be 
reviewed in the first part of this introduction. 
Influenza A . virus infection was chosen as the model 
system to study the development of local B cell responses in 
3 
this thesis. Influenza A virus has caused recurrent 
epidemics of febrile respiratory disease every 1 to 3 years 
for at least the past 400 years. Epidemics of world wide 
scope (pandemics) have occurred less often. The greatest 
pandemic occurred in 1918/1919 when 21 million deaths were 
recorded. Even between epidemics, influenza is an important 
cause of mortality responsible for 10,000 deaths per annum 
in the U.S.A. (Mostow, 1986) 
morbidity. The immune response 
vaccines is reviewed in the 
introduction. 
and considerably greater 
to influenza 
second part 
. 
virus 
of 
and 
this 
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1.2 Respiratory Tract Immunity 
Before . . rev1ew1ng the development of local immunity to 
viral infections of the respiratory tract, the structural 
basis of immune responses in the respiratory tract, at both 
the tissue and cellular level, and general concepts of 
respiratory tract immunity will be briefly described. 
1.2.1 Organization of Lymphoid Tissues in the Lung 
The respiratory tract may be structurally and 
functionally divided at the broncho-alveolar junction. The 
upper division includes the mucosal surfaces of the trachea, 
bronchi and terminal bronchioles. The lower division, the 
lung parenchyma, includes the respiratory bronchioles and 
alveoli, which are lined by alveolar epithelium only and the 
supporting interstitium. Within the mucosal division of the 
respiratory 
organized 
tract, 
lymphoid 
there 
tissue 
are several compartments of 
(Bienenstock, 1984a). In 
contrast, the normal lung parenchyma contains only a small 
number of lymphocytes and macrophages scattered diffusely 
throughout the interstitium. 
The most organized compartment of mucosal lymphoid 
tissue 1s the submucosal lymphoid follicle referred to as 
bronchus-associated-lymphoid-tissue (BALT) (Bienenstock, 
1984b). These follicles are morphologically and probably 
functionally analogous to the gut-associated- lymphoid-tissue 
5 
(GALT) . BALT has been identified, 1n va rying degrees , 1n 
humans and many animals (McDermott et al., 1982 ). 
Morphologically, 
lymphoid aggregates 
SALT 
with 
lymphoepithelium containing 
consists of well - organi z ed 
an o ver lying s pecialized 
lymphocyte s and non-ciliated 
epithelial cells possessing microv illi (M cells) . The 
lymph(?epi thelium appears to be important 1n the uptak e of 
soluble and particulate antigens fr o m the lume n of the 
respiratory tract. The lymhoid tissue o f BALT , divisible 
into dome, follicular and parafollicul ar areas, contains 
predominantly B cells, most of which exp r e ss IgA and 1s 
considered to be the principal source of pr e cur s ors of 
IgA-antibody secreting cells (ASCs). 
A second compartment of lymphoi d ti ssue c o n s ists of 
intra-epithelial lymphocytes. The majori ty of thes e cells 
have not been identified, though 30% expr e ss Thy 1 and 55% 
express Lyt 2, but surprisingly not Thy 1 . Whilst the 
function of the majority of these ce ll s 1s unknown, small 
subsets have been identified as natu r al killer cells, 
cytotoxic T cell precursors and mas t cell precursors 
(Bienenstock, ASI Proceedings, 1986). 
A third compartment of l ympho id tissue consists of 
loosely organised lymphoid 
throughout the submucosa 
aggregates 
and l ami n a 
scattered 
propr1a. 
diffusely 
These 
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aggregates contain T and B cells, of which the maJor class 
is IgA. 
The cellular constituents of the spaces of 
peripheral bronchioles and alveoli have been sampled by 
broncho-al veolar lavage (Young & Reynolds, 1984) • In most 
species, approximately 90% of broncho-alveo lar cells are 
macrophages and the remainder are mostly lymphocytes. _ 
1.2.2 Immunocompetent Cells in the Lung 
1.2.2.1 Alveolar Macrophages 
The alveolar macrophage (ALM) lS a mononuclear 
phagocytic cell present 1n broncho-alveolar . air spaces and 
in the lung interstitium and mucosa. These cells are 
originally derived from the bone marrow and have the 
capacity to proliferate locally 1n the lung. The principal 
nonspecific functions of the ALM appear to be the 
phagocytosis of inhaled substances and the regulation of 
inflammation through the 
leukotrienes, 
release of 
pros tag land ins 
soluble mediators 
and complement including 
components. However, it 1s the interaction of the ALM with 
specific components of the immune response which will be 
considered further. 
There are several lines of evidence supporting an 
important role for the ALM in antigen presentation: 
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(i) ALMs possess the characteristics essential fo~ an 
antigen-presenting-cell (APC) 1.e. they express la 
antigens (Lipscomb et al., 1981; Mason et al., 1982), . 
are able to process antigens ( Schuyler & Todd, 1981) 
and can synthesize and release interleukin-1 
( McDermott et al. 1982) 
(ii) ALMs can support mitogen and antigen induced 
lymphoproliferation in vitro (Lipscomb et al., 1981); 
(iii) antigen-pulsed ALMs can induce specific T cell 
proliferative responses 1n . VlVO (Lyons & Lipscomb, 
1983) . 
Although the site of antigen presentation has not been 
determined, ALMs may migrate within the lung to enter the 
interstitium or mucosal lymphoid tissue, including BALT, or 
migrate outside the lung to extrapulmonary lymphoid tissue . 
ALMs may also selectively recruit sensitized T cells into 
the lung (Lyons & Lipscomb, 1983). 
ALMs also participate as effector cells 1n the immune 
response by phagocytosing opsonized organisms 
antibody-dependent 
1979). 
cell-mediated cytotoxicity 
and 1n 
(Whitcomb, 
8 
The role of ALMs 1n the regulation of immune responses 
1s variable (McDermott et al ., 1982; Holt, 1986) . .~lthough 
ALMs have been shown to support lymphoprol i fer at ion , ALMs 
may also suppress lyrnphoproliferation and ASC responses by 
the release of soluble products, including pros taglandin 
(An sfield et al., 1979; Demenkoff et al., 1980) . This 
functional h eterogeneity of ALMs ma y be explained by 
different stages 1n maturation or activati on (Sh e llito & 
Kaltreider, 1984 & 1985). 
1.2.2.2 Antigen -presenting Cells other than ALM s 
Cells other than ALMs have been identified within the 
respiratory tract which, by virtue of their ability to 
expres s la antigens or their dendritic morphology, may act 
as APCs, although there 1s no direct evidence to suppor t 
this . 
Cells morphologically resembling Langerhan's cells and 
expressing the F4 / 80 antigen of the mur1ne mononuclear 
phagocyte s y stem h ave been found spread along the basement 
membrane of the bronchial and bronchiolar epithelium (Hurne 
et al . , 1984 ) . 
Epithelial cells of the ~rachea and bronchi may express 
la an~igens (~irnan et al, 1978; atali et al., 1981). 
Whether t e 
lymphoepitheliurn 
epithelial 
over lying 
cells ( M 
SALT 
cells ) of the 
are caoable of 
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antigen-presentation 1s unknown. In addition, there are 
cells within BALT (Racz, 1977) resembling the 
interdigitating cells of T cell areas which are thought to 
be the in vivo counterpart of the isolated Steinman lymphoid 
dendritic cells. 
1.2.2.3 Natural Killer (NK) cells 
Natural killer activity has been found 1n normal mur1ne 
(Puccetti, 1980) and human (Bordignon et al., 1982) lung 
cell suspensions, though 1n varying degrees. Al though the 
precise location of NK cells 1n the lung has not been 
determined, intra-epithelial lymphocytes in the gut possess 
NK cell activity (Tagliabue et al., 1982). 
In addition, approximately 20-30% of lymphocytes 1n 
broncho-alveolar cell preparations are "null" cells which 
may include NK cells. However NK cell activity has not been 
detected 1n broncho-alveolar cell preparations (Puccetti, 
1980; Bordignon et al., 1982). 
1.2.2.4 B Lymphocytes 
The distribution of B cells throughout the lung has 
been largely characterized by immunofluorescence studies. 
The principal Ig-bearing cells found throughout the 
respiratory mucosa express IgA. Although over 50% of the 
lymphocytes in BALT are surface IgA positive (Rudzik et al., 
10 
1975), mature plasma cells have rarely been found ~ithin the 
lymphoid follicles of the . BALT (Chamberlain et al., 1973) . 
BALT, like GALT, is thought to be a source of precursors of 
IgA plasma cells which are already committed to specific 
antigens (Gearhart & Cebra, 1979). By analogy with the 
findings in GALT, antigen-specific precursor IgA B cells 1n 
SALT might locally proliferate upon exposure to antigen 1n 
the presence of IgA-specific T helper cells. IgA ASCs would 
then migrate within the respiratory mucosa or enter the 
lumen via the lymohoepithelium. Cells with surface IgG, IgE 
and to a lesser extent IgM, have also been found throughout 
the respiratory mucosa. The source of precursor cells for 
these different isotypes is unknown, although based on the 
finding of percursor IgE cells in GALT (Ngan & Kind, 1978) 
it is likely that the BALT is also a source of precursor IgE 
cells. 
B cells constitute 10-20% of the lymphocytes found 
. 1n 
broncho-alveolar cell preparations. The proportion of 
isotype-specific ASCs 1n human broncho-alveolar cell 
preparations quantitated by a reverse haemolytic-plaque 
assay differs from that 1n peripheral blood lymphocytes by 
virtue of the higher proportion of IgA ASCs 1n 
broncho-alveolar cells (Lawrence et al., 1978). Overall, 
IgA- and IgG-secreting cells are more numerous than 
IgM-secreting cells. B cells 1n broncho-alveolar cell 
preparations may be either derived from the respiratory 
mucosa and/or the blood (Daniele et al., 1977) • 
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1.2.2.5 T Lymphocytes 
T cells have been identified within the . respiratory 
epithelium, the lamina propria, the lymphoid follicles of 
BALT and in broncho-al veolar cell preparations. However, 
there is little data available on the precise identification 
of these cells according to phenotypic and functional 
characteristics. 
Whilst approximately 20% of BALT lymphocytes are T 
cells (Rudzik et al., 1975) there is no evidence that there 
is a fixed T cell area within BALT analogous to other 
lymphoid follicles. IgA specific T helper (Th) cells (Elson 
et al., 1979) and IgE specific T suppressor (Ts) cells (Ngan 
& Kind, 1978) have been found in GALT and probably exist in 
BALT as well. 
T cells constitute approximately 50% to 70% of 
lymphocytes in broncho-alveolar cell preparations. In human 
studies, approximately 45% of broncho-alveolar· T cells were 
identified as helper/inducer cells (OKT4+) and approximatel y 
25% were identified as T suppressor/cytotoxic cells (OKT8+) 
(Hunninghake & Crystal, 1981). 
1.2.3 Immune Responses in the Lung 
In this section the induction and expression of 
specific immune responses in the lung, including the 
generation of local memory, 
biological activities of 
will be considered. 
the various responses 
12 
The 
with 
particular regard to their role in viral immunity will be 
considered later (Section 1.2.4). 
1.2.3.1 Induction of Local Immune Responses 
Within the upper division of the respiratory tract, 
antigen uptake may occur across the mucosa via the 
lymphoepithelium of BALT and where the epithelial integrity 
of the mucosa has been disrupted as in viral infections. 
Antigen presentation may subsequentl y be mediated by 
submucosal macrophages, including those in BALT and by other 
putative APCs. In the parenchymal division, local immune 
responses may be induced by antigen presented by ALMs either 
within the alveoli or the interstitium. 
There are three basic mechanisms by which specific 
immune responses expressed . 1n the lung may arise 
(Kaltreider, 1984): 
( i) local antigen may stimulate specific T and B cell 
precursors already present in the lung; 
( ii) local antigen may stimulate specific T and B cell 
precursors which have been recruited into the lung; 
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(iii) circulating antigen may stimulate specific T and B 
cell precursors 1n extrapulmonary lymphoid tissue; 
effector cells being subsequently recruited into the 
lung by local antigen. 
The relative roles of these mechanisms 1n the 
expression of T and B cell responses 1n the mucosal and 
parenchymal divisions in the lung . have not been adequately 
defined. 
1.2.3.2 B Cell Responses 
Secretory IgA (sigA) constitutes the maJor Ig found in 
bronchial secretions under normal conditions and following 
antigenic stimulation. Although specific precursor IgA B 
cells are found . in BALT, the local cellular interactions 
responsible for B cell activation have not been determined. 
However, by analogy with events within the gut, antigen in 
the presence of sensitized Th cells initially acti vates 
precursor IgA cells in BALT (Cebra et al., 1983) which then 
migrate to other mucosal sites where final differentiation 
into ASCs occurs. Dimeric IgA with J-chain is secreted into 
the interstitium and binds to the secretory components (SC) 
expressed in epithelial cells. The sigA molecule 
. is 
transported across the cell and secreted into the lumen· 
Whereas the bulk of sigA found in respiratory secretions is 
14 
derived from local synthesis, additionally serum dimeric IgA 
may be selectively · transported into the lumen via SC 
receptors on epithelial cells (McDermott et al., 1982). 
Under normal conditions, the relative concentration of 
IgM 1n respiratory secretions 1s very low. This lS 
presumably derived from local synthesis as transudation from 
serum would be limited by the high molecular weight of IgM. 
In the presence of inflammation, IgM levels may increase as 
a result of exudation. In addition, specific IgM ASCs may 
appear in the lung parenchyma following intrapulmonary 
immunization. 
Using a haemolytic-plaque assay, direct plaque-forming 
cells were detected in broncho-alveolar cell preparations of 
dogs immunized with sheep red blood cells ( SRBCs) 
(Kaltreider et al, 1974; Kaltreider & Turner, 1976; Bice et 
al., 1980) • In contrast, . primary intrapulmonary 
immunization of mice with SRBCs failed to induce the 
appearance of ASCs in the lung (McLeod et al., 1978). 
However, both direct and indirect (IgG) plaque-forming cells 
were detected in the lungs of mice after repeated 
immunization. In both the canine and mur1ne models, it was 
concluded that pulmonary ASCs were derived from 
extrapulmonary lymphoid tissue according to the third 
15 
mechanism described above. This conclusion was based on the 
following observations: 
( i ) ASCs appeared 
subsequently 1n 
Turner, 1976); 
first 
the 
1n 
blood 
hilar 
and 
lymph node s and 
lung (Kaltreider & 
(ii) ASCs appeared 1n the hilar lymph node only, after low 
immunizing doses (Kaltreider & Turner, 1976); 
(iii) intratracheal challenge resulted 1n 
recruitment of adoptively transfered 
the local 
sensitized 
splenic lymphocytes (Kaltreider et al., 1983). 
Whilst these observations support the conclusion that 
ASCs may be derived from extrapulmonary sources, the 
alternate possibility that ASCs may also originate from 
resident precursors has not been excluded. 
The relative concentration of IgG 1n respiratory 
increases further down the secretions progressively 
respiratory tract to become 
lung parenchyma (Kaltreider, 
the principal i sotype 1n the 
1n bronchial 1984) . IgG 
secretions 1s thought to be principally derived from the 
serum by transudation, although some local synthesis by 
submucosal plasma cells does occur. In the lung 
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parenchyma, transudation 1s also important as indicated by 
the similar IgG to albumin ratios in broncho-alveolar lavage 
fluid and 1n serum under both normal conditions and 1n 
response to antigenic stimulation (Young & Reynolds, 1984). 
As indicated above though, specific IgG ASCs presumably 
derived from extra-pulmonary sources do appear in the lung 
parenchyma after immunization with foreign erythrocytes. 
IgE 1s present 1n minute quantities 1n respiratory 
secretions under normal conditions. Precursor IgE cells are 
present in BALT and presumably most of the IgE in bronch ial 
secretions lS locally 
lavage 
synthesized whereas IgE 1n 
broncho-alveolar fluid . lS thought to be largely 
derived from serum. Following local antigenic stimulat ion 
IgE ASCs increase in the respiratory tract (Sedgwick & Holt, 
1983b). 
1.2.3.3 T Cell Responses 
Apart from the role of T cells in BALT regulating IgA 
and IgE responses, there are no data conclusivel y 
demonstrating 
determined 
the occurrence of regulatory T cells, 
by either 
characteristics, 1n the 
However, antigen-reactive 
phenotypic 
lung during 
cells 1n 
or functional 
immune responses. 
lymphoproliferative 
assays, which have been reasonably assumed to represent Th 
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cells, do appear in the lung af t er antigenic s timulation 
(Lipscomb et al. 1981). 
Specific cytotoxic T (Tc ) c e ll s h a ve been detected in 
lung cell suspensions during vira l in f ections (Section 
1.2.4) and after local stimulat ion with allo- antigens 
(Emeson et al., 1982; Liu et al., 1982 ). Evidence for the 
appearance of T cells (Td) med i at ing delayed type 
hypersensitivity (DTH) reactions was i n i t i ally based on the 
demonstration of macrophage i nhibit i o n factor (MIF) in 
broncho-alveolar cell preparations followi ng local antigenic 
stimulation (Galindo & Myrvik, 1970; Waldman et al ., 1972). 
However, as the secretion of MIF i s not exc lusively 
restricted to Td cells, more convinc ing evi d e nce was 
provided by demonstrating that cells mediating DTH reaction 
could be recovered from the lungs of inf lue nza inf ec ted mice 
(Leung & Ada, 1980). These cells were ident ified as Class 
II restricted Lyt 2- T lymphocytes. 
The source of T cells in immune respon s es in the lung 
is largely unknown. Following adoptive transfer of 
sensitized T cells, Th and Tc cells can be recovered in the 
lung, although the effect of -local ant i gen on recruitment is 
variable. Using influenza-specif ic T cell clones, 
Bienenstock et al. (1983) showed s triking increases in 
numbers of cells in the lung parenchyma of infected mice 
compared with non-infected mice but only with the Lyt 2+ 
(Tc) clone and not with an Lyt 2- (Th ) c l one . The alternate 
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source of T cells involving stimulation of resident T cell 
precursors 1n the lung 1s suggested by the finding of 
influenza-specific Tc cell precursors in the normal murine 
lung at a frequency comparable to that 1n the spleen (Mak 
et al., 1984). 
1.2.3.4 Interaction of Pulmonary and Extrapulmonary Immune 
Responses 
The concept of a common mucosal immune system describes 
the integration of mucosal immune responses through the 
selective migration of immunocompetent cells and antibodies 
originating at one mucosal site to other mucosal sites . 
There 1s considerable evidence that oral presentation of 
antigen will result 1n the appearance of antigen-specific 
precursor IgA cells in the mucosa of the gut and lung as 
well as 1n other mucosal sit es (Weisz-Carrington et al., 
1979; Pierce & Koster, 1980) • Furthermore, T-lymphoblasts 
from mesenteric lymph nodes may localize in the epithelium 
and lamina propr1a of the bronchial mucosa (McDermott & 
Bienenstock, 1979). These findings provide a rationale for 
the successful immunization against adenoviruses (Smith et 
al., 1970) and influenza virus (Waldman et al., 1981) using 
oral vaccines. 
The co r o 11 a r y that c e 11 s from the resp i rat or y tract 
may migrate to other mucosal surfaces lS also true. 
However, B and T lymphocytes obtained from bronchial lymph 
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nodes localize preferentially, t hough not exclusively, to 
the lung (McDermott & Bienenstock, 1979). 
Systemic immune responses may also contribute to immune 
responses 1n the lung, especially within the parenchymal 
division. Although there 1s considerable evidence that 
antibody 1n respiratory secretions may be derived from 
extrapulmonary sources, the migration of immunocompetent 
cells into the lung parenchyma has not been studied in any 
great detail. 
1.2.3.5 Immunological Memory 1n the Lung 
Immunological memory 1n the respiratory tract has been 
demonstrated by either increases 1n antigen-specific cells 
or by the kinetics of secondary responses. Antigen-specific 
IgA containing cells have been demonstrated in the bronchial 
mucosa of primed animals ( Pierce & Koster, 1980; Joel et 
al., 1980). However, anamnestic IgA responses have not been 
consistently observed following secondary stimulation 
( Clancy & Bienenstock, 1984). This may reflect the ef feet 
of local regulatory influences, including Ts cells, and the 
nature and dose of the boosting antigen. In particular, 
secondary IgA responses may not develop after challenge with 
homologous virus if infection 1s prevented by pre-existing 
neutralizing antibody. 
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Immunological memory for T cell responses has also been 
demonstrated by increases in antigen-reactive cells in 
lymphoproliferative assays (Clancy & Pucci, 1978) and Tc 
cell precursor frequency after priming (Mak et al., 1984). 
In addition, local T cell responses develop earlier in 
previously sensitized animals (Yap et al., 1979; Ganguly & 
Waldman, 1983) . 
1.2.4 Viral Immunity in the Lunq 
Immune responses to viral infections of the respiratory 
tract may lead to recovery from infection and protection 
against re-infection or may contribute to the pathogenesis 
of disease. These roles will be considered in the broader 
context of viral immunity initially and then specifically 
for the maJor respiratory viral pathogens. Data on local 
immune responses to viruses are largely limited to the 
development of secretory antibody responses and to a lesser 
extent cell mediated responses. There is little information 
on non-specific immune responses, although the components of 
this system have been identified in the respiratory tract. 
1.2.4.1 Protective Role of Local Immune Responses 
Non-Specific Responses 
The components of the non-specific immune system, 
including macrophages, NK cells, interferon ( IFN) and 
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complement appear to be important 1n limiting viral spread 
and initiating recovery. 
Macrophages may limit viral spread by several 
mechanisms (reviewed by Morahan et al., 1985): 
(i) virus phagocytosis leading to inactivation of virus or 
abortive replication; 
(ii) lysis of virus-infected cells by either antibody-
dependent or independent mechanisms; 
(iii) release of alpha-IFN; 
(iv) presenting viral antigens to T cells and activating T 
cell responses by the release of interleukin-1. 
All of these functions have been ascribed to ALMs. 
The direct antiviral effects of IFN 
inhibition of viral replication. 
alpha or gamma, may modulate 
(Rager-Zisman & Bloom, 1985) by: 
In addition, 
other immune 
relate to 
IFN, either 
responses 
(i) augmenting the expression of MHC antigen on cells; 
(ii) activating macrophages and increasing the expression 
of Fe receptors for IgG; 
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(iii) augmenting NK cell activity. 
In addition, antibody synthesis may be either enhanced 
or suppressed by IFN depending on the dose and the time of 
exposure relative to antigen stimulation. 
NK cells may non-specifically lyse virus-infected cells 
1n vitro. However, there is little evidence documenting the 
role of NK cells in resistance to viral infections 1n vivo 
(Rager-Zisman & Bloom, 1985). 
The complement system either independently of, or 1n 
the presence of specific antiviral antibody, plays a role 1n 
host defence against viral infection (Lachman, 1985). 
Complement can interact with viruses in the absence of 
detectable antiviral antibody resulting in either lysis of 
enveloped viruses (virolysis) or neutralization of viruses. 
The interaction of complement 
enhances antibody-mediated . virus 
and lysis of virus-infected cells. 
B Cell Responses 
with anti vi r a 1 
neutralization, 
antibody 
virolysis 
Virus-specific sigA constitutes the principal antibody 
response to viral respiratory pathogens. Responses 
involving other isotypes also occur, although whether 
responses originate locally or systemically 1s largely 
unknown. The degree of local antibody response lS 
23 
influenced by the local availability of antigen and the 
ability of the virus to replicate in the respira tory tract. 
Anti-viral activities of antibodies include: 
( i) neutralization of viral infectivity by inhibition of 
virus attachment, penetration, uncoating or 
transcription of viral nucleic acid; 
(ii) enhancement of virus phagocytosis by opsonization; 
(iii) lysis of virus-infected cells by antibody-dependent 
cell-mediated cytotoxicity; 
(iv) virolysis 
. 
and lysis of virus-infected cells by 
complement-mediated antibody-dependent cytotoxicity . 
sigA has been shown to be capable of . virus 
neutralization (Ogra et al., 1968; Taylor & Dimmack, 
1985a). In contrast to IgM and IqG, sigA is relatively 
ineffective 1n opsonization and in activation of the 
complement cascade. Although ALMs were intially thought not 
to possess Fe receptors for IgA, more recently IgA receptors 
have been detected on activated ALMs (Gauldie et al., 
1983) . IgA does not activate complement by the classical 
pathway and it 1s uncertain whether non-aggregated IgA can 
activate the alternate pathway (McDermott et al., 1982). 
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The principal role of local antibody is the prevention 
of re-infection. However, protection may not necessarily 
correlate with sigA and may be mediated by other isotypes. 
T Cell Responses 
T cells interact with virus-infected cells, rather than 
cell-free virus, 1n an MHC restricted manner, either by 
direct lysis of infected cells or by the release of 
lymphokines (Doherty, 1985) . The generation of 
virus-specific Tc cells and their ability to clear virus 1n 
vivo 1n mice has been shown for many viral infections. 
Mononuclear phagocytes are recruited and activated by the 
release of chemotactic factors, gamma-IFN, macrophage 
activating factor and migration inhibition factor. 
T cell responses appear to be principally involved 1n 
recovery from viral infections. Patients with selective 
deficits of T cell immunity may continue to shed RSV, 
parainfluenza virus and other respiratory viruses from the 
respiratory 
association 
tract 
with 
for prolonged 
extrapulmonary 
(Fishaut et al., 1980). 
periods, often 10 
spread of · the virus 
1.2.4.2 Immunopathology of Viral Respiratory Infections 
The only available data on the role of immune responses 
in the pathogenesis of viral respiratory infections pertain 
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to antibody and T cell responses. Pathological con sequences 
may arise from antibody responses due to the formation of 
immune complexes and development of homocytotropic IgE 
responses. Whereas there is no evidence to suggest that 
sigA contributes to immunopathology, other isotypes may do 
so. Immune complex format ion has been demonstrated during 
RSV infection and may contribute to the development of 
bronchospasm through the release 
metabolites (Faden et al., 1983). 
of arachidonic acid 
The development of a 
virus-specific homocytotropic IgE response, associated with 
increased histamine levels in naso-pharyngeal secretions, 
has been implicated the development of bronchial 
hyperactivity during viral respiratory infections (Welliver 
& Og r a , 1 9 8 3 ) • 
The role of T cell responses in the pathogenesis of 
viral respiratory infections has only been studied with 
influenza. Although the development of a Tc cell response 
is essential for complete recovery, evidence for a 
pathological role of Tc cells is suggested in murine studies 
using live attenuated influenza viruses (Section 1.3.7.4). 
In addition, influenza-specific Td cells mediating Class II 
restricted DTH activity are known to have a detrimental 
effect on recovery, although the induction of these cells 
may be regulated by Ts cells during infection (Section 
1.3.7.3). 
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1.2.s Local Immune Responses to Specific Viral Respiratory 
Pathogens (excluding influenza) 
1.2.5.1 Respiratory Syncytial Virus (RSV) 
RSV 1s the maJor cause of lower respiratory tract 
infections (bronchiolitis and pneumonia) 1n infants and 
small children and is also frequently responsible for croup 
and minor upper respiratory infections. Re-infection occurs 
frequently, although attack rates are lower 1n older 
children and adults and the clinical course 1s usually 
milder. 
Local antibody responses, involving IgA, IgM, IgG and 
IgE develop in the respiratory tract after natural RSV 
infection (Scott & Gardner, 1970). However, the development 
and persistence of RSV specific sigA in infants correlates 
poorly with protection against re-infection and development 
of bronchiolitis in subsequent infections (McIntosh et al., 
1978). The development of bronchiolitis and bronchospasm 
during subsequent infections appears to relate to t h e 
development of homocytotropic IgE responses. IgE bound to 
respiratory epithelial cells develops following infection 
and usually disappears in 10 to 14 days. However, patients 
with persistent IgE responses are significantly more likely 
to have bronchiolitis and bronchospasm. The presence of RSV 
IgE 1s associated with increased histamine levels 1n 
nasopharyngeal secretions and the development of 
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bronchospasm during subsequent infections (Welliver et al., 
1981) . The persistence of IgE responses in these patients 
is associat~d with a defect in RSV specific Ts cell function 
and recovery of Ts function correlated with protection 
against RSV-induced bronchospasm (Welliver et al., 1983). 
Local cellular responses, including the development of 
NK cell activity and RSV specific Tc cell responses, have 
been ·described in the lungs of cotton rats infected with RSV 
(Taylor et al., 1985; Kumagai et al., 1985). In children 
infected with RSV there is an increase in 
lymphoproliferative responses of peripheral blood 
lymphocytes which correlates with the severity of illness 
(Welliver et al., 1979). The detrimental effect of 
inactivated RSV vaccine is thought to have resulted from the 
induction of Td cells mediating DTH reactions (Sissons & 
Borysiewicz, 1985). 
1.2.5.2 Parainfluenza Viruses 
Parainfluenza viruses (Types 1-3) are important causes 
of respiratory illnesses, especially 
. 
croup, in young 
children. 
respiratory 
Specific antibody 1s detectable in serum and 
secretions after natural parainfluenza 
infection. Clinical studies with parainfluenza virus, Types 
1 and 2, have suggested a closer correlation between 
protection against re-infection and nasal antibody levels 
rather than serum antibody levels (Smith et al., 1966; 
Tremonti et al., 1968). However, neutralizing activity in 
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nasal secretions has not always correlated with IgA levels 
(Yanagihara et al., 1978). Protection mediated by antibody 
is type specific (Welliver et al., 1982a). Virus specific 
IgE responses occur regularly, though are of greater 
magnitude in patients with croup and are associated with 
increased histamine levels in nasopharyngeal secretions 
(Welliver et al., 1982b). The role of these responses in 
the pathogenesis of croup is unknown. 
There is no data available on cell-mediated responses 
to these . viruses in humans. Considerable data, however, 
exist on Sendai virus, a murine paramyxovirus closely 
related to para influenza Type 1 virus. Specific Class I 
restricted Tc and Td cells are induced by Sendai virus, 
provided the virus retains its fusion capability (p+). p-
Sendai virus preparations (inactivated by ultraviolet 
irradiation) fail to elicit Tc cell responses but induce 
Class II restricted Td cells (Ada et al., 1981). 
1.2.5.3 Rhinovirus 
Rhinovirus, of which there is over 100 serotypes, is 
the major known cause of the common cold. Unlike RSV and 
parainfluenza virus infections, rhinovirus infection does 
not commonly involve the lower respiratory tract. Specific 
secretory antibody of the IgA, IgM and IgG classes appear in 
nasal secretions and may protect against homotypic 
re-infection. It is not known whether antibody contributes 
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to immunopathology 1n rhinovirus infections, although 
bronchospasm 
reactivity. 
may develop 1n 
There are no data 
( Ogr a et al . , 1984) • 
patients with bronchial 
on cell-mediated responses 
1.2.5.4 Adenovirus and Coronavirus 
The data on the immune responses to adenovirus and 
coronavirus are limited to studies correlating protection 
with serum antibody responses. 
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1.3 Immune Responses to Influenza Infection 
The purpose of this section is to review the nature of 
the immune response to influenza A virus, both in hosts 
which experience natural infection, particularly man, and in 
hosts which are experimentally infected, particularly mice. 
1.3.1 Properties of the Components of the Influenza Virion 
Influenza is a myxovirus which can be highly 
pleomorphic but, where well adapted, most particles are 
spheres with a diameter between 80 and 120nm. When examined 
by negative staining, the particles show the presence of 
11 spikes II which represent the two surface glycoproteins, the 
haemagglutinin (HA) and the neuraminidase (NA). 
1.3.1.1 The Haemagglutinin 
The HA molecule accounts for about 25% of the viral 
protein. It mediates the initial attachment of the virion 
to a cellular receptor and possesses a fusion capability 
that enables the virus envelope to integrate with an 
intracellular membrane, so allowing the internal components 
access to the cell cytoplasm. The HA molecule is present in 
the vi r ion as a trimer ( = 11 spike 11 ) • Each monomer exists as 
two chains, HAI and HA2, linked by a disulfide bond. The 
precursor single polypeptide must be cleared to produce HAI 
and HA2 for the virus particle to be infectious. HA2 ' is 
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anchored 1n the membrane by a sequence of 25-32 hydrophobic 
amino acids at the C terminus. Each HA molecule contains 
two main regions, a triple-strand coil of alpha helices and 
a globular region of anti-parallel beta-sheets (Wiley et 
al., 19817 Wilson et al., 1981). The cell-receptor binding 
site and the variable antigenic determinants are located on 
the globular domain. Complete amino acid sequences of the 
HA for two H3 strains and partial sequences, deduced from 
cDNA copies, for 32 A strains are available. The highest 
homology (80%) is between H3 and HS, and the lowest (25%) 
between Hl and H3. There is generally > 90% homology 
between strains of a given subtype. 
1.3.1.2 The Neuraminidase 
The NA is an enzyme which cleaves sialic acid residues 
from any oligosaccharide chain possessing that terminal 
sugar with the correct glycosidic linkage, including 
residues on both the HA and NA. Before replication, the NA 
may act on non-specific inhibitors in ·the extracellular 
fluids and possibly release virus from mucous. After 
assembly of the virus, the NA acts not only on substrates in 
or on the infected cell, but also on the virion itself. The 
NA exists as a spike on the virion with a "head" containing 
four coplanar and approximately spherical subunits, a 
centrally attached "stalk" with a transmembrane hyrophobic 
region (Laver & Valentine, 1969). Complete amino acid 
sequences of five N2 neuraminidases and partial sequences of 
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others are known. The overall homology between Nl and N2 
proteins lS 39%. The three-dimensional structure of 
pronase-isolated NA heads has been determined by X-ray 
crystallography to a 2.9A ·resolution (Varghese et al., 1983; 
Colman et al., 1983). The polypeptide chain is arranged in 
SlX topologically identical four-stranded anti-parallel 
beta-sheets, giving an overall appearance of propeller 
blades. The catalytic site appears to be a large pocket on 
the distal surface which is formed by some 18 residues which 
are conserved between subtypes. 
1.3.1.3 The Matrix Protein 
The virion contains a third envelope associated protein 
the matrix ( M) protein, which 1s the major component . 1n 
the v1r1on. The complete amino acid sequence of the protein 
has been deduced from base sequences and indicates that the 
sequences are very highly conserved. 
1.3.1.4 Other Virion Proteins 
Inside the viral envelope there are eight RNA segments 
and products of five of these. The influenza virus genome 
consists of eight single-stranded (negative sense) RNA 
molecules . ranging in size from 890 to 2,341 nucleotides . 
All RNA segments encode a single polypeptide, except the two 
smallest, each of which encodes two polypeptides. 
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The three polymerase (P) proteins - PA, PBl and PB2 -
transcribe the viral RNA. The nucleoprotein (NP) probably 
constitutes · the backbone of the helical complex that 1s 
sometimes displayed by disrupted v1r1ons. The virus also 
encodes two non-structural proteins - NSl and NS2 - neither 
of which are found in the virion, and an M2 protein which 1s 
not found in the virion but is expressed on the surface of 
infected cells. 
An aspect of increasing interest 1s the expression of 
viral proteins other than HA and NA at the surface of the 
infected cell. It has been shown (Virelizier et al., 1977) 
and confirmed (Yewdell et al., 1981) that NP is expressed at 
the infected cell surface and this may also occur in cells 
transfected with DNA encoding NP (Townsend et al., 1984). 
Different results have been found with matrix protein. 
Investigators using polyclonal antisera suggested that M was 
expressed at the cell surface (Ada & Yap, 1977; Biddison et 
al., 1977; Reiss & Schulman, 1980a); in contrast, workers 
using monoclonal antibody preparations have found only very 
small amounts expressed at the cell surface (Hackett et al., 
1980; Yewdell et al., 1981). The different results may 
either be explained by contamination of the polyclonal 
antisera with anti-HA antibodies, though this has not been 
demonstrated and steps were taken to eliminate such a 
possibility (Reiss & Schulman, 1980a) or possibly by the 
anti-matrix sera . . recognizing those amino acid sequences 
shared between Ml and M2. M2 orotein has been found to be 
l 
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expressed 1n considerable amounts at the infected cell 
surface (Lamb & Choppin, 1983), as has NS1, a nonstructural 
protein (Shaw et al., 1981). 
The extent to which other internal virion proteins may 
be expressed at the infected cell surface is not clear. It 
1s assumed that a similar surface expression pattern occurs 
1n infected cells 1n vivo. 
Recent data on the susceptibility of virus infected 
target cells to Tc activity suggests that antigenic 
fragments of some viral proteins are expressed at the cell 
surface and are recognized in an MHC restricted fashion. 
This has been demonstrated for NP and HA and may be the case 
for other influenza viral proteins (Germain, 1986). 
1.3.2 Antigenic Properties of the Viral Proteins 
1.3.2.1 B Cell Recognition 
It has been known for a long time that antibodies which 
neutralize the infectivity of influenza virus bind 
predominantly to the HA. There 1s general agreement that 
there are four maJor antigenic sites which have been 
variously designated as: Site A (loop), a.a. 140-146; Site 
B (tip), 187-196; Site C (hinge), a bulge in the tertiary 
structure at the disulfide bond between Cys 52 and Cys 277; 
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and Site D (interface), which 1s the interface between 
subunits 1n the HA trimer (Webster & Laver, 1980; Wiley et 
al., 1981; Gerhardt et al., 1981). Recently a panel of 
monoclonal antibodies were tested for their binding to 
different physical forms of the HA molecule and their 
ability to neutralize virus infectivity (Nestorowicz et 
al., 1985). Antibodies, including neutralizing antibodies 
to important antigenic sites of a viral surface antigen, 
reacted with conformational determinants, some of which may 
be quaternary structures and therefore are nonlinear 
(discontinuous) amino acid sequences. 
Variation 1n amino acid sequence of the NA has been 
observed to occur in regions which form a nearly continuous 
surface at the top of a subunit. The catalytic ?ite, which 
is a large pocket of the distal surface, thus appears to be 
surrounded by variable regions. Studies with monoclonal 
antibodies to laboratory-derived mutants indicate that these 
variable sequences are also antigenic (Colman et al., 1983). 
The internal viral proteins of the virus have not been 
examined to the same extent as the two surface 
glycoproteins. Antigenic variability 1n the NP and M 
protein have been detected by the binding of monoclonal 
antibodies; these changes occurred independently of those in 
the surface glycoproteins (Van Wyke et al., 1980 & 1984). 
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1.3.2.2. T Cell Recognition 
Regulatory T Cells 
Studies on the ability of human and mur1ne HA-specific 
T cell clones to respond in proliferation assays to either 
synthetic peptides of the HA molecule or virus mutants with 
known amino acid substitutions have yielded comparable 
results (Lamb et al., 1982; Hackett et al., 1983; Hurwitz et 
al., 1984). Three immunological regions were identified - a 
25 amino acid segment at the carboxyterminus of HAI, a 
nonapeptide (residues 111-119) located at the globular head 
region and a third sequence including residue 136. These 
sites are distinct from the four proposed antibody-binding 
sites involved 1n virus neutralization. Interestingly, T 
cell antigenic sites tend to have amphipathic structures, 
that lS 
hydrophilic 
structures 
surfaces, 
with 
with 
separated hydrophobic and 
the hydrophobic residues 
displaying periodicity (Allen et al., 1985; Streicher et 
al., 1984) . Amphipathic periodicity has also been 
demonstrated for the two well-defined determinants of HAI 
(De Lisi & Berzofsky, 1985). 
There have been several reports of T cell clones which 
recognize viral proteins other than HA, including NA, Mand 
NP and which exhibit helper activity (Lamb et al., 1982; 
Sterkers et al., 1985). An early report that Th cells 
recognizing an internal antigen (M) could provide help for a 
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subsequent anti-HA antibody response (Russell & Liew, 1979) 
has recently been confirmed but only for an IgM response 
· ( Scher le & Gerhard, 1986) . In contrast, Th cells 
recognizing the HA are cross-reactive for an IgG response. 
There is little information available about antigen 
recognition by Ts cells. High concentrations of a synthetic 
peptide of HA rendered cloned Th cells unresponsive to 
subsequent re-stimulation, however the dose of the peptide 
required was sufficiently high to doubt whether such a 
mechanism could operate in vivo (Lamb et al., 1983). 
Effector T Cells 
Our knowledge about antigen recognition by effector T 
. 
cells comes almost entirely from recent studies of one 
subset of T cells - cytotoxic cells. Several groups have 
demonstrated that Tc cells raised to one A strain virus 
could lyze target cells infected with any A strain, but not 
a B strain virus (Doherty et al., 1977; Zweerink et al., 
1977; Braciale, 1977). Limiting dilution analysis 
subsequently showed that the majority of Tc cells were 
"cross-reactive 11 ( Owen et al. , 1982) and work with mur ine T 
cell clones showed that they could be divided into three 
groups: those that were specific for the HA of the 
stimulating virus; those which recognized HA of all viruses 
of a given subtype; and those which recognize target cells 
infected with any A strain virus (Braciale et al., 1981). 
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The pattern of association required to render a target 
cell susceptible to lysis is generally considered to reflect 
a similar pattern on the presenting cell respon~ible for the 
induction or effector stage, but has been mainly done at the 
latter. 
A variety of methods has been applied. The most direct 
involve the treatment of inducer or target cells with one of 
three techniques: (1) transfection with known DNA sequences 
coding for particular proteins; ( 2) infection with 
recombinant (hybrid) viruses which express the protein coded 
for by the inserted DNA; and (3) fusion with preparations, 
usually liposomes, containing defined proteins. Another 
approach has been to compare parental viruses with 
reassortant or mutant strains and this may implicate a 
specific viral protein. In Table 1.1 results are assembled 
which indicate the viral proteins recognized by Tc cells. 
There can be little doubt that in both murine and human 
studies HA is recognized by Tc cells, but the evidence now 
suggests that ( i) about 10-15% of Tc precursor cells 
recognize HA, and (ii) there 1s some cross-recognition 
between Hl and H2, but very little, if any, between H2 and 
H3. There is little known about the epitopes recognized by 
Tc cells (Section 1.3.1.4). There are no reports 
unequivocally demonstrating that NA . lS recognized by Tc 
cells, though this 1s likely to be the case (Sterkers et 
al., 1985). Kees and Krammer (1984) using limiting dilution 
analysis of early responses to reassortant viruses found 
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that up to 90% of Tc cells 1n C57Bl/6 mice recognized 
internal proteins. Yewdell et al. (1985) claim a 
"significant" proportion of cross-reactive Tc cells 1n 
BALB/c mice recognize NP. Andrew et al. (1986) using 
limiting dilution to determine precursor frequency find 
about 30% recognizing NP. 
Pala et al. ( 1986), using L cells trans f ected with NP 
and Db genes found a great variation in the frequency of 
NP-specific Tc between individuals in an inbred mouse 
strain, with some showing no recognition of NP, though 
having a strong A virus-specific cross-reactive Tc 
response. It has also been pointd out that there are at 
least two classes of NP-specific Tc, one which 1s fully 
cross-reactive between all A strains and another which 
distinguishes NP in two groups of type A viruses, isolated 
between 1934-1943 and 1943-1979 (Townsend & Skehel, 1984). 
There may be three determinants on the NP molecule 
recognized by Tc ( Townsend et al., 1985) • Bennink and 
colleagues 
constructed 
( J. Bennink, 
. . . 
vaccinia virus 
personal communication) have 
recombinants containing the DNA 
coding for other viral antigens and have found that all 
three polymerases are recognised by murine Tc cells. 
Are nonstructural viral antigens - M2, NS1, and NS2 -
recognized by Tc cells because it is clear that M2 and NS1 
are well expressed at the infected cell surface, a finding 
which per se would suggest that these antigens are 
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candidates for recognition? Bennink and colleagues (J. 
Bennink, personal communication), using recombinant vaccinia 
preparation, find that NSl but not M2 is recognized by Tc 
cells. 
In contrast to the extensive work with effector cells 
expressing Tc-cell activity, little work has been done on 
effector cells expressing DTH, 
populations which are specific 
except 
to one 
to show 
subtype or 
that 
are 
cross-reactive may be produced (e.g. Ada et al., 1981). 
Preparations may be class I or II 
In view of the fact that cloned 
MHC antigen-restricted. 
T cells may show both 
cytotoxic and DTH activities (e.g. Lin and Askonas, 1981) 
and cells expressing cytotoxic activity may be class I or II 
MHC antigen-restricted (Lukacher et al., 1985), the 
antigenic recognition patterns seen 
apply also to cells expressing 
activity. 
1.3.3 Antigenic Drift and Shift 
with Tc cells probably 
only (detectable) DTH 
The two surface antigens of influenza A viruses undergo 
two types of antigenic change. Antigenic drift is the term 
describing minor changes in the HA and NA; antigenic shift 
involves major changes in these two surface glycoproteins . 
At present, there is no method available for predicting the 
precise changes which occur in either of the se two 
processes. 
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Antigenic drift in both the HA and NA occurs by point 
mutation in the genes, resulting in an accumulation of amino 
acid sequence changes. Three mechanisms have been proposed 
to explain antigenic shift. 
1968 when H3 replaced H2 
The change which occurred 1n 
. is so large that it has been 
proposed that the H3 human virus could only have been 
derived by genetic reassortment between human and animal or 
human viruses. Viral genetic reassortment between humans 
and between humans and lower animals have been observed and 
several studies involving genetic and biochemical analysis 
support this mechanism for the appearance of H2 and H3 
strains. In contrast, the strain of HlNl that appeared in 
northern China in 1977 and spread worldwide is so similar . in 
all genes to the virus which caused an epidemic in 1950 that 
it is reasonable to propose that the earlier virus had 
remained dormant for the 27-year interval, e.g. in a frozen 
state. The third possibility is that an animal or bird 
virus changed and became infectious for humans. An example 
is the isolation of identical influenza viruses from pigs 
and humans on the Wisconsin farm in the mid-1970s (Hinshaw 
et al., 1978). 
1.3.4 Patterns of Infection 
1.3.4.1 Influenza in Humans 
Human influenza is primarily an infection of the upper 
respiratory tract and major central airways. The pathology, 
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characterized by desquamation of the epithelium, involves 
the nasal mucosa, larynx and tracheobronchial tree. 
Influenza pneumonia occurs rarely and is characterized 
histologically by a desquamat i ve interstitial pneumoni tis. 
Although physiological abnormalities of small airways 
function may be demonstrated in uncomplicated influenza 
(Hall & Douglas, 1980), these abnormalities relate to airway 
hyperreactivity 
infection. 
and do not necessarily reflect local 
The maJor method of transmission of influenza virus is 
airborne; direct spread . via infectious droplets is less 
common ( Murphy & Webster, 1985 ) . Inhalation of infected 
aerosols may result in the deposit ion of . virus throughout 
the respiratory tract, including the alveoli. It is unclear 
why there is subsequently less pathological involvement at 
the alveolar level. Influenza virus may be more efficiently 
cleared by local defense mechanisms, especially the alveolar 
macrophage, preventing alveolar infect ion. Alternatively, 
the alveolar epithelium may be less susceptible to infection 
as suggested by in vitro studies (Rosztoczy et al., 1975). 
1.3.4.2 Influenza in Animals and Birds 
Influenza infection occurs naturally in many avian 
species and in some mammals including pigs, horses, seals 
and mink. The study of infection in these hosts has 
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provided valuable data on the epidemiological links between 
avian, mammalian, and human influenza viruses, particularly 
on the basis of antigenic shift of human influenza viruses. 
However, studies on the immune response have been largely 
restricted to experimental infections in mice and ferrets. 
The mouse has been the most widely used animal for 
studies of influenza . virus infection. experimental 
advantages over other animal models, aside from 
Its 
the 
similarities between murine and human influenza pneumonia, 
include the ease of breeding and availability of inbred 
strains, the extensive background knowledge of the murine 
immune system and the MHC, and the availability of 
well-defined reagents for characterizing the components of 
the immune response. The pattern of infection in mice 
depends on the degree of host adaptation of the virus. 
Infection with unadapted strains generally does not produce 
overt disease, unless very high inocula are used, although 
virus may replicate in the lungs, bronchi, and nasal 
mucosa. Infection with mouse-adapted strains, either 
intranasally or by aerosol, results in severe disease with 
alveolar involvement as the predominant finding. The 
pulmonary pathology . similar to that seen 1n in mice lS 
influenza pneumonia 1n humans. Lung viral titres peak 
within 3-4 days and decline to undetectable levels by 10 
days, although viral antigen may be detected, by ELISA , up 
to 2 months after infection (Astry et al., 1984). 
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Intranasal inoculation of ferrets with influenza virus 
results a similar disease to uncomplicated human 
influenza, with a similar distribution of viral antigen ' 1n 
the respiratory tract. There 1s little evidence for 
alveolar involvement even during infection with virulent 
clones (Sweet et al., 1981 ) . These observations are 
consistent with the demonstration that ciliated epithelial 
cells from ferrets are better able to support ' virus 
replication and to release virus than are alveolar cells 
(Cavanagh et al., 1979). However, the ferret is limited as 
a model for studying the immune response, primarily by 
lacking the advantages of the murine model as well as by the 
difficulty and expense in maintaining sufficient numbers of 
ferrets for detailed experiments. 
1.3.5 Nonspecific Responses 
The nonspecific immune system in influenza infection 
has been evaluated either by delineating the components of 
the system separately - namely fever, macrophages, NK cells, 
IFN and complement - or by examining the system collectively 
and independently of the specific arm of the immune 
response. The complex interactions within this system and 
with the specific arm of the immune response, however, make 
it difficult to dissect the roles of the respective 
components in recovery from influenza infection. 
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1.3.5.1 In Experimental Influenza 
In experimental influenza the nonspecific immune 
response is implicated in limiting viral spread and 
initiating recovery. Several observations have been made 
which tend to substantiate this role. Firstly, pretreatment 
of mice with P. acnes ( C. parvum) before a lethal virus 
challenge results in lower lung viral titres and lower 
mortality (Mak et al., 1983; Gangemi et al., 1983). This 
protective effect correlates with increased lung IFN levels, 
macrophage content, and NK cell activity in the absence of 
any demonstrable change in either T or B cell function. 
Secondly the survival of athymic mice following a sublethal 
infection with influenza virus is dependent on either the 
nonspecific immune response or IgM antibodies (Yap & Ada, 
1979) . The persistence of virus in the lungs of surviving 
mice for prolonged periods suggests, however, that neither 
mechanism is sufficient for complete recovery. Finally, the 
early decline, during the 2nd and 3rd day, of nasal virus 
titres in infected ferrets precedes the development of a 
measurable specific immune response and correlates with the 
degree of preceding . pyrexia and inflammatory cellular 
infiltrate (Toms et al., 1977). 
The role of fever as a host defense mechanism is 
suggested by the correlation between the height of fever and 
subsequent rate of decline of nasal virus titres . in 
ferrets. Furthermore viral replication in nasal turbinate 
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organ cultures is inhibited at pyrexial temperatures (Sweet 
et al., 1978) and suppression of fever in ferrets by 
nonpharmacological means results in delayed clearance of 
virus (Husseini et al., 1982). 
ALMs from normal murine lungs are susceptible to 
infection by influenza virus in vitro (Rodgers & Mims, 1981; 
Wells et al., 1978). Although the virus undergoes abortive 
replication only, infectious virus, possibly on the surface 
of macrophages, may form infectious foci when cocultured 
with susceptible cells. Alveolar macrophages recovered from 
influenza-infected mice acquire resistance to 1n vitro 
infect ion which is induced by IFN ( Rodgers & Mims, 1982b) . 
Macrophages recovered from influenza-infected lungs may also 
mediate lysis of infected cells independent of antibody (Mak 
et al., 1982a). Influenza-infected macrophages also produce 
IFN and may act as APCs (Wyde et al., 1982; Lyons & 
Lipscomb, 1983). The effect of influenza virus infection on 
release of interleukin-1 has not been studied. 
NK cells may play a role 1n limiting viral spread by 
lysis of virus-infected cells and production of IFN (Welsh, 
1981) . Enhanced levels of NK cells can be detected . in 
pulmonary lymphocytes 48h after influenza infection in mice 
(Leung & Ada, 1981; Stein-Streilein et. al., 1983). 
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Pulmonary levels of type 1 (alpha-, beta-) IFN rise 
rapidly during murine influenza infection and correlate 
directly with the degree of viral replication (Wyde et al., 
1982). Alveolar macrophages and lymphocytes recovered early 
from infected lungs are the major sources of IFN released in 
vitro. Intranasal instillation of anti-IFN serum results in 
an increase in viral titres and an increase in host 
mortality ( Hoshino et al. , 1983) . In mice bearing the Mx 
gene an increased resistance to influenza virus, 
attributable to enhanced sensitivity to alpha/beta IFN can 
be abolished by pretreatment with anti-IFN serum (Haller, 
1981) . These observations indicate a definite role for IFN 
in limiting viral spread. 
Virus particles themselves, virus-infected cells, and 
virus-induced desialation of cells may activate complement 
by either the classical or alternate pathways (Lambre et 
al., 1983). Subsequently binding of complement in the 
absence of specific antibody may neutralize virus or result 
in lysis of virus particles. The importance of complement 
in influenza infection is shown by the increased mortality 
in mice depleted of complement and in CS-deficient mice, 
although the maJor protective effect of complement was 
mediated late in infection and probably through 
antibody-dependent lysis of infected cells (Hicks et al·, 
1978). 
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1.3.5.2 In Human Influenza 
While there are no data in humans comparable to that in 
experimental 
nonspecific 
influenza which support a role for the 
immune system 1n recovery from influenza, 
descriptions of the responses 1n humans are consistent with 
those in animal models. 
ALMs recovered from human bronchoalveolar cell 
preparations are susceptible to influenza 1n vitro, though 
replication 1s abortive (Rodgers & Mims, 1982a). ALMs 
infected in vitro produ~e alpha-IFN and retain the ability 
to act as accessory cells (Ettensohn & Roberts, 1984). 
Large granular lymphocytes (LGLs) from peripheral blood 
lymphocytes may be stimulated in vitro by influenza virus 
( D j e u et al . , 1 9 8 2 ) , res u 1 t in g 1 n enhanced NK act i v i t y and 
production of alpha- and gamma-IFN. Furthermore, LGLs 
provide an accessory function 1n the generation of 
influenza-specific Tc cells through unidentified soluble 
factor(s) (Burlington et al., 1984). Enhanced NK activity 
may also be detected in circulating lymphocytes early after 
influenza infection in volunteers (Ennis et al., 1981a). 
Alpha-IFN 1s detected in acute-phase sera during 
natural infection (Ennis et al., 1981a; Green et al., 
1982). Local nasopharyngeal IFN levels peak early after 
artificial challenge and correlate directly with nasal virus 
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titres (Murphy et al., 1973). In vitro stimulation of 
peripheral blood lymphocytes results 1n the product ion of 
both alpha- and gamma-IFN, higher levels of gamma-IFN being 
produced 1n recently vaccinated volunteers (Ennis & Meager, 
1981). 
1.3.6 The Antibody Response 
1.3.6.1 Dynamics of the Response 
The class-specific antibody 
haemagglutinin subunit has been 
response 
studied 1n 
to the 
persons 
challenged with live attenuated vaccines, using the ELISA 
technique. 
was observed 
A characteristic primary serological response 
in children . . exper 1 enc i ng a primary infection 
(Murphy et al., 1982). Serum IgM and IgG responses occurred 
in all cases whereas IgA responses occurred less frequently 
and were less marked. IgA formed the maJor response 1n 
nasal secret ions and occurred in most cases. A secondary 
antibody response was detected 1n young adults primed by 
natural infection and challenged subsequently with a live 
attenuated subtype variant (Burlington et al., 1983). Serum 
IgG and IgA responses occurred in most cases; there was a 
correlation between serum and secretory IgA responses but 
not IgG responses. IgM responses were detected infrequently 
in serum and not in nasal secretions. 
Serum HI titres gradually decrease over the first 6 
months after infection and may then persist for several 
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years as subsequent infections by related virus strains 
boost titres ( "original antigenic sin"). The finding of 
antibody to H3 in 1968 in persons born before 1892, and to 
Hl 1n 1976 1n persons born before the early 1950's, 
illustrates this (Couch & Kasel, 1983). In contrast, only 
about 30% of adults will have detectable neutralizing 
antibody 1n nasal secretions 1 year following intranasal 
immunization with an inactivated . vaccine (Waldman et al., 
1973). Nasal wash IgA was detectable, by ELISA, in children 
3-6 months after natural infection but not 10-18 months 
after immunization with a live attenuated virus vaccine 
(Wright et al., 1983). 
Data on the antibody response in the lower respiratory 
tract of humans are limited. Waldman has demonstrated a 
threefold increase in HI antibody in bronchoalveolar lavage 
fluid following aerosol administration of an inactivated 
vaccine (Waldman et al., 1973). Following intranasal 
challenge with a low dose of live attenuated . vaccine, an 
antibody response in the lower respiratory tract was 
observed in primed individuals and was predominantly IgG in 
nature (Zahradnik et al., 1983). Antibody responses in all 
classes develop in mice within the 1st week, though titres 
1n bronchial washings were markedly lower than those 
serum (Zee et al., 1979). 
. 1n 
ASCs 
production 
have 
from 
been detected by 
cultured human 
measuring 
peripheral 
antibody 
blood 
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lymphocytes. Immunization with either live or inactivated 
vaccines has been shown to result in the appearance of 
circulating ASCs (Yarchoan et al., 1981; Mitchell et al., 
1982) . In experimental infection in ferrets and mice, ASCs 
detected by the haemolytic-plaque technique have been found 
in medias t in a 1 1 ym p h nodes and s p 1 e en ( McLaren & Butchko , 
1978, Reiss & Schulman, 1980b). 
Responses to Other Viral Proteins 
Using sensitive assays, antibody to the NA subunit can 
be detected in serum during both primary and secondary 
infections and may subsequently persist for many years. The 
dynamics of anti-NA antibody formation and duration in nasal 
secretions in primed individuals after natural infection are 
similar to those for the anti-HA response, with IgA the 
maJor isotype (Hruskova et 
to the M protein and NP 
al., 1976) . Antibody responses 
also develop frequently after 
infection. There are no reports of the antibody response in 
man to minor viral pioteins though polyclonal antisera and 
monoclonal antibodies to the polymerase and NSl protein have 
been prepared in animals. 
1.3.6.2 Specificity of the Response 
The specificity of antibody to the HA subunit 1n the 
context of the broad antibody response following infection 
has been characterized using virus-adsorbed sera. The 
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antibody population consists of antibodies to strain-
specific determinants of the HA of the infecting strain and 
of previous infecting subtype variants and cross-reacting 
antibodies to shared determinants of different subtype 
variants. The relative composition of the antibody response 
is largely dependent on the host's prior antigenic 
experience. After natural infection, the majority of 
unprimed children produce predominantly strain-specific 
antibodies to the infecting virus; cross-reacting antibodies 
constitute only a small component of the response (Oxford et 
al., 1981a). In contrast, the majority of adults, 
previously exposed to an ear 1 ier subtype variant, produce 
predominantly cross-reacting antibodies as well as 
strain-specific antibodies to the previously encountered 
strain (Oxford et al., 1979). 
These observations have been subsequently confirmed at 
the clonal level by analysis of the specificity of 
antibodies produced by stimulation of individual B cell 
precursors in limiting dilution cultures (Yarchoan & Nelson, 
1984). It was further shown that viruses of one subtype may 
stimulate the production of antibodies specifically directed 
to the HA of a different subtype or cross-reactive 
antibodies to shared determinants on either the HA or other 
proteins of different subtype viruses. The availability of 
monoclonal antibodies to known epitopes on the HA molecule 
now allows an examination of the response of individuals to 
particular epitopes, by testing the ability of their sera to 
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compete with the monoclonal preparations for binding to the 
HA. 
The specificity of the secretory antibody response is 
less defined although similar patterns of a predominantly 
homotypic response with reports of a broadened heterotypic 
response dependent on previous antigenic exposure have been 
described (Waldman et al., 1970; Shvartsman et al., 1977). 
In some instances the specificity of the secretory response 
has been broader than that of the corresponding serum 
response. 
1.3.6.3 Antiviral Effects of Antibody 
Neutralization of Infectivity 
Dimmack and colleagues ( Possee et al., 1982; Taylor & 
Dimmack, 1985a, b) have recently studied this aspect using 
different forms of antibody IgG, IgM and ' monomeric and 
sigA. Profound differences were found between the monomeric 
(IgG, IgA) and oligomeric (IgM, sigA) forms. The surprising 
initial finding was that type A influenza viruses, 
neutralized by polyclonal or monoclonal anti-HA IgG, 
at attached to a variety of 
temperatures between 40 
indistinguishable from those 
susceptible 
and 37°c, 
cell 
with 
types, 
kinetics 
of nonneutralized virus. 
Furthermore, the kinetics of internalization of neutralized 
virus, its subsequent uncoating, and the transport of virion 
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RNA to the cell nuclei was unchanged compared with 
infectious virus. Loss of infectivity seemed to result from 
the inhibi-tion of a later stage in the replication cycle, 
thought to be inactivation of the viral transcriptase. 
Virus neutralized by monomeric IgA did not prevent 
attach~ent of the virus to susceptible cells, but its action 
was not investigated further. 
In contrast, neutralizing IgM and sigA prevented the 
attachment of up to half the ' virus to the cells and the 
portion which did attach was not internalized. These 
authors point out that virus-IgM complexes on the cell 
surface could well render that cell susceptible to 
complement-mediated lysis. 
Lysis of Virus-Infected Cells 
Antibody may modify infection by restricting viral 
spread by lysis of virus-infected cells. This ef feet is 
mediated either by the lytic action of complement or by 
antibody-dependent cell-mediated cytotoxicity (ADCC). 
Complement-mediated lysis of virus-infected cells 
proceeds through the alternate pathway of complement (Perrin 
et al., 1976). Although the alternate pathway may be 
activated by virus-infected cells independent of antibody, 
lysis only occurs 1n the presence of specific antibody. 
Antibody mediating this effect is subtype specific and 
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develops after influenza infection and vaccination 
(Verbonitz et al., 1978). 
Similarly, antibody responsible for ADCC appears after 
natural infection and vaccination (Hashimoto et al., 1983). 
Effector cells 1n human blood mediating ADCC include NK 
cells, neutrophils, and monocytes. The NK cells are the 
most efficient effector cells and require less antibody to 
produce cytolysis than the complement-mediated mechanism. 
As the responsible antibody primarily recognizes the HA 
molecule on the infected cell surface, ADCC is also subtype 
specific. 
1.3.6.4 Protective Role of Antibody 
Anti-HA Antibody 
Evidence for the protective role of antibody is either based 
on demonstrating a correlation between antibody level and 
resistance to infection or, more directly, prevention or 
modification of infection mediated by passive transfer of 
antibody. Field and volunteer studies have shown that 
resistance to infection is correlated with serum anti-HA 
antibody levels. However, direct evidence that antibody is 
the mediator of protection has largely come from animal 
studies. Passive transfer of immune serum will protect 
recipients against homotypic challenge (Virelizier 1975). 
This is more clearly seen in irnmunosuppressed recipient mice 
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unable to mount an active host response. That antibody is 
essential for protection is demonstrated by the finding that 
mice selectively suppressed for antibody production can 
recover from infection, yet are susceptible to reinfection 
in the absence of RIA-detectable antibody (Kris et al., 
1985) . A beneficial effect of seroprophylaxis in human 
influenza has also been claimed in studies cited by 
Shvartsman & Zykov (1976). 
Infection also confers a significant but lesser degree 
of immunity to subtype variants, although the extent to 
which this is due to antibody is unclear. The observations 
that heterotypic immune serum passively transferred in mice 
is less protective than homotypic serum (Virel iz ier 197 5), 
and that cross-reacting antibody to shared determinants on 
subtype variants is less effective in neutralizing virus in 
vitro (Haaheim & Schild, 1980), are not inconsistent with a 
role of antibody in modifying infection. 
Epidemiological observations in humans also indicate 
that infection with one subtype does not confer immunity to 
other subtypes and . mice are not protected by the passive 
transfer of immune serum prior to challenge with a different 
subtype virus (Virelizier, 1975). 
Relative Importance of Serum and Secretory Antibody 
To be protective, anti-HA antibody must be present at 
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the mucosal surface, having been either produced locally or 
derived from serum. Resistance to infection in humans has 
been correlated with anti-HA in nasal washings of either the 
IgG or IgA isotypes (Couch et al., 1981; Clements et al., 
1983). Further evidence that IgG is protective has been 
inferred from the inverse relationship between 
transplacentally acquired antibody in infants and the 
frequency of influenza infection (Puck et al., 1980) . 
Maternally derived antibody in animal studies has also been 
shown to be protective though protection is mainly acquired 
during suckling (Reuman et al., 1983; Husseini et al., 
1984) . However, the protective effect of passively acquired 
antibody from immune mothers or in transfer experiments is 
limited to the lower respiratory tract, primarily the lung, 
in ferrets and . mice infection 1n the upper respiratory 
tract and trachea 1s not prevented. The protection afforded 
by serum-derived IgG to the lower respiratory tract . is 
consistent with the greater proportions of IgG relative to 
IgA in lower respiratory tract secretions compared with the 
lower proportion of IgG in nasal washings. 
Immunoglobul in isotypes are distributed in the human 
respiratory tract in a similar pattern with the relative 
proportion of IgG to IgA increasing in the lower part. The 
degree to which serum-derived IgG contributes to orevention 
of infection may accordingly vary, depending on the site of 
virus deposition. 
apparent greater 
IgA in nasal washings may assume an 
importance in orotection L against virus 
challenge in human volunteer studies when virus is usually 
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administered by intranasal droplets. When virus lS 
transmitted naturally by aerosol, it is deposited throughout 
the respiratory tract and locally produced antibody, IgA and 
possibly IgG, with an additional effect from serum-derived 
IgG, primarily to the lower respiratory tract, prevent 
infection. 
Role of Antibody in Recovery 
Since patients with agammaglobulinemia recover from 
influenza infection, it is evident that antibody . lS not 
essential for recovery. However, the beneficial effect of 
hyperimmune serum in modifying disease in humans with 
influenza suggests an additive role for antibody in recovery 
(Shvartsman & Zykov, 1976), and this is supported by animal 
studies. Passive transfer of immune serum to normal mice 
early after infection had an additive effect in reducing 
lung . virus titres (Yap & Ada, 19 79) . However, . passive 
transfer of antibody to infected nude mice, though it 
initially lowers lung . virus titres and prevents 
dissemination, has a transient effect as virus shedding 
reappears in 1-2 weeks (Askonas et al., 1982a). By 
selectively suppressing the antibody response with anti-IgM, 
Kris et al. have shown that mice can recover in the absence 
of antibody (Kris et al., 1985). 
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Antibody to Other Viral Proteins 
Antibody to the NA can neutralize viral infectivity in 
vitro or in vi VO only . in extremely high concentrations, 
probably due to steric hindrance of HA-binding sites. 
However, smaller amounts of anti-NA antibody inhibit the 
release of virus from infected cells, possibly by 
cros~-linking budding virus particles. The protective 
effect of anti-NA antibody in human influenza has been 
evaluated in field studies following the introduction of the 
H3N2 subtype and in challenge studies, 
with volunteers 
primed naturally or artificially by NA-specific vaccines, 
allowing an assessment of protection independent of an 
anti-HA an.tibody response. The presence of anti-NA antibody 
has been inversely correlated with infection rates and more 
consistently with a reduction in clinical illness (Schulman, 
197 5) . Similarly, studies in animals have shown a 
protective effect of actively acquired anti-NA antibody, 
primarily in modifying infection rather than prevention. 
This effect can be reproduced by passive transfer of anti-NA 
serum though the ef feet is less pronounced than that of 
anti-HA antibody (Virelizier, 1975). 
There is no evidence that antibodies to the M protein 
or NP have a significant role in immunity to influenza. 
Mice passively immunized against these components are not 
protected and antisera to either component has no 
neutralizing activity in vitro (Virelizier et al., 1976). 
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1.3.7 The Cell-Mediated Immune (CMI) Response 
1.3.7.1 Cell Characteristics 
T-lymphocytes have the past been classified 
according to their activities as follows: regulatory T 
cells, Th and Ts, with helper-inducer and suppressor 
activity respectively7 and effector T cells, Tc and Td, 
mediating cytotoxic and DTH activities. Table 1.2 lists the 
characteristics of T cells from human and murine sources 
with respect to their MHC requirements for activation, some 
surface markers commonly used to distinguish them, and the 
biological properties which cell preparations from primary 
responses (in vivo responses in naive hosts, e.g. mice) or 
secondary responses (usually . 1n tissue culture with 
responder cells derived from primed hosts) or which cloned 
cells display. It is apparent that T cells occur in two 
maJor cell lineages according to (1) the MHC activation 
profile and (2) the presence of specific surface markers, 
Lyt 2 and L3T4 . 1n the mouse (Lyt 1 differs only 
quantitatively) and T4 and TB 1n humans. In contrast, work 
on influenza virus-specific T cells has been largely 
responsible for showing that a particular cloned cell line 
may mediate a number of activities, e.g. in the case of 
class I MHC restricted cells, Tc and Td activities. Though 
it has not been formally shown yet, it may well be found 
that one clone of class I or II MHC restricted T cells may 
mediate cytotoxicity, DTH, and helper-induced activity. (An 
61 
alloreactive, class II MHC-restricted T-cell clone has shown 
all these activities - Dennert et al., 1981). 
Until recently, all Th cells tested were shown to be 
class II MHC restricted. Recently, Sinickas et al. ( 1985) 
have found that class I MHC-restricted Th cells could help 
Tc cell responses to murine cytomegalovirus infections 
(Sinickas et al., 1985). 
IL-2. 
Both classes of Th cells produced 
1.3.7.2 Kinetics of T Cell Response 
In a primary response, effector T cells expressing Tc 
activity are first detected in the lung 4 to 5 days after 
virus inoculation and depending on the dose of virus 
inoculated, reach a maximum 6 to 8 days later and decline 
thereafter to be no longer detectable after about 14 days. 
In mice primed to a serologically different A strain virus, 
Tc cells were detected in the lungs of challenged mice 
between day 2 to 3 and were usually absent by day 14. The 
kinetics of generation of Td cells after intranasal 
inoculation of virus was similar to that seen for Tc cells. 
There is no data on the kinetics of regulatory T cells in 
the infected lung. By analogy with findings in the spleen 
after intravenous injection of virus, Th cells would be 
found in the lung within 48 hours after virus inoculation. 
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1.3.7.3 Regulation of the Response 
There are few studies on the role of Th or Ts cells 1n 
regulating the cell-mediated response. Although there is a 
basic requirement for T help in effector T cell generation, 
there lS little evidence that 1n normal mice the 
availability of Th cells 1s a limiting factor 1n the 
generation of a cellular response to influenza virus (e.g. 
Leung et al., 1982). 
Liew & Russell ( 1983) showed that Lyt 2- cells which 
suppressed DTH activity could be detected 1n the ' mur1ne 
spleen between 2 and 7 weeks after intranasal inoculation of 
infectious virus. 
1.3.7.4 Roles for Effector T Cells 
Effector T cells or their precursors per se cannot 
prevent infection of susceptible cells by virus. The 
induction of effector T cells requires that viral antigen be 
presented by appropriate cells, such as macrophages or 
dendritic cells, or possibly by B cells. 
Effector T cells may contribute to two processes - to 
recovery from infection and/or to immunopathology which 1s 
part of the infectious process 1n normal hosts. Yap et al. 
(1978) showed that secondary effector T cells, obtained from 
the spleens of mice immunized with infectious ' virus and 
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restimulated in vitro with infectious virus, were able to 
reduce lung virus titres when transferred to infected 
. . 
syngeneic mice. The cells responsible were Lyt 1-2+, were 
class I MHC antigen restricted and possessed Tc activity. 
Transfer of the same cell preparation to infected recipients 
which were class II MHC antigen compatible did not cause a 
reduction in lung virus titres. Similar cell preparations 
upon transfer to . syngeneic recipients were found to 
cross-protect against different A strain viruses (Yap & Ada, 
1978b) . 
1983). 
These findings were later confirmed (Wells et al., 
Lin & Askonas ( 1981) and Braciale and colleagues 
(e.g. Lukacher et al., 1984) subsequently showed that, when 
adoptively transferred, cloned T cells would reduce lung 
virus titres and protect mice from death. These findings 
agree with other related work. Thus, when nu+/nu+ mice are 
infected with virus, the virus persists to high titre in the 
lungs for prolonged periods; transfer of immune spleen cells 
or secondary effector T cells to such mice rapidly reduces 
the level of virus in the lungs. 
Experiments with human volunteers also support the 
contention that Tc cells are important in the recovery from 
influenza virus infection. In studies at the Common Cold 
Centre in England, Tc cell memory (in PBLs) correlated with 
rapid clearing of administered virus in individuals, some of 
whom lacked specific antibody to HA or NA (McMichael et al., 
1983 ) . 
64 
Following the early work of Cate and Mold (1975), there 
is considerable evidence showing that the action of effector 
· T cells induces pathological damage in the lungs, but it is 
not the only cause of such damage. Thus , Yap et al . ( l 9 7 9 ) 
showed that nu+/nu+ mice inoculated with about one LDso dose 
of infectious virus displayed marked pathological lesions. 
On the other hand, a vigorous CMI response to an influenza 
virus infection can be mounted in the mouse lung with 
minimal pathology occurring, a deciding factor probably 
being the level of virus replication in the lung (Mak et 
al., 1982b) . A limited amount of replication, occurring 
with a cold-adapted mutant virus, gave rise to a low level 
only of lung consolidation. If mice are treated with 
Cyclosporin A (CsA) and infected with virus, the virus 
replicates to high titr~ but little immunopathology occurs 
because, al though effector T cells develop, their activity 
is inhibited (Schiltknecht & Ada, 1985a). 
Adoptive transfer of class II MHC-restricted effector T 
cells with DTH but undetectable Tc activity has been shown 
by two groups (Leung & Ada, 1982; Liew & Russell, 1980) not 
to reduce lung virus titres but to reduce the survival of 
infected mice given a high dose of virus. Some evidence was 
obtained to show a linkage between this effect and the DTH 
activity of the transferred cells. 
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1.3.7.5 Mode of Action of Effector T Cells 
Effector T cells mediate DTH activity ·by secreting 
lymphokines7 in contrast, the in vitro expression of 
cytotoxic activity by Tc cells does not require lymphokine 
secretion, as witnessed by the failure of Cyclosporin A to 
affect their activity (Borel, 19817 Andrus & Lafferty, 1982; 
Schiltknecht & Ada, 1985b). As expected from the in vitro 
results, effector Td cells, upon transfer to CsA-treated 
mice, do not mediate a DTH reaction, but a similar finding 
with transferred Tc cells was unexpected, even though it was 
shown that CsA did not affect the traffic of the transferred 
cells to the mouse lung. This finding provided, however, a 
possible key to understanding the in vivo findings. The 
first suggestion of a requirement for lymphokine release by 
Tc cells was the observation (Taylor & Askonas, 1983) on the 
activity of virus-speci fie Tc cell clones. Only the clone 
which secreted gamma-IFN on contact with a target cell in 
vitro could upon transfer reduce lung virus titres. The 
release of gamma-IFN by the Tc cell was dependent upon 
antigen recognition (Askonas & Pala, 1985). In apparent 
contrast to this finding, Lukacher et al. (1984) using two 
Tc cell clones in transfer experiments, one subtype-specific 
and the other cross-reactive, showed the induction and 
expression of antiviral activity ( reduction of lung viral 
titres) by both clones was highly specific. This result did 
not support the earlier finding that lymphokine secretion by 
these cells was a critical factor in the reduction of lung 
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virus titres. Yap and Ada (1978b) had earlier observed that 
upon transfer of Tc cells to mice either 24h before or after 
infection of the mice, lung viral titres did not decrease 
until about day 4-5 after initiation of viral infection. 
Th i s i s 1 n contrast to f ind i n gs 1 n the e ctr o me 1 i a v 1 r us 
(Kees & Blanden, 1977) and LCM virus (Dunlop, 1978) systems 
where transfer of specific Tc cells results in a rapid drop 
(within 24h) of viral titres in target organs. A possible 
explanation of these apparently conflicting findings 1s to 
postulate that the function of the lymphokine(s) secreted by 
the effector Tc cells was to enhance the expression of MHC 
antigens on the infected lung cells so that they became more 
susceptible to Tc cell lysis. 
1.3.8 The Generation of Memory 
1.3.8.1 B Cells 
The persistence of serum antibody over decades and the 
occurrence of secondary antibody responses during successive 
influenza infections dictate that B cell memory 1s long 
lasting. Specific B "memory" cells have been detected, 
following 
lymphocytes 
(Callard, 
1n vitro 
(PBLs), 
1979). 
stimulation of 
1n the majority 
IgG-producing cells 
peripheral blood 
of primed adults 
have been the 
predominant cell type detected. The duration of B "memory" 
cells 1n the circulation after natural infection 1s 
unknown. However, B memory cells have been detected in the 
67 
spleen, lymph nodes, and tonsils of primed individuals in 
the absence of circulating B memory cells (Callard et al., 
1982) . In mice, HA-specific B cell precursor frequency in 
the spleen increased 10- to SO-fold after primary infection 
(Cancro et al., 1978). In addition, specific ASCs generated 
spleen cell cultures and detected by the 
haemolytic-plaque assay increased tenfold after priming 
(McLaren & Pope, 1980). 
Evidence for B cell memory in the respiratory tract is 
suggested by the brisk IgA response in nasal secretions in 
primed children, after intranasal challenge with inactivated 
virus vaccine. Nasal wash IgA was not detectable by ELISA 
prior to viral challenge (Wright et al., 1983). 
Furthermore, in vitro stimulation of human tonsillar tissue 
results in the production of specific IgA as well as IgG and 
IgM (McGaughan et al., 1984). 
1.3.8.2 T Cells 
Memory for Tc cell responses is the only aspect which 
has been examined in detail. One to 6 months after . i. V. 
injection of virus, the frequency of Tc cell precursors 
found in mouse spleens was at least tenfold higher than in 
spleens from immunized mice (Askonas et al., 1982b). The 
level of Tc precursor cells in mouse spleens 2 years after 
i.v. injection of the virus was shown to be about half the 
level observed 3 weeks after i.v. injection of virus 
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(Ashman, 1982). Cells taken from the immunized mice at 2 
years also showed Th cell activity but this was not 
quantitated. 
Possibly more relevant were studies on Tc cell 
precursor frequency in mouse . lung. Mice were inoculated 
intranasally with moderate doses of egg-grown influenza A 
virus, either of a parental strain or a cold-adapted strain, 
with a mouse-adapted strain or with an UV-inactivated virus 
preparation. Infect ion with either of the egg-grown virus 
preparations caused a 20-fold increase in Tc cell precursor 
frequency in the lungs of . mice 2-6 weeks after virus 
administration, despite the fact that the parental strain 
replicated to much higher titres. With the mouse-adapted 
strain, precursor cell frequency was about 100-fold higher, 
whereas administration of inactivated virus had very little 
effect on precursor cell frequency (Mak et al., 1984). 
Though the possibility was not eliminated, little evidence 
was obtained for major traffic of Tc cells to or from the 
lungs during infection so the findings suggest that the 
precursor cells found in the lungs some time after viral 
replication are to a large extent progeny of the resident 
cells in normal lung. 
Experiments in humans have been confined to PBL 
stimulation. Using PBLs from 198 human volunteers, Mitchell 
et al. (1985) measured Tc cell levels following stimulation 
with virus and culture for 6 days. Natural infection with 
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influenza virus was shown to stimulate Tc cell "memory" two-
to four fold. McMichael et al. ( 1983) reported that there 
had been a low prevalence of influenza A infection 1n the 
Oxford and surrounding "catchment" areas since 1978, and 
they noticed that over a 5-year period there had been a 
sharp decline 1n the proportion of subjects examined who 
gave positive Tc cell responses following 1n vitro 
stimulation of PBLs. They were led to conclude from this 
that the half-life of Tc memory cells in the circulation was 
2-3 years. This is surprising in view of (1) the prolonged 
production of antibody to influenza virus and (2) the 
prolonged memory, sometimes said to be lifelong and ' 1n many 
cases 10 or more years, to a number of di seas es such as 
smallpox and measles in which T cell memory is probably an 
important component. It needs to be demonstrated 1n some 
way that sampling of PBLs 1s a reliable indication of the 
T cell immune status of an individual at different times. 
1.3.9 Vaccination Against Influenza 
1.3.9.1 Inactivated Virus Vaccines 
Inactivated ' virus ' vaccines are prepared from the 
allantoic fluid from virus-infected eggs which is purified 
and concentrated by zonal centrifugation and in activated. 
The main procedures used for inactivation of virus are 
treatment with formalin or S -propionolactone or UV light 
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irradiation. Differences 1n the immunogenicity of 
inactivated vaccines, primarily the ability to prime the 
host for a Tc response, have been related to different 
methods of activation (Ada et al., 1981). 
Whole-virus vaccines contain intact inactivated virus. 
Split-product 
formalin-treated 
vaccines are prepared from purified 
virus disrupted with chemicals to 
solubilize the viral envelope. The virus HA and NA may be 
isolated and purified to produce subunit vaccines. 
Immunogenicity 
Sufficient data are now available to make an assessment 
of the immunogenicity of inactivated virus vaccines (Potter, 
1982). In primed individuals, parenteral vaccination with 
either whole-virus or split-product . vaccines results . 1n a 
protective level of serum HI antibody 1n over 85% of 
recipients 
protective 
shortly 
levels 
after vaccination. 
of serum HI antibody 
In contrast, 
develop . 1n 
approximately only 60% of unprimed recipients of whole-virus 
vaccines and 
split-product 
to 
and 
an even 
subunit 
lesser extent after 
vaccines, requiring 
the 
the 
administration of two doses of these vaccines to achieve an 
adequate response. 
The induction of a secretory antibody response to 
inactivated virus vaccines is dependent both on the route of 
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administration and on the recipient's prior antigenic 
experience. In unprimed subjects, local antibody responses 
(i.e. in nasal washes) are of low magnitude and occur 
infrequently 
administration 
after 
of 
both 
vaccine. 
parenteral 
Parenteral 
and intranasal 
administration 
produced a local IgG response, detected by ELISA, in 94% of 
primed recipients, whereas local IgA responses developed in 
only 38% ( Clements et al., 1985) . In contrast, local IgA 
responses develop in the majority of primed recipients after 
intranasal administration (Wright et al., 1983). Although 
intranasal immunization with inactivated vaccine can induce 
protection against challenge . virus infection, there are no 
comparative studies with parenteral administration. The 
oral administration of 
induces a nasal wash 
inactivated virus 
antibody response 
vaccine 
in 
also 
primed 
individuals, though data on efficacy are lacking (Waldman et 
al., 1981) . 
The duration of serum HI antibody after vaccination 
also varies according to the recipient's prior antigenic 
experience. Primed subjects retain protective levels of 
antibody for at least 1 year, whereas antibody levels 
decline rapidly in unprimed subjects. 
The specificity of the antibody response after 
vaccination with inactivated virus in primed individuals is 
similar to that following natural infection (Oxford et al., 
1979), although a lesser degree of cross-reactivity to 
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subtype variants is induced 1n persons initially immunized 
to a new subtype virus by inactivated vaccine rather than by 
natural infection (Masurel et al., 1981). 
The T cell responses to inactivated virus vaccine 
differ in several respects to those to infectious . virus. 
Several groups (e.g. Braciale & Yap, 1978; Webster & 
Askonas, 1980) have shown that . . in mice, infectious virus was 
far more effective at inducing a primary class I restricted 
Tc cell response than was inactivated virus. Furthermore, 
inactivated virus was relatively ineffective in priming mice 
for a secondary Tc response. A secondary in vitro Tc cell 
response can be obtained from human PBLs by exposure to 
different virus preparations (McMichael et al., 1981; Ennis 
et al., 1981b). There is general agreement that whole 
inactivated virus adequately stimulates the response though 
the duration of the response has not been determined. 
Efficacy 
The protective efficacy of the different inactivated 
vaccines, including whole-virus and split-products, after 
parenteral administration are comparable, though the latter 
are less reactogenic, ranging from 60% to 80%. 
In primed people (i.e. adults who have experienced one 
or more infections by influenza virus) immunized 
parenterally with inactivated vaccines, either whole- or 
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split-virus preparations, and challenged with infectious 
homologous virus, vaccination may afford protection for 
several years. Though it is known that cross-reactive Tc 
cells are generated under these conditions, the extent to 
which they contribute to this result . is not clear. In 
unprimed people, usually young children, this immunization 
is less protective, probably because of the poor ability of 
parenterally administered inactivated virus to prime for a 
local (respiratory tract) humoral or Tc cell response. Even 
if given intranasally, inactivated virus does not induce a 
primary local humoral response in unprimed people. In 
contrast, a primary infection in children induces a local 
antibody response (Murphy et al., 1982) and primes for a 
secondary IgA response (Wright et al., 1983). 
In view of antigenic drift, how effective lS 
inactivated vaccine in protection against a challenge with a 
subtype variant virus? The study which best addresses this 
question is by Hoskins et al. (1979), who showed that the 
protective effect of inactivated . virus vaccine was limited 
to nonimmune schoolchildren who were vaccinated for the 
first time with the prevailing strain. Revaccination with 
later prevailing strains (inactivated) did not provide 
protection against subsequent challenge, whereas natural 
infection afforded almost complete protection during 
successive outbreaks involving drift viruses for more than 4 
years. As the specificity of the antibody response after 
vaccination and infection 1s similar, differences 1n the 
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extent of cross-reactive Tc responses to vaccination and 
infection may account for the lesser degree of heterotypic 
protection seen after vaccination . . 
1.3.9.2 Attenuated Virus Vaccines 
Influenza viruses have been effectively attenuated and 
the genes determining attenuation, which are located on the 
RNA segments coding for nonsurface antigens, transferred 
into reassortant viruses bearing the desired surface 
glycoproteins of current human influenza viruses. 
Host Range Mutants 
Attenuation of human influenza virus can be affected by 
the transfer of genes from host range mutants which are 
selected during repeated passage of human ' virus 1n eggs 
(e.g. A/PR/8/34(H1Nl)). However, attenuation ' lS not 
achieved if all of the six transferable PRB genes are 
transferred, as unexpectedly a mixture of the PRB and 
wild-type human influenza polymerases lS required to 
restrict replication of the reassortant virus. Subsequently 
attenuation of reassortant viruses cannot be checked by 
simple in vitro methods, imposing a significant restriction 
in their use. 
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Temperature-Sensitive (ts) Mutants 
ts mutants, produced by exposing virus-infected cells 
to a chemical mutagen (5-fluorouracil), are identified by 
being restricted in their ability to replicate in vitro at 
37°-38°c. Although influenza A reassortant viruses bearing 
ts genes were satisfactorily attenuated, their genetic 
instability, leading to reversion to virulence, has 
precluded further use. 
Cold-Adapted (ca) Mutants 
ca mutants are produced by serial passage at 
successively lower temperatures (33°-25°C) in primary chick 
kidney cell culture. This causes mutations in each of the 
six transferable genes. The resulting ca mutant is also 
temperature sensitive and reassortant ' viruses receiving all 
six of the nonsurface antigen genes exhibit the ca and ts 
phenotypes. These reassortants are genetically stable (Cox 
& Kendall, 1984) and retain their ca phenotype even during 
infection in unprimed children who continue to shed virus 
for up to 12 days (Belshe & Van Voris, 1984). Furthermore, 
ca reassortant viruses were not transmitted to fully 
susceptible children who were exposed to vaccinated children 
(Wright et al., 1982). 
The median human infective dose (HID50), determined by 
antibody response and virus shedding, in seronegative adult 
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volunteers (though presumably primed), 1s approximately 
to 106.l TCID50 for HlNl and H3N2 reassortant 
viruses (Murphy & Webster, 1985). At a dose of 107.5 
TCID50 or greater 1n adults, mild reactogenicity lS 
observed. The HID50 for a HlNl reassortant 1n unprimed 
children 1s 100-fold lower (Belshe & Van Voris, 1984). In 
children immunized with a comparable dose (106.3TCID50) of 
either an HlNl or H3N2 reassortant, the HlNl reassortant was 
less immunogenic than the H3N2 reassortant (Wright et al., 
1982) . The dynamics of the serum and secretory antibody 
responses 1n primed and unprimed individuals have been 
previously described (Section 1.3.6.1). 
Data on the T-cell response to live attenuated vaccines 
in humans are limited to the development of secondary Tc 
responses 1n primed individuals vaccinated with a PR8 
reassortant virus (Ennis et al., 198bl); there are no data 
on the Tc responses in humans to ca reassortants. In mice, 
ca reassortants can induce a primary Tc response and can 
sensitize the lungs for a secondary Tc response (Mak et al., 
1982b; Mak et al., 1984). H3N2 reassortants are more 
effective than HlNl reassortants at inducing a Tc response 
(Tao et al., 1985) . The dose of a ca mutant of 
A/AA/6/60(H2N2) required to induce the same level of Tc 
response was 100-1000 times greater than that of the 
parental strain ( Mak et al., 1982b) . A similar difference 
1n dosage was required to prime mice to resist subsequent 
challenge with a mouse-adapted strain, A/WSN(HlNl). The 
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difference 1n dosage required for pr1m1ng could be overcome 
by giving two small doses 3 weeks apart (Tannock et al., 
1984) . Using this approach, ca reassortants may induce 
cross-protection against different subtype viruses, although 
the duration of cross-protection in mice is short (Tannock & 
Paul , 198 5 ) . 
The protection afforded by ca reassortants has not been 
extensively evaluated. Seronegative adult volunteers were 
challenged with the homologous wild-type virus 1-2 months 
after vaccination with either an H3N2 ca reassortant 
(107.STCIDso) or inactivated vaccine (Clements et al., 
1984) . Ca recipients were completely protected against 
illness compared with a 72% efficacy in the inactivated 
virus vaccinees. Infection occurred in 19% of ca vacc1nees 
and in 63% of inactivated virus . vaccinees. Furthermore, 
nasal wash viral titres were 1000-fold lower 1n ca vaccinees 
shedding virus. Adult recipients of HlNl ca reassortant 
( 107 · 6TCID50) were similarly protected against illness on 
challenge 1-3 months later (82% efficacy) and against 
infection 18% of vaccinees were infected with 1000-fold 
lower viral titres than nonvaccinated controls (Betts et 
al . , 1985 ) . At 6-7 months after vaccination, protective 
efficacy remained at 91% (Clements et al., 1985). Field 
trials on the protection afforded by ca ·reassortants against 
natural infection have not demonstrated superiority over 
inactivated virus vaccines in adults within the first year 
after vaccination, though ca reasssortants were claimed to 
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be more efficacious 2 years after vaccination against 
natural infection with heterotypic HlNl virus (Couch et al, 
1985) . 
The efficacy of ca reassortants has also been studied 
in unprimed children. Children receivina an H3N2 ca 
_, 
reassortant vaccine appeared to be protected against 
subsequent natural infection with related H3N2 strains 
(Wright et al., 1982; Belshe et al., 1984). 
Avian Influenza Viruses 
The genetic determinants of attenuation of avian 
viruses in primate cells reside on one or more of the genes 
coding for nonsurface antigens. These attenuating genes 
. 
have been transferred into an avian-human reassortant which 
is restricted in its replication in primate cells. 
Infection with avian-human reassortant virus in monkeys 
induces significant resistance to subsequent challenge with 
wild-type human influenza virus. In humans, the reassortant 
was satisfactorily attenuated and irnmunogenic (Murphy & 
Webster, 1985). However, the difficulty in confirming 
attenuation in vitro and the possible interaction with wild 
avian viruses may restrict this approach. 
Deletion Mutants 
Del et ion mutants may be produced by treatment of DNA 
with restriction endonucleases. These mutants should be 
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stable because of their inability to revert and low 
likelihood of suppression by a new mutation at another site 
on the viral genome. The potential for producing deletion 
mutants of influenza virus exists, as cloned DNA of the 
influenza genome has been inserted into SV40 vectors and the 
HA expressed in eukaryotic cells. However, the transfer of 
genetic information in cloned DNA into a reassortant 
influenza virus has not been reported. 
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1.4 Aims of Thesis 
Local humoral immunity of the respiratory tract plays 
an important role in the prevent ion of viral respiratory 
tract infections, including influenza. However, the B cell 
response to viral infections 1n the respiratory tract has 
been largely characterized by measurements of antibody 1n 
serum and respiratory secretions. Essential data on local B 
cell responses pertaining to the origin of antibody 1n 
respiratory secretions and the generation of B cell memory 
in the respiratory tract are limited. The aim of this 
thesis has been to study the generation of influenza 
virus-specific ASCs and B cell memory 1n the . mur1ne lung. 
The characterization of these responses following influenza 
infection and following immunization with existing and 
potential influenza vaccines will provide original data 
relevant to the development of an effective influenza 
vaccine as well as broadening our knowledge of viral 
respiratory tract immunity. 
Specific areas relating to influenza infection which 
have been addressed 1n this thesis aim to provide data on 
the following questions: 
(i) Do influenza-virus specific ASCs appear 1n influenza-
infected lungs? 
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(ii) What is the or1g1n of influenza-virus specific ASCs in 
influenza-infected lungs? 
(iii) Do influenza virus-specific ASCs persist 1n the lung 
after influenza infection? 
(iv) I s there any evidence for inf 1 u en z a virus - spec i f i c B 
cell memory in the lung? 
These questions are also addressed 1n ' mice immunized 
with different vaccination strategies comparing the ability 
of different vaccines to induce local B cell responses. 
Finally, the development of local cellular immune responses, 
including NK cells, ASCs and Tc cells, to a novel influenza 
vaccine preparation as described. 
TABLE 1.1 Viral Proteins Recognized by Influenza Virus-specific Tc Cells 
Cellular Expression 
Proteins Stimulator Target Speciesa 
Structural: 
HA + + H,M 
NA + H 
M + + H,M 
M 
NP + H,M 
Polymerases 
PA + M PBl + M PB2 + M 
Non-Structrual 
M2 M 
NSl + M 
NS2 M 
a. H, Human; M, mouse. 
Methodb 
T,RV,F,Ab 
RM 
Ab, RM 
RV 
T,RV,RM 
RV 
RV 
RM,RV 
RV 
RV 
RV 
b. T, transfection; RV, recombinant virus; RM, reassortant or mutant virus; F, cell fusion; Ab, inhibition by antibody. 
TABLE 1.2 Characteristics of Human and Murine Influenza-immune T Cells 
MHC antigen 
requirement for 
activation 
Class I 
Class II 
Lymphocyte antigen 
expressed 
Human Mouse 
TB 
Lyt 2+ 
L3T4-
Lyt 1-
T4 
L3T4+ 
Lyt 2-
Lyt 1+ 
Biological 
Activities 
Cytotoxic 
?Suppressor 
?DTH 
Cytotoxic 
DTH 
Helper 
Helper 
Cytotoxic 
?DTH 
Helper 
DTH 
Cytotoxic 
Cell 
Preparation 
Secondary 
Primary, Secondary, 
Primary, Secondary, 
Primary 
Secondary, Clones 
Clones 
Primary, Secondary, 
Primary, Secondary, 
Secondary, Clones 
Clones 
Clones 
Clones 
Clones 
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MATERIALS AND METHODS 
2.1 Mice · 
BALB/c mice were bred at the John Curtin School of 
Medical Research. All primary inoculations were performed 
in mice 8 to 12 weeks old and mice of the same sex were used 
for each experiment. 
2.2 Viruses 
2.2.1 Normal Virus Preparations 
Influenza virus strains used in this work included: 
A/PR8 
A/Jap 
A/AA 
A/PC 
A/Jap-Bel 
B/Sing 
A/Puerto Rico/8/34 (HlNl) 
A/Japan/305/57 (H2N2) 
A/Ann Arbor/6/60 (H2N2) 
A/Port Chalmers/1/73 (H3N2) 
[A/Japan/305/57 (H2N2)xA/Bellamy/ 42 (HlNl)] 
(H2Nl) 
B/Singapore/79 
Influenza viruses and Sendai virus were grown in the 
allantoic cavity of 10 day old embryonated eggs for 40 to 
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48h at 35°C. The infectious allantoic fluid was harvested, 
centrifuged at 2000g for 30 min. to remove cell debris and 
then aliquoted and stored at -70 °c. The virus titre w·as 
expressed as the median egg infective dose (EID50) or as 
haemagglutination units (HAU). 
2.2.2 Cold-adapted Virus Preparations 
The cold-adapted influenza virus A/Ann Arbor/6/60-ca 
(H2N2) was kindly supplied by Dr. G. Tannock, University of 
Newcastle (Mak et al., 1984). 
2.2.3 Purification of Viruses 
Influenza virus was purified from infectious allantoic 
fluid by sucrose gradient centrifugation (Laver, 1969). 
Initially the virus was partially purified and concentrated 
by one cycle of adsorption and elution from chicken red 
blood Gells (CRBC) followed by ultracentrifugation (85,000g, 
90 min.). Virus particles were resuspended in a small volume 
(approximately 2-3ml) of Ca-Mg saline and then further 
purified by sedimentation through a continuous 10-55% 
sucrose gradient (SW 28 motor, 20,000 r.p.m., 60 min.). The 
virus band was collected, dialyzed against Ca-Mg saline for 
48h at 4 °C and stored at 4 °c in Ca-Mg saline with O .1% 
sodium azide. 
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2.2.4 Disruption of Virus 
Purified A/Jap virus was disrupted by sodium 
deoxycholate as previously described (Webster & Laver, 
1966). Virus was diluted to a concentration of 4xlo5 HAU/ml 
and dialyzed against 0.15M NaCl containing 0.01M Tris-HCl 
pH7.5. 2ml of virus suspension was mixed with 0. 5ml 5% 
(w/v) sodium deoxycholate and allowed to stand for 5 min. at 
35 °C leading to a reduct ion in opalescence of the virus 
suspension. Intact virus particles were removed by ultra-
centrifugation (32,000g, 30 min.) and the supernatant 
dialyzed against water. 
2.2.5 Ultraviolet Inactivation of Virus 
Infectious allantoic fluid was dialyzed against PBS for 
2-3h at 4°c. The virus suspension was then exposed to a 30 
watt Phi 1 ips germicidal ultra violet lamp at a di stance of 
15cm for 7 min. (intensity: 320uW/cm2 as measured by a 
Blak-Ray ultraviolet meter, U.V. Products Inc.). This 
procedure rendered the virus non-infectious, as judged by 
egg infectivity, with minimal change . 1n the 
haemagglutinating activity. 
2.3 Influenza-specific Micelles and Iscoms 
Micelles and iscoms ('irnmuno-stimulatory complexes') 
containing the HA and NA of A/PRB virus were kindly prepared 
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by B. Morein, Department of Microbiology, Swedish University 
of Agricultural Sciences, Uppsala, Sweden. Briefly, 10mg of 
purified A/PR8 virus (lOmg/ml) were solubilized in 2% of the 
detergent MEGA-10 (Hildreth, 1982) for lh at room 
temperature. The solubilized virus was applied on a cushion 
of 20% (w/w) sucrose containing 0.5% MEGA-10 and centrifuged 
for lh at 200,000g, 20°C. Fractions containing the 
solubilized envelope proteins 
absorbance at 280nm and pooled. 
were traced by their 
Micelles were prepared by dialysing 1mg of solubilized 
proteins 
micelles 
(0.5-1.0mg/ml) extensively 
were further purified by 
against PBS. The 
pelleting through a 
cushion of 5% and 10% sucrose, the upper layer containing 
0.1% Triton X-100. 
1n PBS, monitored 
The pelletted micelles were resuspended 
by electron microscopy and filtered 
th h O 45 t ·1 f'lt and stored at 4°C roug a . urn s er 1 e 1 er (Fig. 
2.la). 
Iscorns were prepared 1n a similar manner 
the solubilized envelope oroteins were mixed 
(Dalsgaard, 1978) to a final concentration of 
except that 
with Quil A 
0.1% (w/v) 
before dialysing against PBS. Free Quil A was removed by 
11 t . h h h a cush1'on of 5% and 10~ pe e 1ng t e 1scoms t roug u 
sucrose, the upper laying containing 0.1% Triton X-100 
(Fig. 2.lb). 
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2.4 Virus Titrations 
2.4.1 Haemagglutination Test 
Two-fold serial dilutions of virus suspension in PBS 
were prepared in a final volume of SOul in round bottomed 96 
well microtitre trays (Cooke, Microtitration). An equal 
volume of 0.5% CRBCs in PBS was added to each well. Control 
wells contained CRBCs only. The trays were shaken gently 
and kept at 4°C for 30 to 45 min. before reading. The virus 
titre was the reciprocal value of the highest dilution of 
virus which gave a positive (haemagglutination) reaction, 
and was expressed as HAU/ml. 
2.4.2 Egg Infectivity · 
Serial 10-fold dilutions of virus suspension were made 
in standard medium (0.85% NaCl, 0.03% CaCl2, 0.8% MgCl2 
and 0.5% gelatine, pH adjusted to 7.2 with 0.2M borate 
buffer) containing 
inoculated into the 
antibiotics. 
allantoic 
lOOul 
cavity of 
volumes were 
10 day old 
embryonated eggs, 4 to 5 eggs per dilution. After 40 to 48h 
incubation at 35°C, SOul of allantoic fluid was removed from 
each egg and tested for haemagglutination. The virus titre 
was expressed as the median egg infective dose (EID50) per 
ml which was determined by the modified Spearman and Karber 
method (Irwin & Cheeseman, 1939). 
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2.5 Experimental Procedures 1n Mice 
2.5.1 Intranasal Inoculation 
Mice were inoculated intranasally with 50ul of saline, 
containing virus or viral preparations, under light ether 
anaesthesia. 
2.5.2 Lung Consolidation 
Lungs were removed from infected mice and the surface 
of all lobes inspected for areas 
discoloration due to consolidation. 
of dark 
This 
purple 
area of 
discoloration was scored from O to 100% with respect to 
total lung surface. Lung consolidation was also assessed by 
dry lung weight. 
2.5.3 Lung Virus Titration 
Infected mouse lungs were removed aseptically and 
stored at -70°C until titrated. The lungs were thawed and 
homogenized 
homogenizer. 
in 3ml standard medium . using a chilled glass 
The homogenized suspension was centrifuged at 
1500g for 20 min. at 4°C. The supernatant was collected and 
virus titre determined by egg infectivity and expressed as 
the EID50 per organ extract. 
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2.5.4 Cell Preparations 
2.5.4.1 Spleen 
Spleen cell suspensions were prepared by finely mincing 
spleens and gently pressing them through a stainless steel 
sieve. Erythrocytes and dead cells were removed by 
centrifugation on a Ficoll-Isopaque gradient. Viability 
counts were performed by trypan blue exclusion method. The 
cells were suspended to the desired concentration in Eagle's 
minimal essential medium supplemented with 10% foetal calf 
serum. 
2.5.4.2 Lung 
Lung cell suspensions were prepared similarly except 
that the finely minced lungs were digested with collagenase 
(Boehringer) . Each pair of minced 1 ungs was suspended in 
minimal essential medium (2ml per pair) containing 2mg 
collagenase per ml and incubated at 37 °C for 30 min. The 
cell suspensions were washed 3x to remove the collagenase 
and then pressed through a stainless steel sieve and 
prepared as for spleen cell suspensions. 
2.5.4.3 Blood 
Blood was collected by cardiac puncture into 0.1ml 
sodium citrate (3.8%) 1n a 1ml syringe. The citrated blood 
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was cenrifuged at 10,000g, 4°C for 15 min. The plasma was 
removed and stored at -20°c. The cells were resuspended in 
minimal essential medium, washed twice and separated on a 
Ficoll-Isopaque gradient. 
2.5.5 Tracheobronchial Washinas 
The trachea was exposed in the neck and cannulated with 
a blunt 20G needle attached to a 1ml syringe containing 
0.5ml PBS. The lungs were gently lavaged 2 to 3x recovering 
0. 3 to O. 4ml of the original volume. The washings were 
centrifuged at 10,000g, 4°C for 15 min. and the supernatant 
stored at -20°c. 
2.6 Antibody Titrations 
2.6.1 Haemagglutination Inhibition (HI) Assay 
All sera and tracheobronchial washings (TBW) were first 
heat-inactivated (56°C, 30 min.) to remove nonspecific 
inhibitors of haemagglutination. Serial two-fold dilutions 
of serum or TBW in PBS were prepared in a final volume of 
25ul. 4 HAU of virus in 25ul was added to each well. After 
30 min. at room temperature, SOul of O. 5% CRBC in PBS was 
added to each well and the haemagglutination pattern read 30 
min. 
the 
later. The 
highest 
haemagglutination. 
titre was 
dilution 
expressed as the reciprocal of 
which still inhibited 
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2.5.2 Indirect Enzyme-linked Immunosorbent Assay (ELISA) 
An indirect ELISA was used to measure isotype-specific 
anti-influenza antibodies. The method 1s shown 
schematically in Fig. 2.2 and described as follows: 
( i) lOOul of 1000 HAU of purified virus per ml 1n 
carbonate-bicarbonate buffer, pH 9.6, was added per 
well to 96 well polyvinylchloride microplates 
(Ti tertek ImmunoAssay-Plate) and left overnight at 
4°c; 
(ii) virus suspension was removed and the plates washed 
3x with PBS-0.05% Tween 20 (PBS-Tw20); 
( iii) 125ul of PBS-Tw20-1%bovine serum albumin 
(PBS-Tw20-BSA) was added to each well and incubated 
(37°C, lh) to block nonspecific binding sites on the 
plate; 
(iv) after removing the BSA solution, SOul of two-fold 
serial dilutions of serum or TBW 1n PBS-Tw20-BSA 
were added to duplicate wells and incubated (37°C, 
lh) ; 
(v) the plates were washed 3x with PBS-Tw20 and lOOul of 
goat anti-mouse antiserum of appropriate heavy chain 
specificity (Cooper Biomedical Inc., Philadelphia; 
(vi) 
(vii) 
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diluted 1:2000 1n PBS-Tw20-BSA) was added and 
incubated (37°c, lh); 
after washing, lOOul of rabbit anti-goat IgG 
alkaline phosphatase conjugate (Cooper; 1:3000 
dilution) was added and incubated (37°C, lh); 
the plates were then washed 3x with PBS-Tw20 and 
once with diethanolamine buffer, pH 9.8. The 
substrate p-nitrophenyl phosphate (Sigma Chemical 
Co; U.S.A.) was dissolved in diethanolamine buffer 
at a concentration of lmg/ml and lOOul added to each 
well and incubated (37°C, lh); 
(viii) after lh, SOul of 3M NaOH was added to each well to 
stop the enzyme reaction and optical density (O.D.) 
measured 1n an Auto ELISA Reader (Dynatech) at 
405nm. 
Two negative controls were included in each plate: (a) 
wells to which no serum or TBW was added, and (b) wells 
containing normal mouse serum and TBW . 1n dilutions 
corresponding to the test sample. The endpoint was defined 
as the highest dilution with a mean O.D. greater than twice 
the mean O.D. of the negative control with the higher O.D. 
The titre was expressed as log2 of the reciprocal of the 
endpoint dilution. All titrations presented in individual 
experiments were performed in parallel. 
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2.7 ELISA-Plaque Assay 
The ELISA-plaque assay for enumerating ASCs 1s similar 
1n principle to the indirect ELISA (Fig. 2. 2). The steps 
involved include: 
( i ) 
( ii ) 
( iii ) 
(iv) 
4ml of 1000 HAU of purified 
carbonate-bicarbonate buffer was 
Linbro six-well plates 
overnight at 4°C; 
(3.5 X 
virus per ml 1n 
added per well to 
1.0cm) and left 
the wells were washed with PBS-Tw20 3x. 
PBS-Tw20-BSA was added (2ml per well) and incubated 
(37°C, lh); 
the BSA solution was removed and 1.5ml of cell 
suspension containing Cytodex microcarriers (lmg / ml ) 
was added to the plates on a levelled surface in a 
gas chamber. The plates were incubated for 3-4h at 
37°c in a humid atmosphere containing 10% CO2· 
after washing 3x with PBS-Tw20, 1ml of goat 
anti-mouse antiserum of appropriate heavy chain 
specificity (Cooper; 1:2000) was added and incubated 
(37°C, 90 min.); 
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(v) after washing, 1ml of rabbit anti-goat lgG alkaline 
phosphatase conjugate (Cooper; 1:1000) was added and 
left overnight at 4°C; 
(vi) th~ substrate solution used was 5-bromo-4-chloro-3-
(vii) 
indolyl phosphate dissolved 1n 2-amino-2-methyl-l-
proponal buffer as described previously (Sedgwick & 
Holt, 1983a) in a final concentration of 0.05%. The 
substrate solution was warmed to 40°C and 3% agarose 
solution (Sigma Type 1) was added to a final 
concentration of 0.6% agarose; 
after the plates were washed, emptied and placed on 
a level surface, 1ml of warmed agarose substrate 
mixture was added to each well. After the mixture 
gelled, the plates were incubated (37°C, 2h); 
(viii) plaques appearing as blue spots were enumerated 
using a dissecting microscope (xl2) (Fig. 2.3). 
The ELISA-plaque assay was modified 1n some experiments 
by initially coating the plates with a monoclonal antibody 
to the HA of A/Jap virus (supplied by Mr. R. Tha Hla). The 
optimal concentration of the anti-A/Jap MAb 1n the 
bicarbonate buffer was coated onto plates overnight at 4°C. 
After blocking with PBS-Tw20-BSA, 4ml of purified A/ Jap 
virus ( 1000 HAU /ml) in PBS-BSA was added to each well and 
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incubated for lh at 37 °c. After washing, cell suspensions 
were added and the assay completed as above. 
2.8 Cytotoxicity Assays 
2.8.1 Tc Cell Mediated Cytotoxicity 
P815 cells (H-2d,methylcholanthrene-induced mastocytoma 
of DBA/2 mice) were used as target cells. The cells were 
maintained in Dulbecco's modified Eagle medium supplemented 
with 10% heat-inactivated foetal calf serum, 100 units/ml of 
penicillin and lOOug/ml of streptomycin sulphate. The cel l 
cultures were kept at 37°C under a gas phase of 10% CO2 and 
subcultured every 2 to 3 days. 
4 to lOx106 target cells were labelled with 300 to 
400uci5lcr (sodium chromate, Amersham, UK) for lh at 37°c 1n 
a total volume of O. 5ml. During labelling the cells were 
shaken occasionally to prevent settling. After labelling 
the cells were washed once and resuspended 1n medium and 
divided into two equal lots. One lot was infected with 
virus ( 15-30 EIDso/ cell) for lh at 3 7 °c and the other lot 
left uninfected. After infect ion the cells were washed 
twice and diluted to 1x105 /ml and O. lml was added to each 
well of a 96 well flat bottomed tissue culture plate 
containing 0.1ml of appropriate dilutions of effector cells. 
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Spontaneous Slcr release (medium release) was 
determined by adding 0.1ml 
containing 0.1ml of medium. 
of target cells to wells 
For total releasable Slcr 
release, 0. lml of target cells were added to O. lml of 1% 
Triton X-100. 
wells. 
All samples were tested 1n quadruplicate 
Effector and target cell contact was initiated by 
centrifugation at lOOrpm (300g) for 1 min. The plates were 
incubated for 6h at 37°C in a gas chamber (10% CO2, 7% 02, 
After incubation 0.1ml of supernatant was removed 
from each well and the radioactivity measured 1n a gamma-
counter. 
The specific 
following formula 
Slcr release was determined by the 
mean counts from 
% Specific= effector cells 
lysis mean counts from 
total release 
mean counts from 
medium release 
mean counts from 
medium release 
The data was processed with a digital PDP 11/34 
computer which calculated % specific lysis and standard 
errors for each set of data. 
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2.8.2 NK Cell Mediated Cytotoxicity 
YAC-1 cells (H-2a Moloney leukaemia virus-induced T 
cell lymphoma of A/ Sn mice) were used as target cells and 
maintained as for P815 cells. 
The assay for NK cell activity was similar to that 
described for Tc cell cytotoxicity assays except that target 
cells were uninfected. 
2.9 Depletion of Ig-bearing Cells 
The method for depleting cell suspensions of Ig-bearing 
cells was adopted, with slight modifications, from Parish et 
a 1 . ( 1 9 7 4 ) . Br i e f 1 y S RB Cs were coup 1 e d w i th sheep 
anti-mouse Ig by CrCl3 treatment. Rosettes formed between 
SRBC and Ig-bearing cells were removed from the cell 
suspensions by centrifugation through a Ficoll-Isopaque 
gradient. The Ig-negat i ve cells were collected from the 
Ficoll-Isopaque/medium interface. 
2.10 Depletion of L3T4+ Cells 
Spleen and lung cell suspensions, at a dilution of 107 
cells/ml, were incubated with a 1:10 dilution of rat 
monoclonal antibody to the L3T4 lymphocyte marker (supplied 
by Dr. R. Ceredig) at 37 °c. After 20 min. a 1: 10 dilution 
of low-toxicity rabbit complement ( Cedar lane Laboratories) 
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was added and incubated for a further hour. After washina 
~ 
twice dead cells were removed on a Ficoll-Isopaque gradient. 
2.11 Generation of ASCs in vitro 
Spleen and lung cell suspensions were cultured 1n 
minimal essential medium supplemented with 10% foetal calf 
serum, 10-4M 2-mercaptoethanol and antibiotics (1 to 2 x 106 
cells/ml). The flasks were incubated at 37°C in a gas phase 
of 10% CO2 in air. Viable cells were obtained from the 
culture after centrifugation on a Ficoll-Isopaque gradient. 
Cultures were stimulated by the addition of purified 
influenza . virus at the beginning of the culture period. 
Cultures from normal mice were stimulated with 20 HAU/ml and 
incubated for 4 days. Cultures from primed . mice were 
stimulated with 10 HAU/ml and incubated for 5 days. 
2.12 Limiting Dilution Analysis 
Lung cell suspensions from normal and primed mice were 
used as responder cell populations. Syngeneic spleen cells, 
infected with 10 to 20 EIDso / cell of A/PR8 virus for 60 min 
at 37°c, were irradiated at 2000 rads from a 60co source and 
used as stimulator cells. Dead cells and erythrocytes were 
removed from both responder and stimulator cell populations 
by centrifugation on Ficoll-Isopaque gradients. 
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Graded numbers of responder living cells, 24 replicates 
for each cell dose, were cultured with 2x106 stimulator 
cells 1n a final volume of 200ul 1n 96 well Linbro 
round-bottom tissue culture plates for 6 days at 37°C in a 
gas phase of 10% CO2. The culture medium was supplemented 
with T cell growth factor (Mak et al., 1984). 
After culture, the plates containing effector cells 
were centrifuged at 300g for 1 min., the medium removed and 
replaced with O. lml of fresh medium supplemented with 10% 
foetal calf serum. Slcr labelled P815 cells, either 
infected or uninfected with A/PR8 virus, were used as target 
cells. 1x104 target cells in 0.1ml medium was added to each 
well. Effector and target cell contact was initiated by 
centrifugation of the plates at 300g for 1 min. and plates 
were then incubated for 6h at 37 °c in a gassed incubator. 
0.1ml of medium was removed from each well and counted in a 
gamma-counter. Spontaneous release from control cultures 
consisting of virus-infected irradiated stimulator cells 
alone was never significantly higher than spontaneous medium 
release. Cultures which caused Slcr release greater than 3 
standard deviations above the spontaneous medium release of 
cultures without responder cells were scored positive for 
cytotoxic activity. 
The logarithm of the percentage of negative cells was 
plotted against the number of responder cells per well. Tc 
cell precursor frequency was determined as the reciprocal of 
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the number of responder cells that gave 36.8% negative 
cultures. 
2.13 Immunohistochemistry 
2.13.1 Fixation 
1mm strips of lung tissue were fixed by immersion ' 1n 
periodate-lysine-paraformaldehyde (McLean & Nakane, 1974) 
for . 3 to 4h at 4°C. After fixation the strips were washed 
1n several changes of 7% sucrose in O.OSM phosphate buffer, 
pH 7.4, and stored 1n this buffer for less than 24h. 
2.13.2 Embedding 
Excess buffer was removed by blotting and the strips of 
lung tissue snap frozen in liquid monochloro-difluoromethane 
(freon 22). The frozen tissue was placed into 15mm diameter 
alfoil cups and covered with cold (4°C) OCT embedding 
compound (Ames Tissue Tek). The cups were suspended over 
liquid nitrogen until the OCT compound was frozen. The 
frozen blocks were removed from the alfoil cups and stored 
at -20°C until use. 
2.13.3 Sectioning 
The blocks were sectioned using a cryostat at -20°C. 
Frozen sections (5-lOum) were allowed to adhere to poly-L-
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lysine coated slides and air dried. 
2.13.4 Immunoperoxidase Technique 
Sections were stained . using the indirect avidin-
biotin-complex (ABC) immunoperoxidase technique (Hsu et al., 
1981) as previously modified (Hume & Gordon, 1983): 
( i ) 
( ii) 
( iii) 
(iv) 
the OCT compound was removed by washing in PBS: 
the sections were dehydrated through graded alcohol 
baths (50-100%), and placed in 0.1% H202 in methanol 
for 30 min. to eliminate endogenous peroxidase 
activity; 
after passing the sections back down the graded 
alcohol baths ( 100-50%) the sections were covered 
with PBS containing 2% normal horse serum and rabbit 
anti-mouse IgG (Litton Bionetics, 1:100 dilution ) 
for 30 min. to block non-specific antibody-binding 
sites. The anti-mouse IgG was omitted when staining 
for lg-bearing cells. 
the blocking solution was removed and the primary 
antibody applied to the sections for 2h. Primary 
rat monoclonal antibodies following . murine to the 
antigens were used F4/80 and PGP, markers of 
mur ine phagocytes (supplied by Dr. D. Hume), la 
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antigens (ATCC TIB120), L3T4 antigen ( supplied by 
Dr. R. Ceredig). In addition, lg-bearing cells were 
stained using affinity purified anti-mouse Ig 
antiserum (Cooper Biomedical); 
( v) sect ions were washed 3x 1n PBS over 10 min. and 
biotinylated sheep anti-rat Ig (Amersham U.K.; 1:200 
dilution) applied to the sections for lh; 
(vi) 
(vii) 
after washing, the sections were covered with a 
preformed avidin-biotin-peroxidase complex 
(Vectastain ABC System, Vector Labs) for lh; 
after washing in PBS, sections were stained with the 
peroxidase substrate, diaminobenzidine and 0.02% 
H202, made up in PBS plus lOmM imidazole, pH 7.4, 
for 5 min. ; 
(viii) the sections were washed 1n water and lightly 
counterstained with Mayers haematoxylin, dehydrated 
through graded alcohol baths, cleared in xylene and 
mounted under coverslips using Depex. 
2.14 Statistical Methods 
Student's t test was used to compare continuous 
variables and linear correlation coefficients determined for 
bivariate groups. 
FIG. 2 .1 Electron micrographs of HANA micelles (a) and 
iscoms (b). 

FIG. 2.2 Schematic outline of 
ELISA-plaque assay. 
indirect ELISA and 
Indirect ELISA 
1 Antigen adsorbed to plate 
Wash 
2 Add serum : specific antibody 
attaches to antigen . 
Wash 
3 Add heavy chain specific 
antiglobulin(secondary antibody) . 
Wash 
4 Add enzyme labelled ant i globulin 
to secondary antibody . 
Wash 
5 Add soluble substrate 
(p-nitrophenyl phosphate ): 
measure O.D . of solution. 
w 
w 
w 
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ELISA Plaque Assay 
1 Antigen adsorbed to plate . 
Wash 
2 Add cell suspension : secreted 
antibody attaches to antigen . 
Wash 
3 Add heavy chain specific 
an tig Io bulin(s econdary antibody) . 
Wash 
4 Add enzyme labelled antiglobulin 
to secondary antibody . 
Wash 
5 Add soluble substrate 
( 5-bromo-chloro-indolyl phosphate ) : 
count plaques formed by insoluble 
color product. 
FIG. 2.3 Appearance of plaques in ELISA-plaque assay. 
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INTRODUCTION 
In order to address the aims of the thesis, it was 
essential to be able to accurately enumerate cells secreting 
influenza-specific antibodies. Since its discovery, the 
Jerne haemolytic-plaque assay, and its modifications, has 
been the most commonly used technique for enumerating ASCs. 
This technique relies upon the complement-mediated 
antibody-dependent lysis of untreated SRBCs or SRBCs coupled 
with either antigen, protein A or antiglobulin for the 
detection of either antigen specific or non-specific ASCs. 
The limitations of the haemolytic-plaque assay include its 
relative insensitivity and the need to enumerate IgG and IgA 
secreting cells by indirect plaque formation. 
Whilst the haemolytic-plaque assay has been extensively 
utilized in studies on immune response to non-replicating 
antigens, it has found only limited application in the study 
of B cell responses to replicating antigens. 
Influenza-specific ASCs have been previously detected using 
the haemolytic-plaque technique by coupling the virus to 
periodate treated SRBCs (McLaren et al., 1978; Reiss & 
Schulman, 1980b). However this method has not been 
universally reproducible. 
A technique employing ELISA methodology for enumerating 
specific ASCs to soluble antigens was recently described by 
two separate groups employing either the alkaline 
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phosphatase or horseradish-peroxidase enzyme-substrate 
sys terns (Sedgwick & Holt, 1983a; Czerk in sky et al. , 1983) . 
This technique referred to as either the ELISA-plaque assay 
or ELISPOT assay, lS more sensitive than the 
haemolytic-plaque assay and can be readily adapted to 
accurately distinguish antibody isotypes. Previous 
applications of this method at the time work on this thesis 
commenced included the detection of cells secreting 
antibodies specific for ovalbumin (Sedgwick & Holt, 1983b) 
rheumatoid factor (Tarkowski et al., 1984) and tetanus 
toxoid (Czerkinsky et al., 1984). 
The ELISA-plaque assay employing the alkaline 
phosphatase enzyme-substrate system was adapted to enumerate 
influenza-specific ASCs. 
detail 1n Section 2.7. 
The technique is described . 1n 
In this chapter, the experiments 
designed to standardize the assay and demonstrate its 
specificity are described. 
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RESULTS 
3.1 Standardization of the ELISA-plaque assay 
3.1.1 Antigen Titration 
The optimal amount of viral antigen needed for coating 
plates was determined by incubating spleen cell suspensions 
from mice immunized i.v. with 1000 HAU A/Jap virus on plates 
coated with variable concentrations of purified intact A/Jap 
virus. There was a significant increase 1n the IgM 
secreting cells detected with increasing concentrations of 
purified virus up to 1000 HAU/ml (Fig. 3.1). Plaques could 
also be reliably discerned at this concentration whereas at 
lower concentrations plaques progressively became fainter. 
Although the sensitivity of the assay . lS slightly 
sub-optimal at 1000 HAU/ml, this concentration was selected 
for subsequent experiments to achieve efficient use of virus 
stocks. 
3.1.2 Culture Conditions 
The volume of medium used during incubation of cell 
suspensions has been previously reported to be an important 
parameter affecting the accuracy of the assay (Czerkinsky 
et al . , 1983 ) . This was examined by enumerating IgM 
secreting cells in spleen cell suspensions from immunized 
mice using constant cell density (2x105 cells/ml) 1n 
10 9 
variable volumes of medium - 1.0ml, l.2ml, · 1.5ml and 2.0ml. 
There was no significant difference 1n the number of 
ASCs/106 cells detected under these conditions. 1. 5ml was 
chosen for subsequent experiments as smaller volumes did not 
cover the surface of the wells completely. 
In order to determine whether the cell density affected 
the accuracy of the assay, variable numbers of immunized 
spleen cells were incubated in a constant volume of medium. 
There was a significant correlation (r = 0.998, p <0.01) 
between the number of cells incubated and the number of ASCs 
detected (Fig. 3.2). Thus 1n subsequent experiments the 
number of ASCs detected could be accurately adjusted to be 
expressed as ASCs/106 cells depending on the number of cells 
incubated. 
The culture medium used for incubating cell suspensions 
was supplemented with microcarrier beads (Cytodex 1) as 
previously described (Czerkinsky et al., 1983). This 
resulted in improved definition of plaques without affecting 
the sensi ti vi ty of the assay. The effect of microcarrier 
beads on plaque formation is supposedly due to accelerated 
sedimentation of the cells onto the solid phase. In 
addition, the beads may also absorb free immunoglobulins 
secreted into the medium either directly or via Fe receptors 
on macrophages which selectively bind to the beads (Ren, 
1982) . 
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3.1.3 Reagents 
Chequerboard titrations were performed to determine the 
optimal dilutions of the primary (goat anti-mouse Ig) and 
secondary ( rabbit anti-goat Ig) antibodies. The substrate 
solution was used at a concentration of 0.05% as lower 
concentrations reduced the accuracy of the assay and higher 
.concentrations increased the background staining. The 
incubation time for the substrate solution was, however, 
varied with the concentrations of the primary and secondary 
antibodies (Table 3.1). There was no significant difference 
1n the number of ASCs detected within the range of 
concentrations tested for each of the primary antibodies. 
experiments were performed using a 1:2000 Subsequent 
dilution. There was both a reduct ion 1n the number of 
plaques and in plaque definition with concentrations of the 
secondary antibody below 1:1000; a 1:1000 dilution was used 
subsequently. There were no plaques formed if either the 
primary or secondary antibody was omitted. Plaque numbers 
and definition were increased by 2h incubation of the 
substrate; longer incubation periods resulted 1n greater 
background staining. 
3.2 Precision of the ELISA-plaque Assay 
The precision of the ELISA-plaque assay was estimated 
by determining the intra-plate and inter-plate variation in 
plaque counts using the same cell suspensions so as to avoid 
that source of biological variation. The coefficient of 
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variation for intra-plate counts, determined 1n over fifty 
experiments, was 9%. Inter-plate variation, determined 1n 
five experiments, was 12%. The total assay variation 
calculated from the~e results was 15%. 
3.3 Effect of Enzyme Digestion of Cell Suspensions 
The effect of digesting lung and ·spleen cell 
suspensions with collagenase prior to assaying for ASCs was 
evaluated to determine if the yield of viable cells and in 
particular ASCs could be increased. 
Lung and spleen cell suspensions were prepared as 
described in Section 2.5.4. Preliminary experiments showed 
that the maximal yield of viable cells from normal lungs was 
achieved by incubating lung cell suspensions with 2ml of 
collagenase (2mg per ml of medium) per lung. This resulted 
1n a 10 to 20 fold . increase in the yield of total viable 
cells from each lung. The effect of collagenase digestion 
on the yield of ASCs from immunized mice is shown in Table 
3.2. Collagenase digestion had no significant effect on the 
yield of viable cells or ASCs from spleen cell suspensions. 
In contrast, the yield of viable cells and ASC's from lung 
cell suspensions was increased by 20 to 30 fold. 
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3.4 Dependence of Plaque Formation on Antibody Production 
and Secretion 
3.4.1 Effect of cycloheximide on plaque formation 
To demonstrate that plaque formation was dependent on 
antibody production, variable concentrations of 
cycloheximide were incubated with spleen cell suspensions 
for lh at 37°c. The cell suspensions were washed to remove 
secreted pre-formed antibodies and then assayed for ASCs 
after re-adding the corresponding cncentration of 
cycloheximide (Table 3. 3 ) • Under these conditions, 
incubation with cycloheximide shortly before and during the 
assay reduced plaque counts but did not completely ablate 
plaque formation probably as a result of the continued 
secret ion of preformed antibodies. In order to inhibit 
antibody synthesis completely, cycloheximide was added to 
primary spleen cell cultures during the final 18 hours of 
culture. Prior to assaying for ASCs, the cell . suspensions 
were washed and dead cells removed by centrifugation on 
Ficoll. The corresponding concentration of cycloheximide 
was added to the cell suspensions at the time of the plaque 
assay. Although increasing concentrations of cycloheximide 
reduced the yield of viable cells after culture, greater 
that 106 cells were recovered for each assay. Plaque 
formation was completely ablated by lug cyloheximide /ml. 
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3.4.2 Effect of depleting cell suspensions of Ig-bearing 
cells 
To demonstrate that plaque formation was dependent on 
the presence of ASCs, spleen cell suspensions were depleted 
of lg-bearing cells by separating out cells forming rosettes 
with SRBCs coupled with anti-mouse Ig. IgM and IgG plaque 
counts in the non-rosetting fraction were reduced to less 
than 5% of the unseparated cell suspensions (Fig. 3.3). 
3.5 Specificity of the ELISA-plaque Assay 
3.5.1 Detection of influenza-specific ASCs by the 
ELISA-plaque assay 
Several experiments demonstrated the specificity 
ELISA-plaque assay to detect influenza-specific ASC s 
of the 
(Table 
3.4). Plaques were infrequently detected in spleen and lung 
cell suspensions from normal unimmunized mice when assayed 
on influenza-coated plates. These were mostly IgM plaques 
( < 5 per 106 cells), and only occasionally IgG and IgA 
plaques ( < 1 per 106 cells). Plaques were rarely detected 
when cell suspensions from influenza infected mice were 
assayed on plates coated with either uninfected allantoic 
fluid or bicarbonate buffer only. In addition, 
influenza-specific ASCs were not detected in significant 
numbers in cell suspensions from mice immunized with Sendai 
virus. 
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The number of plaques formed by influenza-specific ASCs 
was also shown to be dependent on the dose of virus used for 
immunization (Fig. 3.4). 
3 . 5. 2 Effect of influenza ' virus type and subtype on the 
specificity of the ELISA-plaque assay 
The specificity of the assay was further evaluated by 
immunizing mice with influenza viruses of different type and 
subtype specificities. Groups of mice were immunized with 
either A/Jap, A/Jap-Bel, A/PC, A/PR8 or B/Sing viruses. The 
ELISA-plaque assay was performed on spleen and lung cell 
suspensions using plates coated with the above viruses 
( Tab 1 e 3 . 5 ) . The greatest number of plaques for al l 
isotypes was seen with the homologous combinations. 
However, significant cross reaction in each isotype was seen 
within the Type A influenza viruses. A very small number of 
cross reactive plaques, of the IgM isotype only, was seen 
with the Type B virus. 
The observation that some cross reaction was seen 
between viruses with different surface antigens suggested 
that this was due to the recognition of non-surface 
antigens. This possibility was supported by the 
demonstration that plaque formation was completely inhibited 
by adding virus disrupted by detergent to the cell 
suspension during the assay, but was still observed in the 
presence of intact virus (Fig. 3.5). 
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3. 5. 3 Detection of subtype specific ASCs by a modified 
ELISA-plaque assay 
The recognition of non-surface antigens occurs as a 
result of disruption of the whole virus during adsorption to 
the plate. To avoid disruption of the virus, A/Jap virus 
was bound to plates initially coated with a monoclonal 
antibody to the HA of the A/Jap . virus. The effect of this 
modification on the specificity of the ELISA-plaque assay is 
shown in Table 3. 6. Whereas approximately 40% of the IgM 
ASCs induced by immunization with A/PR8 formed plaques on 
plates coated with A/Jap virus alone, less than 2% formed 
plaques on plates initially coated with antibody. 
Approximately 55% of the IgM ASCs induced by immunization 
with A/Jap virus formed plaques on the antibody coated 
plates. 
FIG. 3.1 Antigen Titration. IgM ASCs in day 4 spleens 
after primary i.v. immunization (1,000 HAU of 
A/ Jap virus). Plates were coated with 
various concentrations of A/Jap virus. 
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FIG. 3. 2 IgM ASCs in day 6 spleens after primary 1.v. 
immunization (1,000 HAU of A/Jap virus). 
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TABLE 3.1 Chequerbo ard Titration of Reagents 
ASCs/106 Cells (Mean± SD)a 
Primary antibody Secondary antibody Substrate 
(goat anti - mouse Ig) (Conjugated rabbit anti-goat Ig) Incubati o n Time (h) 
Specificity Dilution 1:1000 1:2000 1:4000 
IgMb 1:1000 54 ± 13 21 ± 5 11 ± 6 1 
65 ± 13 28 ± 6 16 ± 8 2 
1:2000 45 ± 4 25 ± 6 12 ± 4 1 
53 ± 3 30 ± 7 19 ± 1 2 
IgGC 1:1000 70 ± 9 42 ± 3 21 ± 1 1 
82 ± 5 60 ± 3 37 ± 6 2 
1: 2000 61 ± 2 42 ± 11 23 ± 2 1 
72 ± 3 59 ± 10 36 ± 7 2 
IgAd 1:10 00 9 4 ± 22 37 ± 7 N.D. 2 
1:2000 110 ± 25 4 7 ± 6 N. D. 2 
a . Values represent mean± SD of triplicate a s s ays 
b . Day 4 spleens after i.v. immunization (1000 HAU) 
c . Day 6 spleens after i.v. immunization (1000 HAU) 
d . Day 14 lungs after i.n. inoculation. 
Collagenase 
Treatment 
TABLE 3.2 Effect of Collagenase on Cell Yields and ASCs 
ASCs/mouse (mean± SD)a 
Viable cells per mouse Spleenb Lunge 
Spleenb Lunge IgM IgG IgM IgG IgA 
1.7 x108 9.6 x105 32,640 18,190 
±2,040 ±2,210 
208 ± 10 86 ± 15 119 ± 12 
+ l.24xlo8 l.63xl07 27,652 15,872 
±1,612 ±1,612 
a. Values represent mean± SD of 5 replicate assays. 
b. Day 6 spleens after i.v. immunization (1,000 HAU). 
c. Day 12 lungs after i.n. inoculation (103EID50). 
3,896 
±244 
3,683 
±342 
3,081 
±326 
TABLE 3.3 
Cycloheximide Concentration 
(ug/ml) 
Nil 
0.5 
1.0 
2.0 
4.0 
Effect of Cycloheximide on Plaque Formation 
IgM ASCs/106 cells (mean± SD)a 
Number of Hours Cycloheximide added to 
Cell Suspensions before Assay 
lhb lBhC 
176 ± 11 381 ± 37 
119 ± 5 12 ± 5 
91 ± 5 1 ± 1 
56 ± 8 0 
57 ± 8 0 
a. Values represent mean r SD of triplicate assays 
b. Day 7 spleens after primary i.v. immunization (1000 HAU) 
c . Suspensions of pooled spleen cells obtained from 2 normal mice stimulated in vitro for 
4 days. Cell suspensions from unstimulated cultures produced < 5 IgM ASCs/106 cells . 
FIG. 3.3 
~ 
(A) IgM ASCs in day 4 spleens after primary 
i.v. immunization (1,000 HAU of A/Jap 
virus). (B) IgG ASCs in day 4 spleens after 
secondary i.v. immunization (two injections 
of 1,000 HAU of A/Jap each). 1, normal 
spleens; 2, suspensions of unseparated cells 
from immunized mice; 3, suspensions depleted 
of lg-bearing cells from immunized mice. 
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TABLE 3.4 The detection of Influenza-specific ASCs by the ELISA-plaque assay 
Virus for Virus on ASCs per 106 cells (mean± SD)a 
Immunization plate IgM5 IgGl'.5 IgAC 
A/Jap 2 ± 1 0 0 
A/Jap - 0.5 0 0 
(Buffer only) 
A/Jap 
- 4 0 0 
(Normal allantoic fluid) 
A/Jap A/Jap 118 ± 6 98 ± 3 81 ± 7 
Sendai A/Jap 4 ± 2 0 0 
a. Values represent mean± SD of triplicate assays 
b. Day 6 spleens after primary i.v. immunization (1000 HAU) 
c. Day 12 lungs after primary i.n. inoculation 
FIG. 3.4 IgM ASCs in day 4 spleens after primary i.v. 
immunization with graded doses of A/Jap 
virus. 
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TALE 3.5 
Virus for 
Immuniza-
tion 
A/Jap 
(H2N2) 
A/Jap-Bel 
(H2Nl) 
A/PC 
(H3N2) 
A/PR8 
(HlNl) 
B/Sing 
Effect of influenza virus type and subtype on 
the specificity of the ELISA-plaque assay 
Ig 
Isotype 
IgM 
IgG 
IgA 
IgM 
IgG 
IgA 
IgM 
IgG 
IgA 
IgM 
IgG 
IgA 
A/Jap 
382 
116 
170 
129 
175 
128 
365 
55 
216 
53 
31 
102 
9 
0 
0 
ASCs per 106 cellsa 
Virus coated on Plates 
A/Jap-Bel 
171 
91 
14 
243 
184 
170 
61 
26 
23 
23 
20 
8 
4 
0 
0 
A/PC 
22 
20 
5 
44 
76 
85 
600 
172 
299 
25 
12 
0 
6 
0 
0 
A/PR8 
39 
0 
5 
11 
6 
4 
180 
16 
10 
422 
88 
158 
13 
0 
0 
8/Sing 
12 
0 
0 
6 
0 
0 
11 
0 
0 
13 
0 
0 
110 
40 
70 
a. Values represent mean of duplicate assays. 
b. Day 5 spleens after primary i.v. immunizations (1000 
HAU). 
c. Day 14 lungs after primary i.n. inoculations. 
FIG. 3. 5 IgM ASCs 1n day 4 spleens after primary . 1.v. 
immunization (1,000 HAU of A/Jap virus). 
Various concentrations of either purified 
intact A/Jap virus (solid line) or 
detergent-disrupted virus (broken line) were 
added to cell suspensions at the time of 
assay. 
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TABLE 3.6 Specificity of Modified ELISA-plaque assay 
IgM ASCs/106 cells (Mean± so)b on plates coated with: 
Virus used for 
immunizationa A/Jap A/PR8 Anti-A/Jap MAb and A/Jap 
I 
A/Jap 308 ± 24 81 ± 35 167 ± 15 
A/PR8 88 ± 9 232 ± 63 3 ± 2 
a. Mice immunized i.v. with 1000 HAU infectious virus. 
b. Values represent mean± SD of triplicate assays using pooled spleen cell suspensions 
from 3 mice at day 4. 
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DISCUSSION 
An ELISA-plaque assay 1s described which can reliably 
enumerate influenza-specific ASCs. The ELISA-plaque assay 
was initially chosen in preference to the haemolytic-plaque 
assay because of the limitations of the haemolytic-plaque 
assay. Subsequently however, 1n experiments designed to 
compare the sensitivity of the ELISA-plaque assay with the 
haemolytic-plaque assay, the previously reported successful 
use of the haemolytic-plaque assay to 
influenza-specific ASCs could not be reproduced. 
detect 
At the 
time work on this thesis was initiated, the ELISA-plaque 
assay had not been applied to enumerate ASCs specific for 
infecting agents. Subsequently, a report describing splenic 
ASCs following intravenous immunization with lymphocytic 
choriomeningitis . virus and vesicular stomatitis virus 
employed the ELISA-plaque assay (Moskophidis & 
Lehmann-Grube, 1984). Just as the ELISA technique for 
antibody detection can be used to measure antibodies of any 
specificity, the ELISA-plaque technique could most likely be 
adapted to estimate the numbers of cells secreting 
antibodies to any infectious agent and probably in any host 
organ. 
A variety of experiments attest to the reliability and 
reproducibility of the ELISA-plaque assay for enumerating 
cells secreting influenza-specific antibodies of different 
isotypes. Plaque format ion was shown to be dependent on 
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antibody production and on the presence of cell s secreting 
antibody. 
by washing 
Although plastic adherent cells are not removed 
after incubation of cell suspensions, the 
possibility that macrophages to which specific cytophilic 
antibody was bound formed plaques is unlikely, as plaques do 
not develop when cell suspensions from immunized mice are 
incubated on antigen-free plates, despite the presence of 
adherent cells. 
The assay specifically detected influenza-specific ASCs 
essentially only in mice immunized with influenza . virus. 
Cells producing type specific antibodies but not cells 
producing antibodies of different subtype specificities 
could clearly be distinguished. This latter result is 
similar to previous experiences with the indirect ELISA 
where whole virus was used as the antigen for . measuring 
anti-influenza antibody (Hammond et al., 1980; Al-Kaissi & 
Mostratos, 1982) and is due to the recognition of common 
antigenic 
proteins. 
determinants, principally on the internal 
These determinants are exposed in the wel l 
probably as a result of physical alteration to the virus 
structure during adsorption to the solid phase, an 
interpretation supported by the complete inhibition of 
plaque formation only by detergent-disrupted virus. 
In view of the lack of subtype specificity of the 
ELISA-plaque assay using whole virus to coat the plates, it 
was necessary to modify the assay so as subtype specific 
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ASCs could be detected. This was achieved by firstly 
coating the plates with a monoclonal antibody to the HA 
molecule to avoid disruption of the virus. This approach 
was preferred to using purified HA to coat the plates as 
determinants on the HA molecule common to all subtypes may 
be recognized after adsorption (Burlington et. al., 1983). 
The standard ELISA~plaque assay as described in Section 
2.7 was used in the experiments described in the succeeding 
chapters except for Section 5.5 where the modified assay was 
used to detect subtype s pee i f i c AS Cs during a he t er o t yp i c 
challenge. 
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SUMMARY 
An ELISA-plaque assay is - described which can reliably 
enumerate 
antibodies 
cells 
of 
secreting 
the IgM, 
influenza 
IgG and 
virus 
IgA 
specific 
isotypes. 
Influenza-specific ASCs were detected in significant numbers 
only 1n mice immunized with influenza virus. Cells 
producing antibodies of different subtype specificities 
could not be reliably distinguished, as with the indirect 
ELISA, unless the assay was modified by binding the virus to 
a monoclonal antibody on the solid phase rather than 
adsorbing the virus directly onto the solid phase. 
CHAPTER FOUR 
B CELL RESPONSES IN THE PRIMARY 
IMMUNE RESPONSE TO INFLUENZA 
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INTRODUCTION 
Previous descriptions of the cellular events underlying 
the humoral response in the respiratory tract during viral 
infections have relied upon 
irnmunofluorescence of lg-bearing 
the demonstration 
cells. Using 
by 
this 
approach, increases in lg-bearing cells have been detected 
in the lungs of mice infected with Sendai virus (Blandford 
et al., 1971) and influenza virus ( Scott & Walker, 1976). 
However, not only does this approach fail to demonstrate the 
viral specificity of the surface antibody on these cells, 
but it provides at best only indirect evidence that specific 
antibody in respiratory secretions is locally synthesized. 
More direct evidence for this would be provided by the 
demonstration of specific antibody secretion at the cellular 
level. 
Previous reports of influenza-specific ASCs, detected 
by the haemolytic-plaque assay, have provided remarkably 
little 
single 
information on events within the lung. 
finding of direct plaque-forming 
There 
cells 
. 
lS a 
. 
1n 
tracheobronchial cell preparations from influenza infected 
ferrets (McLaren & Butchko, 1978). 
In this chapter, the ELISA-plaque assay has been used 
to study the B cell response at the cellular level to 
primary influenza virus infection in mice. 
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4.1 Influenza-specific ASCs after Primary Intravenous 
Immunization 
ASCs were enumerated in the spleen after primary 
intravenous immunization with 1000 HAU infectious A/Jap 
virus (Fig 4.1). IgM ASCs were first detected at 48h after 
injection and peaked at day 4. Thereafter the level of IgM 
ASCs declined rapidly and by one month only a small number 
of IgM ASCs were still present (10 ASCs/106 cells). IgG 
ASCs were first detected at day 4, peaked at day 6 and 
subsequently plateaued at a lower level; at one month 
approximately 50 ASCs/106 cells were still present. There 
was a minimal IgA response. 
the level of ASCs had not 
observed at one month. 
At three months after injection 
changed appreciably from that 
ASCs were also enumerated in the lung after intravenous 
immunization to determine if an IgA response was induced in 
the lung in the virtual absence of an IgA response in the 
spleen. Mean lung virus titre at 3 days after intravenous 
injection was 4.5 log10 EIDso• The peak IgM response in the 
lung occurred 48h later than in the spleen and, in 
magnitude, was only one-third that of the splenic IgM 
response. As expected, IgA ASCs were more numerous in the 
lung than the spleen (Table 4.1). 
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4.2 B cell Res onses after Primar Intra~asal Inoculation 
4.2.l Influenza-specific ASCs 
Mice were inoculated intranasally with 104 EID50 
infectious A/Jap virus causing peak lung consolidation of 
45±20% and 5-10% mortality. Mean lung virus titre measured 
at day 3 was 6.6 log10 EIDso• Class-specific ASCs cells to 
influenza virus were enumerated in the lung, spleen and 
blood (Fig. 4.2). ASCs were more numerous in the lung than 
in the spleen for each isotype7 in each organ ASCs producing 
IgM were the predominant cell type found. IgM ASCs were 
first detected in the lung at day 5 and subsequently peaked 
at day 10. IgG and IgA ASCs were not detected in the lung 
until the second week and thence both peaked during the 
third week with slightly more IgG than IgA ASCs. At one 
month after infection, numerous ASCs of each isotype were 
still present in the lung. 
The onset and peak of the splenic IgM response preceded 
the pulmonary IgM response by 24-48 hours. Splenic IqG 
ASCs were first detected at day 6 in very small numbers and 
peaked by day 18. A very small number of IgA ASCs (7 per 
106 cells) was detected in the spleen during the third 
week. At one month, only IgG ASCs (30 per 106 cells) were 
detected in the spleen. 
1 24 
ASCs producing IgM also constituted the maJor respons e 
1n the blood; IgM ASCs appeared at day 6 and had declined by 
the end of the second week. IgG and IgA ASCs a l so 
circulated during the second and third weeks 1n small 
numbers ( < 20 per 106 cells) . 
In mice infected with a ten-fold lower dose of A/ Jap 
virus, the onset of the response in both lung and spleen was 
delayed by 48 hours compared to mice infected with the 
higher dose. The pattern of the response was subsequent ly 
similar, though of lesser magnitude (Fig. 4.3). Peak 
responses in both the lung and spleen for each isotype wer e 
40-60% lower than those seen with the higher primary dose . 
In the preceding experiments, ASCs were enumerated 
using suspensions of pooled cells from several mice. To 
determine the extent of biological variation 1n the onse t 
and magnitude of the ASC responses, IgM ASCs were enumerated 
using suspensions of cells from individual mice afte r 
intranasal inoculation (Table 4.2). There were no IgM ASCs 
detected in the spleen until day 5 or in the lung unti l day 
6. The coefficients of variation of the mean number of 
ASCs detected at each time point averaged 40% with a maxi mum 
. 
of 64%. In view of the extent of biological variation 1n 
the number of ASCs individual . mice, less t h an 2-fold 
differences 1n results obtained using suspensions of poo l ed 
cells could not be regarded as biologically significant. 
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4.2.2 Influenza-specific Antibodies 
Influenza-specific antibody titres were measured, using 
an indirect ELISA, in the sera and tracheobronchial washes 
of mice infected with 104EID50 infectious A/Jap virus (Fig. 
4.4). In general, the onset and peak of the antibody 
response for each isotype coincided with or shortly followed 
the corresponding phase of the ASC response. 
4.3 Generation of ASCs in vitro 
The primary response to influenza was further evaluated 
by using lung and spleen cell cultures obtained from 
unprimed mice and stimulated in vitro with influenza virus 
to determine if precursors of influenza-specific ASCs were 
present in these tissues. 
4.3.1 Conditions of Primary 1n vitro Cultures 
To determine the optimal method for in vitro generation 
of ASCs, spleen and lung cell cultures were stimulated with 
either purified virus or virus-infected irradiated syngeneic 
spleen cells. The titre of purified virus or the amount of 
virus used to infect cells was varied to determine the 
optimal concentration for stimulation (Fig. 4.5). The 
maximum number of IgM ASCs detected in both spleen and lung 
cell cultures followed stimulation with purified virus at a 
concentration of 20 HAU/ml. 
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4.3.2 Influenza-specific ASCs 1n Primary 1n vitro Cultures 
Spleen and lung cell cultures obtained from unprimed 
mice were stimulated in vitro with 20 HAU A/Jap virus per ml 
and the number of ASCs generated determined over the 
following week (Fig. 4.6). ASCs producing IgM were detected 
1n spleen cell cultures after 48h incubation and 1n lung 
cell cultures at 72h. The peak IgM response developed in 
both cell cultures at day 4 and was slightly greater in the 
spleen cell culture. IgG ASCs were not detected in either 
cell culture, whereas a small number of IgA ASCs ( 5 / 106 
cells) were detected in the lung cell culture. 
ASCs were not detected in cultures of peripheral blood 
lymphocytes stimulated under the same conditions, indicating 
' 
that the ASCs found in lung cell cultures were not derived 
to any maJor extent from precursors in the pulmonary 
vasculature. 
4.3.3 Specificity of ASCs Generated in vitro 
The specificity of the AS Cs generated in vitro was 
determined . using different viruses for stimulation (Table 
4. 3) . The number of background IgM ASCs detected on plates 
coated with buffer only or from unstimulated cultures was 
greater than that observed using cell suspensions which had 
not been cultured 1n vitro (see Table 3.4). This most 
likely was related to the mitogenic activity of foetal calf 
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serum. This finding probably also underlies the apparently 
greater degree of cross-reactivity observed between the type 
A and B influenza viruses than that seen using immune cell 
suspensions obtained in vivo. 
As influenza A viruses of the H2, H3 and H6 subtypes 
behave as T cell - independent B cell mi togens for murine 
lymphocytes (Anders et al., 1984), the generation of ASCs 
using A/Jap . virus (H2 subtype) may have been related to 
nonspecific mitogenic activity. However, spleen cell 
cultures stimulated by a less mi togenic Hl subtype virus 
(A/PR8) produced similar results:- 486 ± 21 IgM ASCs/106 
cells at day 4. Furthermore, in later experiments (see 
Table 5 .1) depletion of L3T4+ cells reduced the number of 
ASCs in spleen cell cultures by more than 95%. 
FIG. 4.1 ASCs 1n spleen after primary 1. V. 
immunization (1,000 HAU A/Jap). Values 
represent mean results from triplicate assays 
performed on suspensions of pooled cells from 
3 to 4 mice. 
Symbols: D IgM, 0 IgG, 6. IgA 
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TABLE 4.1 
Time after 
immunizationb 
Day 4 
Day 6 
Day 8 
ASCs in the Lung after Primary Intravenous Immunization 
ASCs/106 (mean± SD)a 
Spleen Lung 
IgM IgA IgM IgA 
466 ± 20 0 8 ± 2 0 
298 ± 22 3 ± 1 147 ± 6 6 ± 2 
98 ± 20 0 82 ± 11 29 ± 4 
a. Values represent mean± SD using suspensions of pooled cells obtained from 2 mice. 
b. Mice were immunized i.v. with 1000 HAU A/Jap virus. 
FIG. 4.2 ASCs in lung, spleen and blood after primary 
intranasal inoculation (104 EID50 of A/Jap). 
Values represent mean results from triplicate 
assays performed on suspensions of pooled 
cells from 3 to 4 mice. 
Symbols: D IgM, 0 IgG, 6 IgA 
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FIG. 4.3 
~ 
ASCs in lung and spleen after primary 
intranasal inoculation (103 EID50 of A/Jap). 
Values represent mean results from triplicate 
assays performed on suspensions of pooled 
cells from 3 to 4 mice. 
Symbols: D IgM, 0 IgG, 6. IgA 
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TABLE 4.2 Biological Variation in Primary in vivo ASC responses 
IgM ASCs/106 (mean± SD) 
Time after intranasal Extent of lung 
inoculationa Mouse No. consolidation ( % ) Lung Spleen 
Day 5 1 <5 < 5 70 ± 4 
2 10 < 5 34 ± 4 
3 5 5 29 ± 1 
4 10 < 5 49 ± 9 
5 ± 5 < 5 45 ± 18 
Day 6 1 45 12 ± 3 186 ± 4 
2 50 6 ± 3 65 ± 5 
3 65 8 ± 2 109 ± 15 
4 20 25 ± 3 67 ± 6 
45 ± 20 13 ± 8 107 ± 51 
Day 8 1 35 93 ± 13 632 ± 11 
2 40 154 ± 2 544 ± 4 
3 40 210 ± 18 479 ± 8 
4 35 137 ± 18 368 ± 17 
37 ± 3 149 ± 48 506 ± 111 
Day 11 l 60 676 ± 74 147 ± 7 
2 50 929 ± 78 137 ± 3 
3 50 780 ± 32 43 ± 4 
4 40 739 ± 65 ·39 ± 4 
50 ± 8 781 ± 107 91 ± 58 
a. Mice were inoculated intranasally with 104EID50 infectious A/Jap virus. 
FIG. 4.4 Influenza-specific antibody titres after 
primary intranasal inoculation (104 EID5o 
A/Jap). Values represent reciprocal of ELISA 
titre (log2) using tracheobronchial washes 
(TBW) and sera pooled from 3 to 4 mice. 
Symbols: D IgM, 0 IgG, 6. IgA 
a: 
w 
1-
-I-
<( 
Cl) 
-
...J 
UJ 
20 
15 
10 
20 
15 
10 
5 
T.8.W. 
, ,,,,,,,,,, 0 0 11111111111111 0 ''" 
.... 
.... 
.... 
.... 
.... D 
, .. :,,, ~ _,,6 ·-i/ ~4' 6..,,,,,.,,,,,,.,,.,,,,.,,,,. I 6. 
l.l o-- 0 
Bl 
/6 
D 
5 10 15 20 25 30 35 
SERUM 
5 10 15 20 2 5 30 35 
DA VS AFTER INOCULATION 
FIG. 4.5 
llfii?Jt..-
IgM ASCs in primary spleen and lung cell 
cultures stimulated with either purified 
virus (open symbols) or virus-infected cells 
(closed symbols). The virus concentration 
represents either the titre of purified virus 
(HAU / ml) or the amount of virus used to 
infect cells ( EID50 per cell) . Values 
represent mean results of triplicate assays 
using suspensions of pooled cells from 3 mice 
stimulated in vitro for 4 days. 
400 
300 
(f) 200 
_J D 
_J 
UJ II 
() 100 
(0 
0 
,-
~ 
() 1.25 5 20 80 320 
(f) 200 
<( LUNG 
D 
' 100 
D 
II -
• 11 
/D D 
1.25 5 20 80 320 
VIRUS CONCENTRATION 
FIG. 4.6 IgM ASCs in primary spleen (solid line .) and 
lung (broken line) cell cultures either 
stimulated with 20 HAU of A/Jap virus per ml 
( D ) or unstimulated (II). 
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TABLE 4.3 
Spleen cell cultures 
stimulated with: 
Nil 
A/Jap 
B/Sing 
Specificity of ASCs generated in Primary in vitro Culture 
IgM ASCs/106 (mean± SD)a on plates coated with: 
Nil Virus A/Jap B/Sing 
7 ± 3 19 ± 4 16 ± 3 
13 ± 6 305 ± 23 48 ± 7 
6 ± 4 31 ± 4 112 ± 15 
a. Values represent mean± SD of triplicate assays using suspensions of pooled spleen 
cells cultured for 4 days. 
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DISCUSSION 
The findings in this chapter provide the first detailed 
description of the appearance and development of specific 
ASCs in the lung during infection. The only previous 
detailed descriptions of specific ASCs in the lung were 
after local immunization with foreign erythrocytes (see 
Section 1.2.3.2). In contrast to previous failures to 
detect ASCs in the lungs of mice after primary local 
immunization with foreign erythrocytes (McLeod et al., 1978; 
Kaltreider et al., 1983) cells secreting influenza-specific 
IgM, IgG and IgA were readily detected in the lungs of mice 
during primary influenza infection. Thus an earlier report 
(Scott & Walker, 1976) of an increase in Ig-bearing cells, 
detected by immuno-fluorescent labelling, in the lungs of 
influenza-infected mice has not only been confirmed but 
extended to demonstrate their specifici ty for antigen. 
These results have provided the most direct evidence yet 
obtained that influenza-specific antibody of each isotype in 
respiratory secretions is most likely locally produced. 
This conclusion is further supported by the close temporal 
relationship between the appearance of class-specific ASCs 
in the lung and the corresponding antibodies in 
tracheobronchial washes. 
Although ASCs were detected earlier in the spleen than 
the lung, the subsequent response in the lung was relatively 
greater for each isotype, particularly the IgA component. 
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The primary response to infection was also characterized by 
the more rapid decline 1n numbers of ASCs 1n the spleen 
compared to the lung. This was probably related to the 
persistence of viral antigen in the lung after infection 
( Astry et al., 1984) compared to the short pulse of 
antigenic stimulation 1n the spleen. The onset and 
magnitude of the primary response was also dose-dependent. 
Influenza-specific ASCs have previously been detected 
by a haemolytic-plaque assay in the spleens and 
intra thoracic lymph nodes of influenza infected mice and 
ferrets. The kinetics of the splenic responses following 
intravenous immunization (McLaren & Butchko, 1978) and 
intranasal inoculation (McLaren et al., 1978; Reiss & 
Schulman, 1980b) were similar to those described here. 
In contrast to the considerable difference observed in 
the sizes of the pulmonary and splenic primary in vivo 
responses, the primary IgM response generated in vitro in 
lung cell cultures was only slightly less in magnitude than 
that in the spleen cell cultures. However, as in vivo, ASCs 
appeared earlier in the spleen cell cultures than in the 
lung cell cultures. Previous work comparing the . immune 
response in the spleens and lungs of . mice inoculated 
intranasally with parental and cold-adapted preparations of 
influenza virus (Mak et al., 1984) indicated that a splenic 
response was due to antigen spillover of virus replicating 
in the lung (i.e., the antigenic challenge in the spleen is 
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both delayed and of smaller magnitude 1n the spleen compared 
to the lung). These findings taken together indicate that 
the antigen-presenting mechanisms 1n the spleen are 
qualitatively and/or quantitatively different from those in 
the lung. 
What is the or1g1n of ASCs in the lung during influenza 
infection? The proposition that these cells may arise from 
influenza-specific B cell precursors 1n the lung is directly 
supported by two findings in this study: (1) The generation 
of cells secreting specific IgM 1n stimulated lung cell 
cultures from unprimed mice; ( 2) The virtual absence of an 
IgA response in the spleen despite the prominent response 1n 
the lung after both intranasal and intravenous 
immunization. Do any circulating B cell precursors or ASCs 
derived from extra-pulmonary lymphoid tissue contribute to 
the lung response? The only evidence which might support 
this 1s the finding in vivo that the IgM response develops 
earlier in the spleen compared to the lung, thus allowing an 
opportunity for some migration to the lung. If this does 
occur, then further migration 1s arrested as indicated by 
the persistence of ASCs 1n the lung. Previous studies on 
the response to foreign erythrocytes has led to the 
suggestion, based on indirect evidence, that the maJor 
mechanism for the appearance of ASCs in the lung was through 
the recruitment of sensitized cells (Section 1.2.3.2), 
though it has also been shown that whilst the spleen 
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contributes to the pulmonary response, it 1s not essential 
(Kaltreider et al., 1983). Of course, migration of other 
cell types such as helper T lymphocytes from the spleen and 
other extra-pulmonary lymphoid tissue could occur. 
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SUMMARY 
The development of influenza-specific ASCs during the 
primary immune response to influenza was characterized. 
Following intranasal inoculation cells secreting 
influenza-specific IgM, IgG and IgA were detected ' in 
greatest numbers 1n the lung and the data presented 
indicated that these cells may have originated from specific 
B cell precursors in the lung which were demonstrable in 
vitro. Influenza-specific ASCs were also detected in the 
spleen and blood. ASCs appeared earlier in the spleen than 
in the lung and declined more rapidly in the spleen. 
CHAPTER FIVE 
PERSISTENCE OF INFLUENZA-SPECIFIC B CELL RESPONSES AND 
B CELL MEMORY AFTER PRIMARY INFLUENZA VIRUS INFECTION 
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INTRODUCTION 
Protection following influenza virus infection 1S 
long-lived as evident by the observation that persons 
infected with the HlNl subtype before the 1950s were 
subsequently protected when this subtype reappeared in 1977 
(Glezen et al., 1982). Since the principal mediator of 
protection is antibody to the HA molecule, persistence of HA 
specific antibody must occur to account for long-term 
protection. The finding of HA-inhibition (HI) antibody to 
H3 in 1968 in the serum of persons born before 1892 and to 
Hl in 1976 in persons born before the early 1950s confirms 
this (Couch & Kasel, 1983). Although there is a correlation 
between serum HI levels and protection, neutralizing 
antibody must be present within the respiratory tract to 
prevent infection of the respiratory epithelium. The 
relative importance of local and systemic B cell responses 
in maintaining a persistent level of protective antibody 
within the respiratory tract has not been previous l y 
addressed. 
This chapter describes the persistence of B cel l 
responses and the development of B cell memory after primary 
influenza infection and the effect of re-infection on these 
parameters. 
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RESULTS 
5.1 Persistence of Influenza-specific ASCs 
Influenza-specific ASCs were quantitated in the lung 
and spleen of . mice at different times after primary 
influenza virus infection. Cell suspensions were obtained 
from mice immunized intranasally with either of two 
different doses of infectious A/Jap . virus. The number of 
ASCs detected in the first 40 weeks after infect ion was 
determined 1n . mice primed with A/Jap virus 
intranasally (group A). The level of IgM-secreting cells in 
the lung declined shortly after infection, whereas the level 
of IgG- and IgA-secreting cells remained elevated for the 
first two months after infection (Fig. 5.1). Thereafter 
there was a gradual decline of ASCs of each isotype in the 
. . lung, with IgG ASCs remaining the predominant type 
throughout. Whereas in the spleen the level of ASCs 
declined within the first month after infection and remained 
fairly constant thereafter with less than 30 ASCs , 
principally IgG-secreting, per 106 cells. In a second 
separate group of mice primed with 5x102 EID50 A/Jap virus 
(group B), ASCs were detected in the lung up to 18 months 
after pr1m1ng (Fig. 5.1). Similarly, a small number of 
IgG-secreting cells ( < 10 per 106 cells) were present in the 
spleen at 18 months. 
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The level of ASCs was further examined at more 
frequent time intervals within a period of approximately six 
weeks in several experiments at different times after 
primary inoculation. In each experiment, cyclical 
variations in the number of . ASCs in the lung were observed, 
as exemplified by the results obtained in mice from group A 
primed three months earlier (Fig. 5.2). Peak levels of IgG 
ASCs occurring every one to two weeks were significantly 
greater than trough levels (p< 0.01). The overall variation 
in the number of IgG ASCs detected in the lung over this 
period was 36%, considerably greater than the 12% interassay 
variation of the ELISA-plaque assay. Similarly, the number 
of circulating ASCs varied, although the significance of 
this finding was uncertain as only a small number of 
peripher~l blood lymphocytes were assayed. However, there 
was no consistent correlation observed between the cycles in 
the lung and in the blood. The number of ASCs detected in 
the spleen was so small that a significant variation could 
not be detected. 
5.2 Persistence of Influenza-specific Antibody 
In parallel with the decline in ASCs in the lung, there 
was an 8- to 16-fold fall in antibody titres in TBW over the 
initial 40 weeks in group A . mice (Fig. 5. 3) . IgG was the 
predominant isotype in TBW although there was a 
proportionately higher level of IgA in TBW compared to 
serum. Serum antibody titres remained remarkably constant 
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during the first 40 weeks following infection in group A 
mice (Fig. 5.3). Furthermore, there was 1 it t le change in 
serum titres by 18 months in group B mice. 
5.3 B Cell Memory after Primary Influenza Infection 
5.3.1 Generation of Influenza-specific ASCs by Secondary in 
vitro stimulation 
The level of B cell memory following primary influenza 
virus infection was determined indirectly by measuring the 
number of ASCs generated in cultures of lung and spleen 
cells derived from primed mice and stimulated in vitro with 
purified influenza virus. The two groups of primed mice 
used to detect persistence of ASCs were also used in the 
following experiments. 
The maximum number of ASCs was generated in both lung 
and spleen cell cultures stimulated with 6 to 25 HAU 
purified ' virus per ml 5. 4) . In subsequent 
from primed experiments, cultures . mice were stimulated with 
10 HAU/ml. 
Lung and spleen cells obtained from group A mice twenty 
weeks after priming were stimulated in culture with 10 HAU 
purified A/Jap virus per ml and the number of ASCs 
enumerated over the following week. Cells continuing to 
secrete antibody spontaneously were enumerated 
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unstimulated cultures (Fig. 5 . 5 ) . ASCs increased 1n 
stimulated lung cell cultures slightly by day 3 and by day 5 
there was over a 10-fold difference between the number of 
ASCs of each class detected in stimulated and unstimulated 
lung cell cultures (p < 0.001). The predominant isotype 
detected 1n stimulated lung cell cultures was IgG. ASCs 
increased in stimulated spleen cell cultures by day 2 and by 
day 5 there was an approximately 1000-fold increase in the 
number of IgM and IgG ASCs detected 1n stimulated spleen 
cell cultures ( p < 0. 001) . The similar proportion of IgM-
and IgG-secreting cells reflect the short duration of 
culture as the relative proportion of IgG- to IgM-secreting 
cells increases with the duration of culture. 
5.3.2 Persistence of B Cell Memory 
The level of B cell memory was determined at different 
times after primary infection. The numper of ASCs generated 
by 1n vitro stimulation was calculated at day 5 of culture 
by correcting for the number of ASCs detected 1n 
unstimulated cultures. The total number of ASCs, including 
IgM-, IgG- and IgA-secreting cells, generated in lung cell 
. 
cultures obtained from mice 3 months after infection was 
50-100 fold higher than the number of ASCs in primary lung 
cell cultures (Fig. 5.6). Thereafter, there was a gradual 
decline 1n the number of ASCs generated 1n lung cell 
cultures derived from mice at later times after the primary 
infection. By 18 months after priming, the total number of 
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ASCs in cultures from primed mice was comparable to that 
found in primary lung cell cultures, though in the primed 
mice the principal cell type was IgG-secreting. 
Within three months of the primary infection there was 
a 100-200 fold increase in the total number of ASCs, 
principally IgM and IgG, detected in spleen cell cultures. 
Thereafter, in contrast to the lung, the level of ASCs 
generated in spleen cell cultures did not change 
significantly. 
5.3.3 Role of T Helper Cells in Declining Level of B Cell 
Memory in the Lung 
The decline in the number of ASCs in lung cell cultures 
from long-term primed mice may have been due to a fall in 
the level of either B memory cells or Th cells. To 
determine whether the 1 imi ting factor was the level of Th 
cells, lung cell . suspensions were co-cultured with 
additional Th cells. Gamma-irradiated ( 2000 rads) spleen 
cells obtained from long-term primed . mice were able to 
provide help to spleen cell suspensions depleted of Th 
cells, but had only a moderate effect on increasing the 
number of IgG ASCs in lung cell cultures obtained from the 
same mice (Table 5.1). In separate experiments using 
short-term primed mice the addition of gamma-irradiated 
spleen cells similarly resulted in less than a 2-fold 
increase in the total number of ASCs generated in lung cell 
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cultures. Spleen Th cells were, however, able to increase 
the response 1n lung cell suspensions depleted of L3T4+ 
cells, e.g. IgG AS Cs 1n cultures depleted of L3T4+ cells 
increased from 510 ± 16 to 2000 ± 13 per 106 cells when co-
cultured with irradiated spleen cells. Similar increases in 
IgM- and IgA-secret ing cells were also detected, suggesting 
that the ability of ASCs 1n intact lung cell cultures to 
respond to spleen Th cells was not being suppressed. As the 
level of Th cells in the lungs of long-term primed mice was 
not a limiting factor in the generation of ASCs, the decline 
in the number of ASCs 1n lung cell cultures predominantly 
reflected a reduction in the level of B memory cells in the 
lung. 
5.4 Effect of 1n vivo Homotyoic Challenge 
5.4.l Effect on ASCs and Antibody Levels 
Mice from group A were initially challenged with a 
10-fold higher inoculum (104 EID50) of infectious A/Jap 
virus intranasally. However, re-infection was completely 
prevented as no B cell response, determined by either the 
ELISA-plaque assay or an indirect ELISA on serum or TBW for 
influenza-specific antibodies, was elicited. The mice were 
then challenged at s 1x months after priming with 7. 5xl04 
EID50 of a recently mouse-adapted A/Jap virus. There was no 
virus detected 1n lung homogenates at day 3 after 
challenge. In unprimed mice inoculated with the same 
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inoculum, mean lung virus titre at day 3 •.vas 6. 3 log
10 
EID50. 
The number of ASCs was determined after the challenge 
and compared with the number of ASCs persisting in primed 
mice which were not challenged. In the lungs of challenged 
mice there was a significant increase in ASCs of each class 
(p< 0.01), greater for IgG- and IgA-secreting cells, by day 
5 (Fig. 5.7). This response persisted until the end of week 
3. In contrast, there was no response detected in the 
spleens of challenged mice. 
Antibody titrations were performed before and after 
homotypic challenge. There was no significant change in 
serum antibody titres 10 days after challenge (Table 5.2). 
By day 23 there had been a 4-fold rise in influenza specific 
IgG in serum (data not shown). In contrast, there was an 
8-fold rise in IgG and IgA levels in TBW at day 10 after 
challenge. There was no significant change in antibody 
titres in primed mice which were not challenged. 
5.4.2 Effect on B Cell Memory 
The ef feet of homotypic challenge on the level of B 
cell memory was determined 5 weeks after challenge with the 
larger inoculum (Table 5.3). There was a significant 
increase in the total number of ASCs generated in both lung 
(5-7 fold) and spleen cell (2-3 fold) cultures obtained from 
the challenged mice (p < 0. 01). 
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5.5 Effect of in vivo Heterotypic Challenge 
5.5.1 Effect on ASCs and Antibody Levels 
In contrast to the large dose of homotypic virus 
required to elicit a secondary in vivo response, mice were 
successfully challenged with a relatively lower dose of 
heterotypic . virus. Mice from group A were challenged 4 
months after priming with 2xlo3 EID50 A/PR8 virus 
intranasally. 
In order to study the effect of heterotypic challenge, 
it was necessary to use the modified ELISA-plaque assay 
(Section 3.5.3) so that subtype-specific ASCs could be 
detected. 
The number of ASCs specific for A/Jap and A/PR8 were 
determined at day 18 after challenge and compared with 
non-challenged primed . mice (Table 5. 4) • There was a 
significant . increase in the number of IgG and IgA ASCs 
directed to the A/Jap . . virus in the lung (p < 0. 05) and of IgG 
ASCs in the spleen ( p < 0. 05) . However, these ASCs were 
predominantly specific for the internal viral proteins as 
there was no significant increase in ASCs specific for the 
A/Jap virus using plates coated with antibody and 
. 
virus. 
The number of ASCs formed on plates coated with A/ PR8 
tended to be smaller in mice primed with A/ Jap virus 
. 
virus 
compared with unprimed mice. 
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There was a 4- to 8-fold increase 1n influenza-specific 
IgG levels 1n serum and TBW, using plates coated with A/ Jao 
virus, at day 18 after challenge (Table 5. 5). 
with the specificity of the ASC response, 
however, no significant increase 1n the 
Consistent 
there was, 
level or 
A/Jap-specific antibodies in either serum or TBW determined 
by either haemagglutinin-inhibition or an indirect ELISA 
using the same modification for detecting subtype-specific 
antibodies. The antibody responses to A/PR8 v1 rus were 
similar in the primed and unprimed mice. 
5.5.2 Effect on B cell memory 
The effect of heterotypic challenge on the level of B 
cell memory was determined one month after challenge (Table 
5. 6) • Further 1n vitro stimulation with purified A/ Jap 
virus of lung cell cultures, obtained from mice primed with 
A/Jap and subsequently challenged with A/PR8, generated a 
slightly greater number of ASCs (2-3 fold) compared with 
cultures from primed . mice which were not challenged. This 
was evident for all ASCs detected on A/Jap-coated plates, 
but not ASCs specific for A/Jap virus. 
The number of ASCs generated in spleen cell cultures 
stimulated with A/Jap virus was similar in cultures obtained 
from challenged 
specificity. 
or unchallenged . mice irrespective of 
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The number of ASCs generated 1n cultures stimulated 
with A/PR8 virus was similar 1n cultures obtained from 
either mice primed with A/ Jap and challenged with A/PR8 or 
mice primed with A/PR8 only (Table 5.7). 
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FIG. 5 .1 ASCs in the lung after primary intranasal 
inoculation 1n Group A and Group B mice. 
Values represent mean results of triplicate 
assays performed on suspensions of pooled 
cells from 3 mice. 
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FIG. 5.2 ASCs in the lung after primary intranasal 
inoculation in Group A mice. Values 
represent mean ± SD of triplicate assays 
performed on suspensions of pooled cells from 
3 mice. 
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FIG. 5.3 ELISA antibody titres in tracheobronchial 
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stimulated with 10 HAU of A/Jap virus per ml 
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cultures on day 5 of culture. Cell 
suspensions obtained from 3 mice in either 
Group A or B. Values represent mean results 
of duplicate assays. 
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TABLE 5.1 Effect of Co-culturing Immune Spleen Helper Cells and Lung Cell Suspensions 
from Primed Mice 
Principal cells 
cultureda 
Spleen 
Spleen 
Spleen 
Lung 
Lung 
Principal 
culture 
depleted of 
L3T4+ cellsb 
+ 
+ 
Immune spleen 
helper cells 
addedc 
+ 
+ 
ASCs/106 (mean± SD) generated 1n 
IgM 
17,467 ± 67 
370 ± 10 
10,533 ± 200 
439 ± 6 
544 ± 20 
IgG 
11,067 ± 
900 ± 
67 
20 
24,867 ± 2,900 
1,105 ± 
1,966 ± 
6 
122 
vitrod 
IgA 
4 ± 2 
17 ± 2 
185 ± 21 
526 ± 53 
520 ± 31 
a. Spleen and lung cell suspensions obtained from group A mice primed 50 weeks earlier 
and stimulated in vitro for 5 days. 
b. Cell suspensions depleted of L3T4+ cells by prior incubation with anti-L3T4 MAb and 
complement. 
c. Gamma-irradiated (2000 rads) immune spleen cells added at ratio of 1:1. 
d. Values represent mean± SD of duplicate assays. 
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FIG. 5. 7 ASCs in the lung in primed mice either 
challenged with 7.5 x 104 EID50 A/Jap virus 
(A) or not challenged ( B) • Mice were 
challenged on day 173 ( t ) after pr 1mary 
inoculation (103 EIDso A/Jap virus). 
Values represent mean results of triplicate 
assays performed on suspensions of pooled 
cells from 3 mice. 
Symbols: D IgM, 0 IgG, L IgA 
900 
800 
700 
600 
(f) 500 
_J 400 
_J 
W 300 
(..) 200 
CO 100 0 
.,-
(..) 
(f) 500 
<( 400 
300 
200 
100 
····· 0 . ,,,,, -:. 
0 ········ : ········ 0 : ,,,, 
.. ,,, : ,,, 
: 0, 
: ~ 
.. ,, 
: ~ 
.. ~ 
.. ~ : ~ 
.. ~ 
.. ~ : ~ 
A 
.. ~ f ;o 
.. 
.. 
.. 
.. 
.. 
.. 
.. 
.. 
.. 
.. 
.. 
... ,,~ .. 
O'''' \ 0 6-
.. .. I ~ ~A .. 
.. .... I ~ ~-~~ 
.. .. ~ C ~ O' I >O ~ --t:::,. 
#rzr1-[ti':"rt,~&'--r:9-, I I I rp yJ 
171 t 1 2 3 4 5 6 7 8 9 10 16 
Days after Secondary Inoculation 
B 
0 111111111 0 ,,, 
,,, •····· 
,,, ····· ,, ., 0 ,,, 
0 ,,, 0 ,, ,,,,,,,, ,,, O''' ....... ,,,, 0 ,,, 0 ,,,,,,,, 
171 173 175 177 179 181 183 189 
Days after Primary Inoculation 
TABLE 5.2 Effect of Homotypic Challenge on ELISA Antibody Titres 
Primary 
Intranasal 
Inoculation 
103EI050 A/Jap 
103EID50 A/Jap 
103EID50 A/Jap 
Secondary 
Intranasal 
Inoculation 
. . . . 
Nil 
7.5x104EI050 A/Jap 
Day 
After 
Challenge 
-lb 
10 
10 
TBW 
IgM IgG 
8 14 
9 14 
9 17 
ELISA Titre (log2)a 
Serum 
IgA IgM IgG 
11 18 22 
11 18 22 
14 18 23 
IgA 
13 
12 
14 
a. Values represent reciprocal (1092) of end-point titre of ELISA performed using pooled 
sera and TBW from 3 mice. 
b. ELISA performed one day prior to challenge. 
TABLE 5.3 Effect of Homotypic Challenge on B Cell Memory 
ASCs/106 cells (mean± SD) generated 1n vitroa 
Primary Secondary Lung Spleen 
Intranasal Intranasal 
Inoculation Inoculation IgM IgG IgA IgM IgG IgA 
103EID5o 
A/Jap 
Nil 74±14 498±23 12± 4 17,267± 867 13,600± 733 34±2 
103EID50 7.5x104 1,039±60 1,990±60 590±82 50,667±2,933 32,600±1,333 57±2 A/Jap EID50 
A/Jap 
a. Values represent mean± SD of duplicate assays performed on suspensions of pooled 
cells from 3 mice obtained 5 weeks after secondary inoculation and stimulated in vitro 
with 10 HAU/ml for 5 days. 
TABLE 5.4 Effect of Heterotypic Challenge on ASCs 1n vivo 
ASCs/106 cells (mean± SD)a 
Primary Seco ndary Plates Lung Spl ee n 
Intranasal Intranasal Coated 
Inoculation Inoculation With: IgM IgG IgA IqM IqG 
103EID50 A/Jap Nil A/Jap 61±12 258±23 105± 36 14± 3 12± 5 
II II Anti-A/Jap MAb 17 75 15± 10 7± 1 11± 3 
& A/Jap 
II II A/PR8 1 3 1 1 0 
103EID5o A/Jap 2xl03EID50 A/PR8b A/Jap 108±22 804± 6 894±141 32± 2 110±13 
II II Anti-A/Jap MAb 27±20 135±38 18± 9 12± 2 
& A/Jap 
II II A/PR8 30 138±40 36± 20 14± 4 
2x10 3E I D5 o A/ PR8b Nil A/PR8 140± 6 146±16 104± 26 64±18 
a . Values represent mean± SD of duplicate assays us i ng suspensions of pooled cel l s 
obtained from 3 mice at day 18 after secondary inoculat i on . 
18± 6 
20± 1 
86±17 
b . Lung virus titres at day 3 were 6 . 5 ± 1 . 1 log10EID5o . In unprimed mice l ung vi r u s 
titres at day 3 were 7.6 ± 0.5 log10EID5o . 
TABLE 5.5 Effect of Heterotypic Challenge on Antibody Titresa 
Primary 
Intranasal 
Inoculation 
103EID50 A/Jap 
II 
103EID50 A/Jap 
II 
II 
2x103EID5o A/PR8 
Secondary 
Intranasal 
Inoculation 
Nil 
II 
2x1o3EID5o A/PR8 
II 
II 
Nil 
HI Titreb 
(log2) 
TBW Serum 
7 8 
7 8 
ND ND 
ELISA plate 
coated with: 
A/Jap 
Anti-A/Jap MAb 
and A/Jap 
A/ '-Tap 
Anti-A/Jap MAb 
and A/Jap 
A/PR8 
A/PR8 
IgG ELISA Titre 
(log 2 ) 
TBW Serum 
13 
9 
16 
10 
15 
15 
19 
16 
21 
17 
20 
18 
a. Assays performed using pooled sera and TBW from 3 mice obtained at day 18 after 
secondary inoculation. 
b. Haemagglutinin-inhibition (HI) titre determined using A/Jap virus only. 
TABLE 5.6 
Primary Secondary 
Intranasal Intranasal 
Inoculation Inoculation 
l03EID50 Nil 
A/Jap 
II II 
II II 
Effect of Heterotypic Challenge on B Cell Memory (A) 
Cultures 
stimulated 
with: 
Plates 
coated 
with: IgM 
ASCs/106 cells (mean± SD)a 
generated in vitro 
Lung Spleen 
IgG IgA IgM IgG 
A/Jap A/Jap 707±21 1387± 80 293± 8 10370±428 9536±110 
II Anti-A/Jap MAb 253±12 250± 36 61± 7 2662±258 1430±147 
and A/Jap 
II A/PR8 5± 2 3± 1 3± 2 20± 3 10± 3 
103EID50 2xl03EID50 A/Jap A/Jap 1060±86 2816±174 1068±21 16800±100 10967±300 
A/Jap A/PR8 
II II II Anti-A/Jap MAb 443±18 487± 70 107± 6 3696± 90 1206±234 
and A/Jap 
II II II A/PR8 3± 1 3± 2 0 64± 4 8± 
a . Values represent mean± SD of duplicate assays using suspensions of pooled cells 
obtained from 3 mice five weeks after secondary inoculation and stimulated in vitro 
for 5 days. 
2 
TABLE 5.7 Effect of Heterotypic Challenge on B Cell Memory (B) 
Primary Secondary Cultures Plates 
Intranasal Intranasal stimulated coated 
Inoculation Inoculation with: with: IgM 
103EID50 2xl03EID5o A/PR8 A/Jap 43± 6 
A/Jap A/PR8 
II II II Anti-A/Jap MAb 0 
and A/Jap 
II II II A/PR8 344±16 
2x103EID5o Nil A/PR8 A/Jap 24± 4 
A/PR8 
II II II Anti-A/Jap MAb 0 
and A/Jap 
II II II A/PR8 313±20 
a. See Table 5.6. 
ASCs/106 cells (mean± SD)a 
generated in vitro 
Lung Spleen 
IgG IgA IgM IgG 
18± 5 6± 2 440± 40 2480± 40 
0 0 12± 3 16± 1 
216±12 70±10 10933±525 3133±216 
33± 7 27± 3 490± 40 2500± 10 
0 0 6± 3 1 
193± 7 40± 2 9467± 83 3533±495 
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DISCUSSION 
The duration of the antibody response in either serum 
or respiratory secretions has in the past been the principal 
parameter used for assessing the duration of B cell immunity 
after influenza virus infection. By quantitating 
influenza-specific ASCs, the duration of both local and 
systemic B cell immunity at the cellular level has been 
analyzed. 
Cells secreting influenza-specific antibodies, 
predominantly of the IgG isotype, persisted after influenza 
infection in both the lung and spleen for essentially the 
lifetime of the laboratory mouse, providing a continuous, 
though diminishing, source of specific antibody within the 
respiratory tract to prevent or minimise re-infection. The 
persistence of ASCs in the lung and spleen could be due to 
one or both of two mechanisms: ( i ) the presence of 
long-lived ASCs; and (ii) the recruitment and maturation of 
B memory cells. Evidence for long-lived ASCs after 
antigenic 
approaches. 
stimulation 
Firstly, 
has 
the 
been obtained 
incorporation 
using two 
of tritiated 
thymidine into dividing cells and the subsequent detection 
of individual labelled specific ASCs (Miller, 1964) . 
Secondly, by preventing replication of B memory cells by 
whole-body irradiation 
confirming that cells 
after antigenic 
from such hosts, 
stimulation and 
upon adoptive 
transfer, could not give rise to hapten-specific B cell 
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responses (Okudaira & Ishizaka, 1981; Holt et al., 1984). 
These approaches have demonstrated the presence of 
long-lived ASCs after antigenic stimulation, but in variable 
proportions. It is probably reasonable to ~uggest that 1n 
most situations, the persistence of ASCs 1s due to the 
existence both of long-lived ASC s and continuing recruitment 
and maturation of specific ASCs. 
The extent to which either mechanism contributes to the 
persistence of influenza-specific ASCs 1n the present 
experimental model was not determined, but two observations 
may be relevant. The first is the cyclical variation in the 
level of ASCs observed . 1n the lung after influenza 
infection. This effect 1s reminiscent of the pattern seen 
after immunization particularly with bacterial 
lipopolysaccharide and sheep erythrocytes (Nossal, 1975) 
which has previously been interpreted as evidence for B 
memory cell recruitment (Stavisky, 1980). The second aspect 
concerns the relative levels of specific B memory cells in 
the lung compared to the spleen. 
The existence of influenza-specific B memory cells 1n 
both the lung and spleen was demonstrated by stimulating 
resting B memory cells into ASCs in vitro. The level of B 
memory cells was greater 1~ the spleen than in the lung and 
whereas the level of the spleen remained constant throughout 
the lifetime of the mouse, there was a decline 1n the 
pulmonary level within six months of infection. The 
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generation of B memory cells depends on the presence of 
complexes of antigen, antibody and the C3 component of 
complement attached to C3 receptors on follicular dendritic 
cells in germinal centres of the spleen and other lymphoid 
tissues (Klaus et al., 1980). These complexes may persist 
1n the germinal centres for many months, leading to the 
continued generation of new B memory cells (Mandel et al., 
1980). Whereas influenza-specific IgA memory cells may have 
developed 1n the follicles of the bronchus-associated 
lymphoid tissue (BALT), it 1s likely that other B memory 
cells found 1n the lung were derived from extra pulmonary 
lymphoid tissue because of the paucity of organized lymphoid 
structures within the lung parenchyma. The subsequent 
decline in the level of B memory cells 1n the lung may 
reflect the continual gene rat ion of ASCs within the lung, 
stimulated by persisting influenza viral antigens (Astry et 
al., 1984). 
The persistence of ASCs after primary influenza 
contrasts with the dynamics of the response of effector T 
cells. Tc and Td cells reach peak levels between 6 and 8 
days 1n both the lung and spleen, but are no longer 
detectable after 2 weeks in either organ (Yap & Ada, 1978a; 
Leung & Ada, 1980) . However, memory for Tc cell responses 
has been demonstrated in murine lung and spleen at six weeks 
after intranasal inoculation (Mak et al., 1984) and in the 
spleen 2 years after intravenous immunization (Ashman, 
1982) . Thus Tc effector cells do not ~develop after 
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infection resol v es d espit e the pre s ence of Tc memory cells. 
Assuming that t h e p ersist enc e of ASC s may be partly due to 
recruitment from the poo l o f B me mo ry cells , these findings 
suggest a disparity between t h e ability of either persisting 
viral antigens or anti-i d iotype antibo dies to stimulate the 
d ifferentiation of B and Tc me mory c e lls . Tc memory cells 
may not be stimulated if vi r al antigen s are either 
sequestered on follicular d endritic cells and inaccessible 
to Tc memory cells or are not present ed in association with 
c 1 ass I MH C rest r i ct i n g 
anti-idiotype antibodies 
elements. It 
may stimulat e 
is unknown 
Tc memory 
whether 
cells, 
although T cell specific anti-idiotype a ntibo dies may induce 
cell-mediated responses in unprimed mic e (Finberg & Ertl, 
1986) • 
The ef feet of further exogenous antigenic stimulation 
was also determined in cha l lenges u s ing either the homotypic 
strain of influenza viru s or a dif fe rent subtype. Homotypic 
challenge using a large inoculum o f virus given six months 
after priming increased t h e l evel of ASCs, principally 
IgG- and IgA-secret ing, in t he lung during the first week 
after challenge. There was no comparable response observed 
in the spleen - presumabl y insu fficient antigen reached the 
spleen to stimulate t h e g eneration of ASCs from resident B 
memory cells. Acco r dingly , homotypic challenge increased 
influenza-specific anti b ody levels in TBW to a greater 
extent than in serum. Ther e was an increase 1n the number 
of ASCs generated in b o th lung and spleen cell cultures 
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obtained from mice 5 weeks after challenge. 
Heterotypic challenge similarly increased the level of 
ASCs in the lung, but also elicited a splenic response, 
presumably because viral replication was not limited in the 
initial stages of infection . in the heterotypically primed 
. 
mice. The cells in both the lung and spleen were secreting 
antibodies predominantly directed to the common internal 
proteins of the influenza A virus, as reflected by the 
antibody responses in both serum and TBW. Similarly, there 
was no increase 1n the level of ASCs specific for A/ Jap 
virus generated in either stimulated lung or spleen cell 
cultures obtained from challenged mice. 
These findings may provide some rationale for 
understanding the persistence of B cell immunity in humans. 
HA-specific antibodies, capable of preventing re-infection, 
may persist for decades 1n humans after the original 
influenza A 
population. 
. 
virus subtype 1s no longer circulating in the 
Although the phenomena of original antigenic 
sin 1s well described during successive infections with 
drift viruses within the same subtype, there is little 
evidence that this occurs to a significant extent when 
different subtypes are involved. Heterotypic responses 
occur infrequently after either infection or immunization 
with different subtypes (Masurel, 1976; Kilbourne, 1976), 
although individual B cell precursors 1n limiting dilution 
cultures may be stimulated by viruses of one subtype to 
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produce antibodies specifically directed to the HA of a 
different subtype (Yarchoan & Nelson, 1984). However, there 
1s no evidence that these heterotypic antibodies possess 
neutralizing capacity. In the absence of significant effect 
from subsequent exogenous antigenic exposure, it is likely 
that the persistence of antibody in humans relates to the 
persistence of ASCs and B cell memory as described 1n the 
murine model. 
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SUMMARY 
Influenza virus-specific ASCs, enumerated using an 
ELISA-plaque assay, were found in the lung and spleen up to 
eighteen months after . primary mur1ne influenza infection. 
The number of ASCs generated in stimulated lung and spleen 
cell cultures increased 50-200-fold after influenza 
infection. Whereas the level of response did not change in 
spleen cell cultures up to eighteen months after infection, 
there was a gradual reduction in ASCs in lung cell cultures 
obtained more than six months after infection, predominantly 
due to a reduction 1n B memory cells. Homotypic 
re-infection increased ASCs 1n the lung only, whereas B cell 
memory increased in both the lung and spleen. Although ASCs 
increased in both the lung and spleen after heterotypic 
challenge, ASCs and B cell memory specific for the original 
subtype were not increased. 
152 
CHAPTER SIX 
CELLULAR IMMUNE RESPONSES TO INFLUENZA VACCINATION 
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INTRODUCTION 
Vaccines currently in use in the West~rn world against 
influenza A virus consist of inactivated whole or disrupted 
virus or of preparations (subunit vaccines) containing the 
two surface glycoproteins, the HA and NA. The maJor 
obstacle to successful vaccination is the unpredictable 
antigenic changes in the HA molecule which occur during 
antigenic drift and shift. The protective efficacy of 
inactivated vaccines is further limited by their low 
immunogenicity in unprimed hosts and their inability to 
induce Tc responses. The latter is thought to be important 
primarily because of murine studies which 
demonstrate that a cross-reactive Tc response 
clearly 
rapidly 
reduces lung virus titres. The available data from human 
studies also support the concept that development of a Tc 
cell response aids recovery from infection (Section 
1.3.7.4). 
Cold-adapted (ca) reassortant vaccines are promising 
candidates for future influenza vaccines. The 
wild-type immunogenicity of ca-variants compared with 
parental strains has been previously determined largely on 
the basis of antibody responses. Ca-reassortant vaccines 
were less immunogenic than wild-type virus in seronegative, 
though presumably primed, adult volunteers as judged by both 
serum and nasal wash antibody responses (Murphy et al., 
1980; Clements et al., 1983). In murine studies, ca-
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variants were less immunogenic than parental strains at 
inducing both primary serum antibody responses and primary 
Tc cell responses (Mak et al., 1982b). There i s 1 i mi t e d 
data on the ability of ca-variants to induce immunological 
memory. Evidence for B cell . memory is suggested by the 
development of secondary nasal wash IgA responses in 
children previously immunized with a ca-reassortant virus 
and challenged intranasally with inactivated virus vaccine 
(Wright et al., 1983). Evidence for Tc cell memory has been 
demonstrated in murine studies by analyzing Tc ce ll 
precursor frequency after immunization (Mak et · al., 1984). 
An alternative approach to successful 
. vaccination is to improve the efficacy of 
influenza 
inactivated 
vaccines. This could be achieved by . . increasing the 
immunogenicity so that high neutralizing antibody levels are 
produced, especially in unprimed hosts, and by using a 
vaccine formulation which . lS effective at inducing 
cross-reactive Tc cell responses. 
One such approach could be based on the amphiphi l ic 
nature of the surface glycoproteins of the influenza virus 
and other enveloped viruses (Morein & Simons, 1985). The 
hydrophobic membrane anchors of the surface glycoprotei n s 
may aggregate to form protein micelles or be reconstituted 
with phospholipids to form liposomes in which the 
glycoproteins are exposed on the external surface. Micelle 
preparations and liposomes containing the influenza HA and 
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NA have induced hi~her antibody responses than protein 
monomers alone (Morein & Simons, 1985; Almeida et al., 1975; 
Oxford et al., 1981b). Recently a related structure has 
been described which consists of multimeric matrices formed 
by the interact ion of the hydrophobic port ion of membrane 
proteins with the glycoside Quil A (Morein et al., 1984). 
These complexes referred to as immuno-stimulatory complexes 
( iscoms) have been prepared with the membrane proteins of 
parainfluenza, measles and rabies viruses and have induced 
higher antibody titres than protein micelles. 
In the first part of this chapter local and systemi c B 
cell responses after immunization with a ca-variant virus 
have been compared with those to the parental virus and 
inactivated virus. In the second part the ability of 
influenza-specific 1scoms and micelles to induce local 
cellular immune responses and immunological memory in both 
unprimed and primed mice, has been examined. 
RESULTS 
6.1 B Cell Responses after Immun i zat ion with Wild- t y p e , 
ca-variant and Inactivated In flu e n za Viruse s 
6.1.1 ASCs after Primary Immunizat i o n with Parental and 
ca-variant viruses 
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Mice were inoculated intranasally with graded doses, 
ranging from 103 to 106 EID50 per mouse, of either the 
parental strain or ca-variant of A/ AA viru s. The ca-variant 
virus was given as either a single i noculum o r two inocula 
three weeks apart. ASCs were measured in the lung and 
the ' primary response and t e n weeks later 
spleen during 
(Table 6.1) . Immunization with a s ingle inoculum of 106 . 
EID50 of ca-variant virus produced a level of ASCs 1n the 
lung during the primary response comparable to that 
following immunization with a 100 f old lower dose of the 
parental strain ( non mouse-adapted ) . There were virtually 
no ASCs persisting in the lung ten week s after immunization 
with a single inoculum of 1 0 6 EID 50 of ca-variant virus 
whereas ASCs were sti l l present in the lungs of mice 
immunized with a 100-fold l ower dose of parental virus. 
Persistent ASCs were, however, d etected 1n the lungs of mice 
immunized with two inocu l a o f 10 6 EID50 of ca-variant virus. 
Whereas immunization with high do ses of parental virus 
resulted in the appearance of a s ma ll number of ASCs in the 
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spleen ( 12 IgG ASCs/106 cells at day 12), there was no 
splenic response following immunization with the ca-variant 
virus. 
6.1.2 B Cell Memory after Primary Immunization with 
Parental and ca-variant Viruses 
The number of ASCs generated in lung and spleen cell 
cultures obtained from primed mice and stimulated in vitro 
with purified A/AA virus was determined 15 weeks after 
primary intranasal inoculation (Table 6. 2). Immunization 
with the parental virus, even at the lowest dose, resulted 
in a significant increase in the number of ASCs generated in 
both lung and spleen cell cultures compared to cultures from 
unprimed mice. Immunization with 106 and 10SEID50 of 
ca-variant virus resulted in a secondary in vitro IgM 
response in both lung and spleen cell cultures comparable to _ 
that obtained with the corresponding dose of parental 
virus. In contrast the number of IgG and IgA ASCs were 
smaller than that obtained with the parental virus. The 
number of IgG and IgA ASCs generated in cultures from mice 
immunized with lower doses of ca-variant virus was not 
significantly greater than the number obtained from unprimed 
mice. Immunization with two inocula of the ca-variant virus 
did not appreciably alter the number of ASCs generated in 
vitro. 
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6.1.3 ASCs and B Cell Memory following Primary Immunization 
with Different Viral Preparations 
The number of ASCs in the lung and spleen were compared 
in 4 groups of mice immunized with either (A) 106 EIDso of 
parental A/AA virus intranasally; or ( B) 106 EID50 of 
ca-variant A/AA virus intranasally; or ( C) 103 HAU of 
ultraviolet-inactivated A/AA virus intranasally; or (D) 103 
HAU of ultraviolet-inactivated A/AA virus intraperitoneally 
( Table 6. 3 ) • As above, immunization with the parental 
strain resulted in the appearance of ASCs during the primary 
response in both the lung and spleen whereas the ca-variant 
virus elicited a 
Inactivated . virus, 
smaller 
given 
pulmonary 
either 
response 
intranasally 
only. 
or 
intraperitoneally, failed to elicit a primary ·response in 
the lung although intraperitoneal inoculation did elicit a 
splenic response. 
At 12 weeks after immunization, a small number of IgG 
and IgA ASCs were still present in the lung - 14 ASCs/106 
cells in mice primed with the parental virus and 6 ASCs/106 
cells in ca-variant primed mice. The largest number of 
ASCs, particularly IgG and IgA ASCs, generated in stimulated 
lung cell cultures, 12 to 15 weeks after . primary 
inoculation, was found in mice immunized with the parental 
virus (Table 6.4). Secondary in vitro responses were also 
obtained, in decreasing order of magnitude, in lung cell 
cultures from mice immunized with the ca-variant virus, 
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inactivated virus given intranasally and inactivated virus 
given intraperitoneally. Secondary in vitro spleni c 
responses were comparable in mice immunized with the 
parental virus or inactivated virus given 
intraperitoneally. The IgG responses in spleen ce ll 
cultures from mice immunized with the ca-variant virus or 
virus given intranasally were of lesser inactivated 
magnitude, though still significantly higher than . in 
cultures from unprimed mice. 
6.1.4 Correlation of B Cell Responses with Protection 
Immunized mice in the four groups described above wer e 
challenged 15 weeks after priming with 1. 5 x 107 EID50 of 
the parental A/AA virus intranasall y . Lung virus titres 
were measured in 4 mice from each group at day 3 after 
challenge (Table 6.5A). Lung virus titres in each of the 4 
immunized groups of mice were significant ly lower (p <0.05) 
than the titres in unprimed mice. Furthermore lung virus 
titres in . mice primed with the parental virus were 
significantly lower (p < 0.05) than in the other 3 immunized 
groups. Correlation coefficients were calculated comparing 
the degree of protection afforded by immunization, as 
assessed by the difference in lung virus titres between 
unprimed and immunized mice, and parameters of the B cell 
response measured prior to challenge ( Tables 6. 5 A & B) · 
Overall there was a trend towards higher correlation 
coefficients with pulmonary responses. In particular, there 
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was a significant correlation between the degree of 
protection and the number of IgG and IgA ASCs 1n the lung at 
the time of challenge (p < 0. 05) (Table 6. SA). In addition, 
protection also correlated significantly with the number of 
IgG and IgA ASCs generated 1n lung cell cultures obtained 
before challenge ( p < 0. 01) but, 1n contrast, there was no 
correlation with the number of ASCs generated in spleen cell 
cultures. Furthermore there was no correlation with serum 
antibody levels irrespective of isotype (Table 6.SB). 
Although a significant correlation was observed with IgM 
levels in tracheobronchial washings, the titres were very 
low and unlikely to have any functional significance. 
Despite the correlation observed with IgG and IgA ASCs ' 1n 
the lung, there was no correlation with IgG and IgA levels 
in tracheobronchial washings. This discordance is probably 
due to the variable effect of diluting secretory antibody 
levels whilst obtaining tracheobronchial washings. 
6.2 Cellular Immune Responses to Influenza A Virus 
Glycoproteins in Iscoms and Micelles 
6.2.1 In vivo Responses after Primary Immunization 
Normal mice were inoculated intranasally with either 
(i) 103 EID50 infectious A/PRB virus; or (ii) HANA iscoms, 
administered either as a single Sug dose or two Sug doses, 
one week apart; or ( iii) HANA micelles, 
administered either once or twice in Sug doses. 
similarly 
There was 
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no pulmonary or systemic toxicity following intranasal 
inoculation with either iscoms or micelles. 
Influenza-specific ASCs were enumerated in lung cell 
suspensions obtained fourteen days after the initial 
inoculation (Table 6.6). There was no ASCs detected in the 
lungs of mice inoculated intranasally with micelles ' in 
either one or two doses. In contrast, inoculation with a 
single dose of iscoms resulted in the appearance of a 
moderate number of IgG ASCs and inoculation with two doses 
of iscoms resulted in numbers of cells secreting IgM and 
IgG, but not IgA, of comparable order to those observed in 
mice primed with the infectious virus. The lack of an I gA 
response was confirmed in two subsequent experiments. 
Tc cell responses and NK cell responses were determined 
at six days after immunization; in mice inoculated twice, 
cytotoxicity assays were performed six days after the second 
inoculation (Table 6.7). There was no Tc cell response 
detected in the lungs of mice receiving either micelles or 
iscoms even after two inoculations. There was an increase 
in NK cell activity above the level in normal lungs in mice 
immunized with both micelles and iscoms. 
6.2.2 B Cell and Tc Cell Memory after Primary Immunization 
The development of B cell and Tc cell memory in the 
lung after primary immunization was determined at four weeks 
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after intranasal inoculation. The number of ASCs generated 
by in vitro stimulation with purified A/ PR8 virus was 
compared 1n lung cell cultures obtained from either 
immunized mice or from normal mice ( Table 6. 8) . In lung 
cell cultures from . mice primed with infectious virus there 
was approximately a 10-fold increase in the total number of 
ASCs generated, including IgG- and IgA-secreting cells not 
found in primary lung cell cultures. A similar increase was 
found in cultures from . mice immunized with iscoms, 
independent of the number of doses g1 ven. In contrast, 
. there was no increase in the number of ASCs generated in 
lung cell cultures obtained from mice inoculated with either 
one or two doses of micelles, although a small number of 
IgG- and IgA-secreting cells were detected in cultures from 
mice given two doses of micelles. 
The level of Tc cell memory present after primary 
immunization was determined by estimating Tc cell precursor 
frequency by limiting dilution analysis. Tc cell precursor 
frequency 1n the lung increased approximately 100-fold 1n 
mice primed with infectious virus. Irnmuniza t ion with two 
doses of 1scoms increased the frequency of Tc cell 
precursors 10-fold. In contrast, inoculation with either a 
single dose of iscoms or two doses of micelles had little 
effect on the Tc cell precursor frequency. 
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6.2.3 In vivo Responses after Secondary Immunization 
Mice were initially primed with 3x102 EIDso A/PR8 virus 
intranasally and 3 weeks later were inoculated intranasally 
with either (i) 104 EIDso A/PR8; or (ii) Sug HANA iscoms; or 
(iii) Sug HANA micelles. The ef feet of this schedule of 
secondary in vivo immunization on the level of ASCs, Tc 
cells and NK cells in the lung was determined six days after 
the secondary inoculation. 
Secondary inoculation with the homologous virus failed 
to elicit an increase in the level of ASCs persisting in the 
lung after primary inoculation (Table 6.9). In contrast , 
secondary inoculation with either iscoms or micelles 
significantly increased the level of ASCs, of each isotype, 
in the lung. The increases in IgM- and IgA-secreting cells 
were similar after inoculation with either iscoms or 
micelles, whereas iscoms induced a greater increase in 
IgG-secreting cells. 
Similarly, in vivo challenge with the homologou s virus 
failed to elicit a secondary Tc cell response (Table 6.10). 
Whereas both iscoms and micelles did induce a Tc cell 
response, the level of Tc cells induced by iscoms was about 
4-fold higher than the level induced by micelles. The Tc 
cells exhibited cross-reactivity by lysing target cells 
infected with an influenza virus bearing both different HA 
and NA proteins. There was little NK cell activity after 
164 
either h omo l ogous virus c h a llenge or secondary inoculation 
with either iscoms or mice ll es (Table 6.10) . 
6.2.4 Effect of Secondary in vivo Immunization on B Cell 
and Cytotoxic T Cel l me mory 
The effect of second a ry 1n vivo immunization on B cell 
and Tc cell memory was determined s ix weeks after secondary 
inoculation by re-stimulating l ung cell suspensions 1n 
vitro. Neither homologous virus cha llenge nor immunization 
with either iscoms or mi c elles h ad a significant effect on 
the number of ASCs generated 1n vitro or on Tc cell 
precursor frequency (Table 6.11 ) . 
TABLE 6.1 ASCs in the Lung after Primary Intranasal Inoculation with Graded doses of 
Parental or ca-variant Virus 
ASCs/106 cells (mean± SD)a 
Day after inoculation 
Primary 15 70 Intranasal Dose 
Inoculation (EID50) IgM IgG IgA IgM IgG IgA 
. 
Parental A/AA 106 192 ± 30 300 ± 25 176 ± 12 <5 58 ± 6 2 ± 1 105 70 ± 2 48 ± 3 2 ± 2 6 ± 1 44 ± 2 2 ± l 104 34 ± 9 37 ± 1 3 ± 1 <5 8 ± 2 l 103 8 ± 5 10 ± 6 2 ± 2 <5 3 ± 1 1 
Ca-variant A/AA 106 35 ± 3 22 ± 3 2 ± 2 < 5 2 <1 105 <5 < 1 < 1 < 5 < 1 <1 104 <5 < 1 < l < 5 < l <1 103 <5 < 1 < 1 < 5 < 1 <1 
Ca-variant A/AA 106x2b ND ND ND 23 ± 8 32 ± 1 13 ± 4 105x2 II II II < 5 1 <1 104x2 II II II < 5 <1 <1 103x2 II II II < 5 <1 <1 
a. Values represent mean± SD of triplicate assays using suspensions of poo led lung cells 
obtained from 3 mice. 
b. Two doses given, 3 weeks apart, on day O and day 21. 
ND = Not determined. 
TABLE 6.2 B Cell Memory in Lung and Spleen after Primary Intranasal Inoculation with 
Graded Doses of Parental or ca-variant Virus. 
Primary 
Intranasal 
Inoculation 
Nil 
Parental A/AA 
Ca-variant A/AA 
Ca-variant A/AA 
Dose 
(EID50) 
106 
105 
104 
103 
106 
105 
104 
103 
106x2 
10Sx2 
104x2 
103x2 
IgM 
231 ± 11 
590 ± sob 
550 ± 63b 
610 ± 30b 
587 ± 38b 
742 ± 63b 
708 ± 40b 
182 ± 23 
234 ± 13 
477 ± 23b 
737 ± 61b 
570 ± 14b 
273 ± 21 
ASCs/106 cells (mean± SD) 
generated in vitroa 
Lung 
IgG 
<1 
± 12b 
± 10b 
7b 
1b 
198 
65 
34 ± 
5 ± 
112 ± 
8 ± 
4 
4 ± 
6b 
3b 
1 
148 ± 13b 
3 
2 
3 
IgA 
<5 
± 21b 
± 6b 
7b 
7b 
326 
76 
22 ±" 
35 ± 
127 ± 
45 ± 
8 ± 
9 ± 
4b 
6b 
2 
4 
115 ± 7b 
20 ± 2b 
29 ± 4b 
24 ± 6b 
Spleen 
IgM 
859 ± 65 
2580 ± 2sob 
1660 ± 120b 
1475 ± sob 
1620 ± 160b 
2267 ± 93b 
1933 ± 267b 
1247 ± 140b 
2160 
1090 
1100 
ND 
± 130b 
± sob 
± 130b 
640 ± 40b 
IgG 
< l 
2520 ± 20b 
1990 ± 130b 
1450 ± 20b 
1950 ± 110b 
1146 ± 
312 ± 
56 ± 
ND 
gob 
6ob 
11b 
± 106b 
± 104b 
16b 
1104 
658 
80 ± 
58 ± 5b 
a. Values represent mean± SD of duplicate assays on suspensions of pooled cells from 3 
mice obtained 15 weeks after primary inoculation and stimulated in vitro with purified 
A/AA virus for 5 days. 
b. Significant increase (p < 0.05) in ASCs generated in vitro over cultures from unprimed 
mice. 
ND = No t determined. 
TABLE 6 .. 3 ASCs in the Lung and Spleen after Variable Primary Immunization Protocols 
Primary Inoculation 
Virus Dose Route 
Parental A/AA 106 EID50 1. n. 
Ca-variant A/AA 106 EID50 1. n. 
Inactivated A/AA 103 HAU 1. n. 
Inactivated A/AA 103 HAU 1. p. 
Lung virus 
titrea 
(log10EID50) 
5.25 ± 0.25 
2.0 ± 0.5 
< 2 
< 2 
IgM 
82 
16 ± 2 
6 ± 4 
0 
ASCs/106 cells (mean± SD)b 
Lunge Spleen 
IgG IgA IgMd IgGC 
189 ± 8 43 ± 19 104 ± 15 15 ± 7 
48 ± 5 13 ± 2 < 5 0 
0 0 < 5 0 
0 0 25 ± 2 7 ± 3 
a. Mean± SD of triplicate titrations obtained at day 3. 
b. Mean± SD of triplicate assays using suspensions of pooled cells from 3 mice. 
c. Day 16 after inoculation. 
d. Day 7 after inoculation 
TABLE 6.4 B Cell Memory in the Lung and Spleen after Variable Primary Immunization 
Protocols 
ASCs/106 cells (mean± SD)a generated in vitro 
Primary Inoculation Lung Spleen 
Virus Dose Route IgM IgG IgA IgM IgG 
Nil - - 125± 25 1 4 ± 1 1033±260 1 
Parental A/AA 106 EID50 . 1775±126b 280±52b 121±3ob 5240±12ob 2300±42Qb 1. n. 
Ca-variant A/AA 106 EID50 1. n. 1167± s1b 30±1ob 25± 7b 4260± 20b 580±2oob 
Inactivated A/AA 103 HAU 1.n. 755± 19b 7± 2b 20± 2b 4220±66Qb 400± sob 
Inactivated A/AA 103 HAU 1. p. 460± 27b 12± 1b 12± 2b 1240±34ob 1290±150b 
a. Values represent mean± SD of duplicate assays using suspensions of pooled cells 
obtained from 3 mice 12- 15 weeks after primary inoculation and stimulated in vitro for 
5 days. 
b. Significant increase (p < 0.05) in ASCs generated in vitro over cultures obtained from 
unpri~ed mice. 
TABLE 6.5A Correlation of ASCs and B Cell Memory with Protection 
Mean no. of ASC's generated in vitro 
Primary Lung virus 
Inoculation titresb 
(Route)a (log10EID5o) 
Nil 6.9 ± 0.2 
Parental 2.9 ± 1.4 
Virus (i.n.) 
Ca-variant 5.1 ± 1.2 
Virus (i.n.) 
Inactivated 5.3 ± 0.8 
Virus (i.n.) 
Inactivated 5.5 ± 0.4 
Virus (i.p.) 
Correlation Coefficient: 
Probability Value: 
Number of 
IgG & IgA 
ASCs in Lung 
0 
14 
6 
2 
0 
0.96 
< 0. 05 
IgM 
125 
1775 
1167 
755 
460 
0.92 
NS 
Lung 
IgG 
< l 
280 
30 
7 
12 
0.99 
< 0. 01 
IgA 
4 
127 
0.99 
< 0. 01 
25 
20 
12 
a. Sarne protocol for primary inoculation as in Tables 6.3 and 6.4. 
b. Lung virus titres measured in 4 mice at day 3. 
NS= Not significant 
Spleen 
IgM 
1033 
5420 
4260 
4220 
7240 
-0.05 
NS 
IgG 
< l 
2300 
580 
400 
1290 
0.84 
NS 
TABLE 6.58 Correlation of Antibody Levels with Protection 
Reciprocal of ELISA Titrec 
Primary Lung virus 
Inoculation titresb 
(Route)a (log10EID5o) 
Nil 6.9 ± 0.2 
Parental 2.8 ± 1.4 
Virus (i.n.) 
Ca-variant 5.1 ± 1.2 
Virus (i.n.) 
Inactivated 5.3 ± 0.8 
Virus (i.n.) 
Inactivated 5.5 ± 0.4 
Virus (i.p.) 
Correlation Coefficient: 
Probability Value: 
a. & b. As in Table 6.5A. 
IgM 
< 3 
14 
14 
14 
13 
0.44 
NS 
Serum 
IgG 
< 3 
22 
20 
20 
20 
0.74 
NS 
IgA 
<3 
13 
11 
12 
9 
0.81 
NS 
(log2) 
IgM 
< 3 
5 
3 
3 
3 
0.99 
< 0. 01 
C • Sera and tracheobronchial washings (TBW) pooled from 3 mice. 
TBW 
IgG 
< 3 
13 
11 
10 
7 
0.81 
NS 
IgA 
< 3 
10 
9 
3 
< 3 
0.72 
NS 
TABLE 6.6 ASCs in the Lung after Primary Immunization with !scorns and Mi c elles 
Primary ASCs/106 cells (mean± SD)a Intranasal 
Inoculation 
Nil 
A/ PRB virus 
HANA !scorns 
HANA !Sc orns 
HANA mi cel l e s 
HANA mi cel l e s 
Dose 
103 EID50 
Sug 
Sug x 2 
Sug 
Sug x 2 
IgM 
3 ± 1 
391 ± 14 
0 
147 ± 1 
0 
0 
IgG 
0 
109 ± 28 
24 ± 2 
250 ± 3 
0 
1 
IgA 
0 
295 ± 36 
0 
16 ± 6 
0 
0 
a . Va lues represent mean± SD of triplicate assays on suspensions of pooled l ung ce l ls 
obtained from 3 mice 2 weeks after primary inoculation . 
TABLE 6.7 
Primary 
Intranasal 
Inoculation 
Nil 
A/PRB virus 
HANA iscoms 
HANA 1scoms 
HANA micelles 
HANA micelles 
Tc Cells and NK Cells in the Lung after Primary Immunization with Iscoms and Micelles 
Dose 
103 EID50 
5ug 
5ug x 2 
5ug 
Sug x 2 
% Specific 5lcr release from: a 
A/PR8-P815b 
C 100:I· 50:1 
11 ± 0.4 
83 ± 1 
3 ± 0.2 
9 ± 0.3 
3 ± 0.2 
11 ± 0.4 
7 ± 0.2 
66 ± 3 
2 ± 0.1 
11 ± 0.2 
2 ± 0.2 
10 ± 1 
100:1 
31 ± 0.6 
70 ± 2 
65 ± 2 
39 ± 1 
69 ± 2 
40 ± 1 
YAC- 1 
50:1 
11 ± 0.3 
67 ± 1 
59 ± 2 
39 ± 1 
62 ± 1 
29 ± 1 
a . Values represent mean± SD of quadruplicate assays on suspensions of pooled lung cells 
obtained from 3 mice 6 days after inoculation. Background medium release from 
infected and uninfected P815 and YAC-1 cells was 7.8, 7.5 and 7.4% respectively. 
b. Specific release from uninfected P815 cells was <1% except in the presence of cells 
from A/PRB primed mice when specific release was 11% (E/T ratio 100:1). 
c. Effector cell :Target cell ratio (E/T). 
Table 6.8 
Primary 
Intranasal 
Inoculati o n 
Nil 
A/ PR8 Virus 
HANA !scorn s 
HANA Iscorn s 
HANA Micelles 
HANA Micelles 
B Cell and Tc Cell Memory after Primary Immunization with !scorns and 
Micelles 
Dose 
103 EI D5 0 
5ug 
5ug x 2 
5ug 
5ug x 2 
ASCs/106 cells (mean± SD) 
generated in vitro:a 
IgM 
235 ± 20 
1200 ± 43 
1167 ± 110 
1230 ± 210 
137 ± 60 
187 ± 4 3 
IgG 
0 
577 ± 63 
130 ± 20 
273 ± 33 
0 
7 ± 3 
IgA 
0 
257 ± 83 
253 ± 63 
177 ± 17 
0 
3 ± 2 
Tc Cell prec u r s o r 
fr e que nc yb 
(x10 - 4) 
.16 
28.6 
.3 9 
2 . 74 
. 15 
.43 
a . Values represent mean± SD of duplicate assays on suspensions of pooled lung cells 
obtained from 3 mice 4 weeks after immunization and stimulated in vitro with purified 
A/PR8 virus for 5 days. 
b. Limiting dilution assays on suspensions of pooled lung cells obtained from 3 mice 4 
weeks after immunization. 
TABLE 6.9 
Secondary 
Intranasal 
Inoculationa 
Nil 
A/PR8 Virus 
HANA !scorns 
HANA Mi celles 
Effect of Secondary in vivo Immunization with !scorns and Micelles on ASCs 1n 
the lungs of primed mice 
ASCs/106 cells (mean± SD)b 
Dose IgM IgG IgA 
34 ± 7 62 ± 8 32 ± 3 
104 EID50 15 ± 9 95 ± 18 10 ± 4 
5ug 314 ± 32 920 ± 62 232 ± 8 
5ug 318 ± 44 470 ± 62 200 ± 2 
a . Mice were primed 3 weeks earlier with 3xlo2 EID50 A/PR8 virus intranasally . 
b . Values represent mean± SD of triplicate assays on suspensions of pooled lung cells 
obtained from 3 mice 6 days after secondary inoculation. 
TABLE 6.10 Tc Cells and NK Cells in the Lung after Secondary in vivo Immunization with 
Iscoms and Micelles 
Secondary 
Intranasal 
Inoculationa 
Nil 
A/PR8 Virus 
HANA !scorns 
HANA Micelles 
Dose 
104 EID50 
5ug 
5ug 
a. As in table 6.9. 
50:lb 
16 
14 
53 
32 
% Specific 5lcr release fromC 
A/PR8-P815 A/PC-P815 
25:1 
14 
13 
48 
31 
12:1 
10 
10 
35 
22 
50:1 
12 
13 
26 
18 
25:1 
11 
12 
23 
18 
b. Effector cell:Target cell ratio (E/T) 
12:1 
7 
9 
17 
13 
YAC-1 
50:1 
11 
10 
13 
7 
c. Values represent mean of quadruplicate assays on suspensions of pooled lung cells 
obtained from 3 mice 6 days after secondary inoculation. Background medium release 
from all target cells < 10%. Specific release from uninfected P815 cells < 1% (E/T 
ratio 50:1). 
TABLE 6.11 Effect of Secondary in vivo Immunization with Iscoms and Mi ce ll e s o n B Ce ll 
a nd Tc Cell Memo ry 
Secondary 
Intranas a l 
Inoc ulati o na 
Ni l 
A/ PR8 Virus 
HANA ! s corn s 
HANA Mi ce ll e s 
Do s e 
104 EIDs o 
5ug 
5ug 
a . As in Table 6.9. 
ASCs/106 cells (mean± SD) 
generated in vitro:b 
IgM 
2467 ± 27 
3019 ± 150 
3478 ± 266 
3049 ± 49 
IgG 
1133 ± 53 
2004 ± 77 
2334 ± 326 
1736 ± 22 
IgA 
1120 ± 147 
1427 ± 253 
1950 ± 80 
1197 ± 22 
Tc Ce ll pr ec u r s o r 
fr e qu e nc y c 
(xio - 4) 
5.0 
2.1 
7.0 
3.3 
b . Values represent mean± SD of duplicate assays on suspens i ons of pooled lung cells 
obtained from 3 mice 6 weeks after secondary immunization and stimulated in vi tro for 
5 days. 
c . Limiting dilution assays on suspensions of pooled lung cells obtained from 3 mice 6 
weeks after secondary immunization. 
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DISCUSSION 
Influenza virus-specific ASCs were detected in the lung 
but not 
ca-variant 
parental 
in the spleen 
virus, 
virus 
whereas 
induced 
following 
primary 
immunization with a 
infection with the 
both pulmonary and splenic 
responses. The discordance between pulmonary and splenic B 
cell responses to ca-variant viruses has also been observed 
with Tc cell responses (Mak et al., 1984) and 1s probably 
related to the restricted replication of the ca-variant 
virus in the murine lung with a resulting lack of anti'gen 
11 
spillover II to the spleen. Ca-variant virus was 100 fold 
less efficient than the parental virus in the induction of 
. primary ASC responses 1n the lung. This difference 1n 
immunogenicity is similar to that previously reported for 
serum antibody responses and primary Tc cell responses (Mak 
et al . , 198 2b) • 
B cell memory, assessed as the ability to prime for 
secondary 1n vitro responses, was established in both the 
lung and spleen after immunization with sufficiently high 
doses of the ca-variant virus. However the number of IgG 
and IgA ASCs generated in vitro was less than that detected 
in the corresponding cultures obtained from mice immunized 
with the parental virus. Thus B cell memory, but not a 
primary ASC response, was detected in the spleen after 
administration of the ca-variant virus (as well as after 
lower doses of the parental virus). 
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The low immunogenicity of ca-variant viruses in 
unprimed mice parallels the lesser degree of protection 
afforded against challenge with homotypic or heterotypic 
wild-type viruses as compared with the parental virus (Mak 
et al. , 1984; Tannock et al., 1984) . In previous studies 
protection against homotypic challenge, which is principally 
mediated by neutralizing antibody, correlated poorly with 
serum antibody responses (Tannock et al., 1984) . The 
ability to accurately localize B cell responses . . in mice 
immunized with different . . priming strategies provided the 
opportunity to determine whether protection correlated with 
local or systemic B cell responses. Accordingly protection 
has been shown to correlate with the development of 
pulmonary B cell responses rather than splenic responses. 
In particular the presence of ASCs in the lung and the 
number of IgG and IgA ASCs generated in stimulated lung 
cultures obtained at the time of challenge correlated 
significantly with protection. In contrast serum antibody 
levels and the number of ASCs generated in stimulated spleen 
cell cultures did not correlate with protection. 
ASCs persisted in the lung for less than ten weeks 
after immunization with a single inoculum of ca-variant 
virus. In contrast ASCs persisted in the lung for up to 
eighteen months after primary infection with a mouse-adapted 
wild-type virus (Section 5. 1). However immunization with 
two inocula of ca-variant virus prolonged the duration of 
ASCs in the lung, although the levels were still lower than 
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the results obtained with mouse-adapted virus. Although 
immunization with two doses of ca-variant virus did not 
appear to appreciably expand the pool of B memory cells, a 
larger amount of residual viral antigen in the lung may have 
lead to increased recruitment of B memory cells. Consistent 
with the observation that the presence of ASCs in the lung 
correlated with protection, immunization with two doses of 
ca-variant virus has previously been shown to afford greater 
protection in murihe studies (Tannock et al., 1984) and 1s 
recommended for 
unprimed humans. 
future use of ca-variant vaccines 1n 
The immunogenicity of 1scoms and related structures has 
previously been assessed almost solely on serum antibody 
titrations following parenteral administration. In this 
cellular . immune responses in the lung involving NK chapter, 
cells, influenza virus-specific ASCs and Tc cells were 
analyzed following local immunization with either iscoms or 
micelles containing the influenza virus glycoproteins. 
In unprimed mice, only intranasal inoculation with two 
doses of iscoms induced a level of IgM and IgG ASCs 1n the 
lung comparable to that following primary inoculation with 
infectious virus. However, there was no 1n vivo IgA 
response following immunization with iscoms possibly because 
aerosols of 1scoms were predominantly delivered to the 
peripheral zones of the lung. Local B cell memory was also 
established only after immunization with iscoms but was less 
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dependent on dose and involved the generation of IgA memory 
cells as well. 
In contrast to the ASC responses, neither 1scoms nor 
micelles even after two inoculations induced primary in vivo 
Tc cell responses. However local Tc cell memory was 
established after immunization with two doses of 1scoms 
although the frequency of Tc cell precursors was only 10% of 
that following inoculation with infectious virus. An 
analysis of Tc cell precursor frequency after . primary 
immunization with a ca-vaccine produced similar results (Mak 
et al. , 1984) • 
In mice primed with infectious virus homologous virus 
challenge failed to elicit both secondary B and Tc cell 
responses presumably because viral replication was prevented 
by neutralizing 
immunization with 
antibody. 
either 
In 
1scoms or 
contrast 
micelles 
secondary 
induced 
significant elevations in the level of ASCs in the lung and 
the appearance of cross-reactive Tc cells. This difference 
probably reflects the greater antigenic load delivered 1n 
the lSCOm and micelle preparations. There was no 
significant change 1n the level of either B cell or Tc cell 
memory after secondary immunization with either 1scoms or 
micelles. 
These findings differ 1n several respects to the murine 
and human responses described after immunization with 
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earlier influenza HANA subunit vaccines. The most important 
difference is the ability of HANA iscoms to induce Tc cell 
responses and Tc cell memory. Previous studies showed that 
earlier subunit vaccines failed both to prime mice for 
secondary Tc cell responses (Reiss & Schulman, 1980b; 
Webster & Askonas, 1980) and also failed to elicit secondary 
Tc cell responses, in mice and ' in humans, whether 
' ' administered in vivo or in vitro (Reiss & Schulman, 1980b; 
McMichael et al., 1981; Ennis et al., 1981b). Accordingly 
immunization with HANA iscoms may afford broader heterotypic 
protection mediated by cross-reactive Tc cell responses than 
current inactivated vaccines. There are no comparable data 
on the development of ASCs or B cell memory in the lung with 
earlier subunit vaccines, but using an influenza specific 
haemolytic-plaque assay, direct plaque-forming cells were 
not detected in the spleens of mice after a 
intraperitoneal injection (Reiss & Schulman, 1980b). 
single 
Data 
on antibody responses have shown that it is necessary to 
give two inoculations of subunit vaccines to achieve serum 
titres comparable to levels obtained after immunization with 
inactivated whole virus (Potter, 1982). Similarly a single 
inoculation of iscoms was poorly immunogenic in unprimed 
mice. 
The basis for the enhanced immunogenicity of HANA 
iscoms over earlier HANA subunit vaccines may relate to the 
ability of iscoms and other amphiphilic-based structures to 
interact with the cell membrane of antigen-presenting 
17 0 
cells. The homogenous preparations of HANA micelles and 
1scoms used 1n this study contrasts with earlier subunit 
vaccines which were composed of heterogenous complexes of 
glycoproteins, lipids and residual detergents (Morein & 
Simons, 1985). In this study HANA . 1 scorns were al so more 
. . 
immunogenic than HANA micelles, particularly 1n unprimed 
mice. The basis for this observation has not been 
determined although 1n other systems it 1s not merely a 
function of the adjuvant effect of Quil A (Morein & Simons, 
1985) . 
Both murine and human studies have shown that the HA is 
recognized by only 10-15% of Tc cells and that there 1s 
little cross-recognition between the HA proteins of the Hl 
and H3 subtypes (Section 1.3.2.2). Although it is likely 
that some Tc cells recognize the NA, there are no reports 
unequivocally demonstrating this. Thus although neither t h e 
HA or NA proteins appear to be major determinants recognized 
by Tc cells, iscoms containing only these proteins were ab l e 
to induce cross-reactive secondary Tc cell responses . 
illustrates the marked immunopotentiating effect of 
This 
. iscom-
based preparations. Ttlhilst it is probable that most if not 
all the influenza viral proteins are recognized by Tc cells, 
the nucleoprotein (NP) appears to be a maJor Tc cell 
determinant. Hence a subunit vaccine containing the HA and 
NP has recently been proposed as an ef feet i ve means for 
inducing both neutralizing antibody and cross-protective Tc 
cell responses (Wraith & Askonas, 1985). However it has 
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also been reported that there is considerable variation 1n 
the frequency of NP-specific Tc cells between mice of 
different MHC haplotypes (Pala & Askonas, 1986 ) and even 
between individual mice within the same inbred strain (Pala 
et al., 1986). Accordingly, the effectiveness of . a vaccine 
containing NP would be limited if similar Ir gene effects 
occurred in humans. It would be interesting to determine if 
an iscom-based preparation of NP would be recognized by mice 
of low responder haplotypes. 
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SUMMARY 
The development of regional B cell responses was 
studied 1n mice immunized intranasally with different 
influenza virus vaccines. The ca-variant virus was 100 fold 
less efficient than the parental virus in the induction of 
influenza virus-specific ASCs in the lung and failed to 
induce ASCs in the spleen. The ca-variant virus was also 
less efficient ' 1n pr1m1ng for secondary IgG and IgA 
responses generated in vitro in both lung and spleen cell 
cultures. Protect ion against homotypic challenge 1n mice 
immunized by different vaccine strategies correlated with 
the development of pulmonary B cell responses rather than 
splenic responses. In particular, protection correlated 
with the presence of ASCs and IgG and IgA memory in the lung 
at the time of challenge. 
Primary immunization with a single inoculum of either 
micelles or 
glycoproteins 
iscoms 
failed to 
containing 
induce 
influenza A virus 
either B or Tc cell 
responses. In contrast, immunization with two inocula of 
1scoms, but not micelles, resulted 1n the appearance of 
influenza virus-specific ASCs but not Tc cells in the lung. 
There was a 10-fold increase in Tc cell precursor frequency 
and an increase 1n ASCs generated by secondary 1n vitro 
stimulation of lung cell cultures obtained from mice primed 
with iscoms but not micelles. 
infectious virus, secondary 
In mice primed 
immunization with 
with 
either 
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micelles or 1scoms increased the number of ASCs 1n the lung 
and elicited cross-reactive Tc cell responses. In contrast, 
homologous virus challenge failed to induce 
detectable secondary B or Tc cell responses. 
either 
CHAPTER SEVEN 
CONCLUSION 
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B cell responses to infection or immunization with 
viral respiratory pathogens have been previously 
secretory characterized by· measurements of serum and 
antibody levels. This approach however does not assess the 
contribution of each target or lymphoid organ to the total 
response. 
described 
previously 
The development of the ELISA-plaque assay, 
1n Chapter 
unavailable, 
3' provided a reliable 
for quantitating 
method, 
influenza 
virus-specific ASCs following both in vivo and 1n vitro 
stimulation. Using this approach the responses of the lung, 
the target organ of influenza infection, and of the spleen, 
a maJor lymphoid organ, have been characterized after both 
murine influenza infection and immunization. 
The development of B cell responses to mur1ne influenza 
virus infection were described 1n Chapters 4 and 5 and 
address the aims of the thesis outlined in Section 1.4. 
7.1 ASCs In Murine Influenza Infection (Table 7.1) 
Influenza virus-specific ASCs secreting specific IgM, 
IgG and IgA, were detected 1n the lung during primary 
influenza virus infection. Subsequently cells continuing to 
secrete influenza specific antibodies, predominantly IgG, 
persisted 1n the lung, 1n the absence of any further 
exogenous antigenic stimulation, for at least 18 months 
after primary infection. These findings provide the most 
direct evidence yet available that specific antibodies 1n 
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respiratory secretions, in response to influenza infection, 
are derived from local antibody synthesis. 
The magnitude of the ASC response relative to the 
number of lymphocytes assayed was greater in lung cell 
suspensions compared to spleen cell suspensions obtained 
during and after primary infection. However, since a 
greater number of lymphocytes were recovered from the spleen 
than from the lung the magnitude of the ASC response was 
greater in absolute terms in the spleen. 
The characteristics of secondary ASC responses were 
dependent on whether the virus used for challenge was 
homotypic or heterotypic relative to the priming virus. The 
ASC response developed ~arlier in the lung after secondary 
homotypic challenge compared to primary infection and 
heterotypic challenge. The presence of pre-existing 
neutralizing antibody to the homotypic virus in the lung 
limited the extent of viral replication, thus necessitating 
the use of a relatively large dose of virus to elicit a 
secondary ASC response and restricting the response to the 
lung. In contrast, viral replication was not significantly 
affected in mice primed with a heterotypic virus. The ASC 
response developed at the same time as in unprimed mice and 
was not restricted to the lung. Furthermore, there was no 
evidence that challenge with a heterotypic virus elicited a 
B cell response to the original priming virus. 
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7.2 Influenza-specific B Cell Precursors 1n Murine Lunq 
That influenza-specific B cell precursors are present 
in the lungs of normal, non-immunized mice is evident by the 
finding of specific IgM-secreting cells 1n stimulated lung 
cell cultures obtained from unprimed mice. This finding 
indicates that the specific ASCs which appear 1n the lung 
during primary influenza infection may well have originated 
from specific B cell precursors already resident in the 
lung. However the appearance of ASCs in the spleen 24-48h 
earlier than in the lung during primary infection suggests 
that ASCs derived from . the spleen and recruited into the 
lung may have also contributed to the pulmonary response. 
7. 3 B Cell Memory after Murine Influenza Infection (Table 
7.2) 
B cell memory was established 1n 
the spleen following primary influenza 
the 1 ung as wel 1 as 
infection. Overall 
the level of memory was of lesser magnitude and was less 
durable in the lung compared to the spleen. The decline 1n 
the level of B cell memory in the lung was probably due to 
the recruitment of pulmonary B memory cells into ASCs due to 
continual stimulation from persisting viral antigen in the 
lung. 
Homotypic virus challenge increased the level of B cell 
memory in both the lung and spleen. Heterotypic virus 
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challenge did not si g nicantly affect the level of B cell 
memory to the original p r iming viru s. However memory to the 
challenge virus was establi s h e d in both the lung and spleen 
at a leve l comparable to t h at d e velope d in unprimed mice. 
7.4 Intrapulmonary Loca li zat i o n of B Cell Re s ponses 
Al though ASCs were detected 1n ce ll suspen s ions from 
whole lungs, either when assay e d immediately after 
preparation or after in vitro st im u lat i on, this approach has 
not provided adequate informat i o n t o determine whether 
intra-pulmonary B cell responses were o c curring within the 
mucosal and / or parenchymal div i s i ons of the lung. Studies 
utilizing irnmunofluorescence h ave s imilarly not provided 
this information as cell suspens ion s were assayed (Scott & 
Walker, 1976) • An attempt to study this aspect further by 
1n situ immunohistochemical localization of the B cell 
response in the lung was under t aken . However this approach 
was unsuccessful because of in s urmountable technical 
difficulties (Appendix). 
Where are the influen za-spec ific B cell precursors, 
demonstrated in cul tu red cel l s u s p e n s ions, localized in the 
lungs? There was no ev idence that these precursors were 
derived to any extent f rom c irculating lymphocytes 1n the 
pulmonary vascu l ature. It ' lS orobable l. that influenza-
specific IgA ASCs o ri g ina t e d 1n the BALT where appropriate 
IgA T switch cells res ide. The or1g1n of ASCs of other 
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isotypes 1s unknown. The relative predominance of IgG over 
IgA ASCs 1n both pr 1mary and secondary resoonses suggest 
that the B cell responses detected were principally 
occurring within the parenchymal division (Fig. 7.1). 
As the induct ion of B cell memory 1s dependent on a 
well organized lymphoid architecture it 1s likely that the 
non-IgA B memory cells detected 1n the lung were derived 
from extrapulmonary lymphoid tissue in view of the paucity 
of organized lymphoid tissue in the lung parenchyma. 
7.5 Protective Role of Lung Responses 
Protection against re-infection by influenza virus and 
other viral respiratory tract pathogens is mediated by 
neutralizing antibody within the respiratory tract the 
predominant isotype involved being determined by the site of 
initial infection within the respiratory tract (Section 
1.3.6.4). It has been previously assumed that influenza 
virus specific IgG in the respiratory tract is derived from 
serum. The data presented 1n this thesis shows that IgG 
ASCs may persist in the lung after infection providing a 
continual source of IgG 1n the respiratory tract. 
Furthermore protection against re-infection was shown to 
correlate with the presence of IgG ASCs in the lung rather 
than serum IgG. Protection also correlated with the level 
of B cell memory 1n the lung rather than the spleen. This 
correlation probably relates to the continual recruitment of 
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ASCs from the pool of B memory cells after primary 
infection. As it is necessary for antibody to be already 
present at the time of virus challenge to prevent infection, 
the activation of B memory cells at this point would not 
contribute to preventing infection. Furthermore, given the 
short inc u bat ion per i od , i t i s u n l i k e 1 y that AS Cs , induced 
from B memory cells at the time of virus challenge, would 
significantly affect the onset of disease. 
7.6 Effect of Antigen on Induction of B Cell Responses 
The induct ion of ASCs was shown to be dose-dependent 
after both intravenous and intranasal inoculation. 
Interestingly however there appeared to be differences 1n 
the dose requirements for the gene rat ion of ASC responses 
compared to the generation of B cell memory. Over a range 
ASC responses of priming doses with wild-type virus, 
declined, whereas the subsequent level of B cell memory did 
not significantly differ. Similarly when viral replication 
was restricted after immunization with a high dose of 
ca-variant virus ASC responses were diminished whereas the 
level of B cell memory was comparable to that obtained with 
the parental virus. 
with a single dose of 
Furthermore, intranasal inoculation 
influenza-specific iscoms resulted . 10 
the generation of B cell memory 1n the absence of a 
significant ASC response whereas two inoculations induced 
both responses. These findings suggest that the generation 
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. of B cell memory is more efficient, i.e. requires less 
antigenic mass, than the generation of ASCs. 
There were also differences observed in the abil~ty to 
generate B cell responses in different sites. ASCs were 
generated in the lung but were not detectable in the spleen 
after inoculation with low doses of virus or when viral 
replication in the lung was restricted e.g. during homotypic 
virus challenge and after immunization with ca-variant 
virus. Whereas ASCs were not detected in the spleen under 
these conditions, there appeared to be no effect on the 
generation of B cell memory. Again these results suggest 
that less antigen is required for the generation of B cell 
memory. Furthermore ASCs are generated more efficiently in 
the region of antigen deposition presumably because less 
antigen is subsequently delivered to distal sites. This is 
also supported by the differences in regional responses 
observed after inoculation with inactivated virus vaccine by 
either the intranasal or intra-peritoneal routes. 
7.7 Implications for Vaccination 
The conclusions drawn so far have important 
implications in the development of a successful vaccination 
strategy against influenza. 
B cell responses in the respiratory tract, which have 
been shown to correlate with protection, are more 
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effectively induced by local immunization. Hence, an 
influenza vaccine should preferably be administered local l y 
rather than parenterally. 
Secondly, the degree of antigenic stimulation should be 
comparable to that of natural infection. In this regard it 
would appear that ca-variant viruses may induce adequate B 
cell responses when administered in two doses to unprimed 
subjects. Furthermore, it has been previously shown that 
ca-variant viruses effectively induce cross-reactive Tc cell 
responses, at least in murine studies (Mak et al., 1984). 
These findings suggest that attenuated virus vaccines wou ld 
be suitable for immunizing unprimed subjects. There is no 
evidence to date however that ca-variant virus vaccines are 
more effective in adults, previously primed by different 
influenza strains, than inactivated virus vaccines. It may 
be that in the presence of cross-reacting antibodies to 
different subtype variants, attenuated viruses are less 
immunogenic. Enhancing immunogenicity by either decreasing 
the degree of attenuation or using higher doses of 
attenuated viruses would induce greater reactogenicity. 
In Chapter 6 an alternate approach to immunization has 
been explored by enhancing the irnmunogenicity of influenza 
virus proteins. B cell responses and · surprisingly Tc cell 
responses were enhanced by incorporating the influenza virus 
HA and NA into iscoms. Further work on this approach has 
shown that the influenza virus NP can also be incorporated 
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into iscoms (Morein, B, personal communication). Work 1s 1n 
progress to determine if 1scoms containing the HA, NA as 
well as NP will induce even greater Tc cell responses. 
7.8 Implications for Other Viral Respiratory Pathogens 
Although the broad conclusions presented 1n this 
chapter are based on data pertaining only to influenza 
virus, the methodology especially the ELISA-plaque assay, 
and the experimental approaches taken to provide these data 
should be applicable to other viral respiratory pathogens as 
well. At present there 1s no comparable data on the 
development of ASCs or B cell memory 1n the lung after 
infection with any of the other respiratory . viruses. 
Although it 1s likely that the conclusions drawn in the 
influenza model would be applicable to other respiratory 
vi ruses, it would be important to establish the relative 
roles of local and systemic immune responses 1n different 
infections where the level of viral replication within the 
respiratory tract differs. Assuming that effective vaccines 
w i 11 be a vai lab le in the future, as is almost the case for 
RSV, the most effective method of vaccination should be 
chosen based on knowledge of the nature of regional immune 
responses. 
TABLE 7.1 ASC Responses in Murine Influenza 
Lung Spleen 
ASC responses following: IgM IgG IgA IgM IgG IgA 
Primary Inoculation +++ ++ ++ +++ ++ 
Secondary Inoculation 
(a) Homotypic challenge + ++ ++ 
( b) Heterotypic challenge 
( i ) Type specific ASCs + ++ ++ + ++ 
( i i ) Subtype specific ASCs 
to priming virus 
TABLE 7.2 B Cell Memory in Murine Influenza 
Lung Spleen 
ASCs generated in vitro following: IgM IgG IgA IgM IgG IgA 
Primary Inoculation ++ ++ ++ +++ +++ + 
Secondary Inoculation 
( a ) Homotypic challenge ++ ++ ++ ++ ++ 
( b) Heterotypic challenge 
( i ) Type specific ASCs - + + 
(ii) Subtype specific ASCs 
to priming virus 
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FIG. 7 .1 Structural and functional divisions of the 
respiratory tract. 
STRUCTURAL and FUNCTIONAL DIVISIONS 
of the RESPIRATORY TRACT 
LYMPHOID TISSUE MAJOR lg ISOTYPE 
MUCOSAL 
• Bronchus-associated 
lymphoid tissue 
(BAL T) 
•Submucosal _ lymphoid 
aggregates 
lgA 
Broncho-alveolar Junction 
., ,,,.,, ,,,.,, __, __,,., __,,.,,., _,.,,., .,._ - ,,,.,, --.Air - ,., .,._.Air,,,.,,.,._.,.,. ~ -·.aF ... ~-Jfa 
PARENCHYMAL 
• Lymphocytes and macrophages 
scattered throughout interstitium 
and alveolar spaces 
lgG 
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APPENDIX 
IMMUNOHISTOCHEMICAL LOCALIZATION OF B CELL RESPONSES IN 
INFLUENZA-INFECTED LUNGS 
185 
Although specific immuno-competent cells can be 
detected in lung cell suspensions obtained from virus 
infected mice, . the precise location of the local immune 
responses 
Localization 
cannot 
of 
be determined 
antibody-containing 
by this approach. 
cells by immuno-
fluorescence in infected lungs (Cassell et al., 1974) has 
provided very limited data which has not answered the 
question as to where the local B cell responses detected in 
the lung are generated. This quest ion cou 1 d be addressed 
more precisely if the localization of the cells involved in 
the induct ion and express ion of B cell responses, namely 
APCs, Th cells and B cells, in the lung could be determined 
during the course of a viral infection. Using an 
immuno-histochernical technique, described previously for the 
localization of class II antigens in murine tissues (Hume, 
1985) (see Section 2.13), an attempt was made to 
characterize the expression of viral antigens, class II 
antigens and surface markers on pulmonary macrophages, Th 
cells and B cells in influenza infected lungs. This method 
was chosen because of improved antigen preservation during 
fixing and embedding and enhanced sensitivity using the 
avidin-biotin-peroxidase complex (ABC). 
In normal uninfected lungs, non-specific staining was 
negligible and soecific ,_ antigens could be satisfactorily 
identified. In contrast, there was extensive non-specific 
staining in the absence of a primary antibody, in influenza 
infected lungs, especially in the bronchial epithelium, at 
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various times after intranasal inoculation. Non-specific 
staining developed only when the ABC was included 1n the 
assay irrespective of whether the biotinylated secondary 
antibody was used indicating that the ABC was binding 
non-specifically to probably virus damaged epithelium. 
The non-specific binding of ABC may have been related 
to either of the following mechanisms: 
(i) Avidin is a basic glycoprotein with a high isoelectric 
po.int (pHlO) which may bind non-specifically by 
electro-static interactions at neutral pH and 
physiologic ionic concentrations (Guesdon et al., 
1979) • 
(ii) Avidin may bind to endogenous biotin which 1s an 
important co-enzyme for transcarboxylation and 1s 
widely distributed in mammalian tissues (Hsu et al., 
1981) • 
In order to . . . m1n1m1ze the extent of background staining 
due to these mechanisms several modifications to the assay 
were tried, including: 
( i) Buff er ing the ABC solution in a high salt alkaline 
buffer e.g. 
carbonate/bicarbonate buffer, pH 9.4 
0.2M glycine/0.2M NaOH/0.SM NaCl, pH 9.0 
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(ii) Pre-treating the sections with a synthetic basic 
polypeptide e.g. 
poly-L-Lysine 0.1% (Bussolati & Gugliotta, 1983). 
(iii) Blocking binding to endogenous 
incubation with excess avidin; 
biotin 
the 
by prior 
rema1n1ng 
biotin-binding sites on the avidin being blocked by 
incubation with excess biotin effectively closing the 
endogenous system to further interaction (Wood & 
Warnke, 1981). 
Although background staining was reduced to some extent 
with these modifications, the level of background staining 
remained too high, even when combining these modifications, 
to allow accurate definition of speci fie staining. It 1s 
possible that the non-specific binding of ABC to the 
respiratory epithelium is similar to the binding of avidin 
to cell surface receptors on liver cells which are unrelated 
to the bi o t in receptor ( Ch al i four & D ak shin am u rt i , 198 2 ) . 
The possibility that avidin was binding to viral proteins 
expressed on the infected cell surface was not supported by 
the observation that ABC did not bind to P815 cells 
expressing the HA glycoprotein (determined by 
haemabsorption). 
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In view of the great difficulties encountered 1n 
obtaining satisfactory definition of specific staini ng 
patterns, it was not possible to proceed with this approach 
using this technique. 
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